https://www.gsk.com/en-gb/ 2026-03-25T10:21:46.81Z https://www.gsk.com/en-gb/behind-the-science-magazine/ 2026-03-06T08:46:30.953Z https://www.gsk.com/en-gb/behind-the-science-magazine/combining-genetics-and-tech-to-double-success-rates/ 2025-04-01T16:44:01.537Z https://www.gsk.com/en-gb/behind-the-science-magazine/getting-ahead-of-infectious-diseases-with-advanced-technology/ 2025-04-01T16:44:10.05Z https://www.gsk.com/en-gb/behind-the-science-magazine/could-tiny-bubbles-released-from-bacteria-cells-pave-the-way-for-new-vaccine-technology/ 2025-04-01T16:43:58.823Z https://www.gsk.com/en-gb/behind-the-science-magazine/how-adjuvants-boost-our-immune-response/ 2025-04-28T13:22:48.113Z https://www.gsk.com/en-gb/behind-the-science-magazine/following-the-science-of-oxygen-to-discover-solutions-for-anaemia/ 2025-04-01T16:44:06.87Z https://www.gsk.com/en-gb/behind-the-science-magazine/ai-and-ml-power-better-predictions-for-patient-impact/ 2025-04-01T16:43:59.66Z https://www.gsk.com/en-gb/behind-the-science-magazine/fresh-insights-could-finally-help-us-tackle-rsv/ 2025-04-01T16:44:02.55Z https://www.gsk.com/en-gb/behind-the-science-magazine/how-were-getting-ahead-of-an-incurable-blood-cancer/ 2025-04-01T16:44:07.773Z https://www.gsk.com/en-gb/behind-the-science-magazine/computational-biology-setting-the-stage-for-future-wins-and-new-medicines/ 2025-04-01T16:44:16.787Z https://www.gsk.com/en-gb/behind-the-science-magazine/targeting-treatable-traits-in-asthma-and-other-respiratory-conditions/ 2025-04-01T16:44:04.433Z https://www.gsk.com/en-gb/behind-the-science-magazine/why-we-re-introducing-shingles-awareness-week/ 2025-04-01T16:44:14.507Z https://www.gsk.com/en-gb/behind-the-science-magazine/tech-for-t-cells-single-cell-rna-seq-measures-shifts-in-immune-cells-to-pinpoint-causes-of-disease/ 2025-04-01T16:44:13.803Z https://www.gsk.com/en-gb/behind-the-science-magazine/what-if-remission-were-the-target-of-lupus-care/ 2025-04-28T12:51:22.63Z https://www.gsk.com/en-gb/behind-the-science-magazine/how-vaccine-science-can-help-tackle-antimicrobial-resistance/ 2025-04-28T12:50:58.48Z https://www.gsk.com/en-gb/behind-the-science-magazine/14-million-reasons-to-get-ahead-of-gynaecologic-cancers/ 2025-04-28T12:50:40.377Z https://www.gsk.com/en-gb/behind-the-science-magazine/how-the-next-generation-of-immuno-oncology-could-help-us-get-ahead-of-cancer/ 2025-04-28T12:50:19.693Z https://www.gsk.com/en-gb/behind-the-science-magazine/the-40-year-fight-against-hiv/ 2025-04-28T12:49:35.363Z https://www.gsk.com/en-gb/behind-the-science-magazine/synthetic-lethality-accelerating-precision-cancer-treatments/ 2025-04-28T12:49:09.98Z https://www.gsk.com/en-gb/behind-the-science-magazine/digital-twin-using-advanced-technology-to-accelerate-vaccine-development/ 2025-04-28T12:48:50.303Z https://www.gsk.com/en-gb/behind-the-science-magazine/tackling-tomorrow-s-health-challenges-today/ 2025-04-28T12:48:16.727Z https://www.gsk.com/en-gb/behind-the-science-magazine/unlocking-the-power-of-the-immune-system-to-get-ahead-of-hepatitis-b/ 2025-04-01T16:43:58.21Z https://www.gsk.com/en-gb/behind-the-science-magazine/time-for-a-change-personalising-asthma-treatment/ 2025-04-01T16:43:57.633Z https://www.gsk.com/en-gb/behind-the-science-magazine/eosinophils-could-be-holding-the-missing-link/ 2025-04-01T16:43:56.68Z https://www.gsk.com/en-gb/behind-the-science-magazine/the-logic-of-biologic-medicines/ 2025-04-01T16:43:55.937Z https://www.gsk.com/en-gb/behind-the-science-magazine/copd-exacerbations-respiratory-disease-new-technology/ 2025-04-01T16:43:54.237Z https://www.gsk.com/en-gb/behind-the-science-magazine/using-new-science-to-get-ahead-of-blood-cancer-myelofibrosis/ 2025-04-01T16:43:54.85Z https://www.gsk.com/en-gb/behind-the-science-magazine/antibiotic-resistance-now-s-the-time-to-prevent-the-next-pandemic/ 2025-04-15T13:12:28.21Z https://www.gsk.com/en-gb/behind-the-science-magazine/cancer-recurrence-tumour-ctdna-technology/ 2025-04-01T16:43:53.657Z https://www.gsk.com/en-gb/behind-the-science-magazine/tripledemic-flu-covid-rsv-older-patients-infectious-disease/ 2025-04-01T16:43:52.75Z https://www.gsk.com/en-gb/behind-the-science-magazine/maps-technology-new-age-vaccine-development-infectious-diseases/ 2025-08-04T14:23:41.46Z https://www.gsk.com/en-gb/behind-the-science-magazine/age-related-decline-immunity-infectious-disease/ 2025-04-28T13:20:38.523Z https://www.gsk.com/en-gb/behind-the-science-magazine/shingles-symptoms-risks-pain-adults/ 2025-04-01T16:43:50.86Z https://www.gsk.com/en-gb/behind-the-science-magazine/men-women-gender-diversity-clinical-trials/ 2025-05-22T11:37:52.573Z https://www.gsk.com/en-gb/behind-the-science-magazine/new-technology-drug-targets-rna-medicine-development/ 2025-04-01T16:43:42.307Z https://www.gsk.com/en-gb/behind-the-science-magazine/malaria-vaccine-children-mosquitos-single-dose-treatment/ 2025-04-01T16:43:43.303Z https://www.gsk.com/en-gb/behind-the-science-magazine/hepatitis-b-patient-quote-story-functional-cure/ 2025-04-01T16:43:41.533Z https://www.gsk.com/en-gb/behind-the-science-magazine/hiv-aids-treatment-pros-digital-patient-survey/ 2025-04-01T16:43:40.5Z https://www.gsk.com/en-gb/behind-the-science-magazine/child-immunity-gap-vaccination-catch-up/ 2025-04-01T16:43:39.687Z https://www.gsk.com/en-gb/behind-the-science-magazine/bio-data-wall-survey-modern-tech-healthcare/ 2025-04-01T16:43:38.95Z https://www.gsk.com/en-gb/behind-the-science-magazine/biomarker-testing-ai-tumours-hepatitis-respiratory-cancer/ 2025-04-01T16:43:38.013Z https://www.gsk.com/en-gb/behind-the-science-magazine/ai-medical-innovation-ethics-responsibility/ 2025-04-01T16:43:36.58Z https://www.gsk.com/en-gb/behind-the-science-magazine/chronic-hepatitis-b-stigma-discrimination-diagnosis/ 2025-04-01T16:43:34.603Z https://www.gsk.com/en-gb/behind-the-science-magazine/pneumonia-symptoms-risks-vaccines-treatment/ 2025-04-01T16:43:31.477Z https://www.gsk.com/en-gb/behind-the-science-magazine/patient-centred-respiratory-prevention-asthma-copd-rsv/ 2025-12-04T13:30:20.68Z https://www.gsk.com/en-gb/behind-the-science-magazine/adult-vaccines-healthy-ageing-comment/ 2025-04-01T16:43:30.42Z https://www.gsk.com/en-gb/behind-the-science-magazine/vaccines-climate-change-health-economy/ 2025-04-01T16:43:28.98Z https://www.gsk.com/en-gb/behind-the-science-magazine/smart-manufacturing-factories-uppermerion-medicines/ 2025-04-01T16:43:28.28Z https://www.gsk.com/en-gb/behind-the-science-magazine/health-equity-gap-medicine-vaccine-access/ 2025-05-19T12:39:10.38Z https://www.gsk.com/en-gb/behind-the-science-magazine/child-immunisation-accelerator-comment/ 2025-04-01T16:43:26.643Z https://www.gsk.com/en-gb/behind-the-science-magazine/asthma-copd-treatment-prevent-lung-damage/ 2025-04-01T16:43:25.793Z https://www.gsk.com/en-gb/behind-the-science-magazine/thomas-breuer-comment-global-health-progress/ 2025-04-01T16:43:24.943Z https://www.gsk.com/en-gb/behind-the-science-magazine/advanced-technology-cancer-care-oncology/ 2025-11-18T09:46:41.61Z https://www.gsk.com/en-gb/behind-the-science-magazine/chris-austin-comment-data-scale-drug-discovery/ 2025-04-01T16:43:23.4Z https://www.gsk.com/en-gb/behind-the-science-magazine/ai-ml-data-computing-power/ 2025-04-01T16:43:22.733Z https://www.gsk.com/en-gb/behind-the-science-magazine/prevention-medicine-hiv-epidemic/ 2025-05-19T12:46:57.183Z https://www.gsk.com/en-gb/behind-the-science-magazine/remission-severe-asthma-treatments-possible/ 2025-04-28T13:17:38.5Z https://www.gsk.com/en-gb/behind-the-science-magazine/rsv-survey-data-symptoms-risk/ 2025-04-01T16:43:19.247Z https://www.gsk.com/en-gb/behind-the-science-magazine/refractory-chronic-cough-patients-symptoms/ 2025-04-01T16:43:20.423Z https://www.gsk.com/en-gb/behind-the-science-magazine/respiratory-disease-sustainability-climate-change/ 2025-10-30T09:53:05.907Z https://www.gsk.com/en-gb/behind-the-science-magazine/amr-prevention-antibiotics-vaccines/ 2025-04-01T16:43:17.197Z https://www.gsk.com/en-gb/behind-the-science-magazine/meningitis-cases-rebound-risks-symptoms/ 2025-04-01T16:43:37.377Z https://www.gsk.com/en-gb/behind-the-science-magazine/prevention-best-medicine-disease-patients/ 2025-09-15T12:59:40.187Z https://www.gsk.com/en-gb/behind-the-science-magazine/gynaecologic-cancer-survey-treatment-access/ 2025-05-16T12:13:44.957Z https://www.gsk.com/en-gb/behind-the-science-magazine/intervening-early-organ-damage-lupus/ 2025-04-01T16:43:14.307Z https://www.gsk.com/en-gb/behind-the-science-magazine/whooping-cough-outbreak-lifelong-vaccination/ 2025-04-01T16:43:13.287Z https://www.gsk.com/en-gb/behind-the-science-magazine/covid-flu-rsv-symptoms-virus/ 2025-11-03T09:05:08.667Z https://www.gsk.com/en-gb/behind-the-science-magazine/long-acting-therapies-hiv-comment/ 2025-10-14T12:28:04.62Z https://www.gsk.com/en-gb/behind-the-science-magazine/rsv-symptoms-risks-protection/ 2025-04-25T11:01:13.207Z https://www.gsk.com/en-gb/behind-the-science-magazine/cancer-chronic-manageable-disease-comment/ 2025-11-18T09:41:41.443Z https://www.gsk.com/en-gb/behind-the-science-magazine/amr-antibiotics-resistance-superbugs-new-medicines/ 2025-05-14T13:29:49.787Z https://www.gsk.com/en-gb/behind-the-science-magazine/vaccinations-children-adult-immunisation-health-economic-benefits/ 2025-06-05T07:59:19.08Z https://www.gsk.com/en-gb/behind-the-science-magazine/rss/ 2025-04-17T11:29:31.457Z https://www.gsk.com/en-gb/behind-the-science-magazine/second-generation-malaria-vaccine/ 2025-05-19T11:06:45.267Z https://www.gsk.com/en-gb/behind-the-science-magazine/prevention-trust-vaccination-community/ 2025-05-20T08:59:36.843Z https://www.gsk.com/en-gb/behind-the-science-magazine/nasal-polyps-asthma-patient-comment/ 2025-09-24T12:54:43.727Z https://www.gsk.com/en-gb/behind-the-science-magazine/blood-cancer-myeloma-myelofibrosis-feature/ 2025-06-04T14:31:12.81Z https://www.gsk.com/en-gb/behind-the-science-magazine/organoids-digital-twin-comment/ 2025-08-27T08:57:06.33Z https://www.gsk.com/en-gb/behind-the-science-magazine/adolescent-risk-meningitis-prevention/ 2025-08-14T12:54:01.907Z https://www.gsk.com/en-gb/behind-the-science-magazine/copd-lung-disease-prevention-comment/ 2025-11-18T09:51:00.997Z https://www.gsk.com/en-gb/behind-the-science-magazine/uti-patient-symptoms-treatment/ 2025-10-17T17:09:36.21Z https://www.gsk.com/en-gb/behind-the-science-magazine/protecting-patients-against-rsv-risk/ 2025-11-19T09:50:04.907Z https://www.gsk.com/en-gb/behind-the-science-magazine/gsk-teichmann-lab-collaboration/ 2025-12-12T12:05:44.243Z https://www.gsk.com/en-gb/company/ 2026-03-05T09:39:55.07Z https://www.gsk.com/en-gb/company/purpose-strategy-and-culture/ 2026-03-05T09:38:58.897Z https://www.gsk.com/en-gb/company/outstanding-people/ 2026-01-13T15:52:03.367Z https://www.gsk.com/en-gb/company/outstanding-people/great-place-to-work/ 2025-04-10T10:19:00.473Z https://www.gsk.com/en-gb/company/outstanding-people/meet-our-veterans/ 2025-04-02T13:07:24.84Z https://www.gsk.com/en-gb/company/outstanding-people/working-together/ 2025-05-14T13:35:01.87Z https://www.gsk.com/en-gb/company/outstanding-people/my-gsk-story/ 2025-05-14T13:35:02.123Z https://www.gsk.com/en-gb/company/outstanding-people/innovating-together/ 2026-01-13T15:52:44.32Z https://www.gsk.com/en-gb/company/gsk-at-a-glance/ 2026-03-05T09:38:07.17Z https://www.gsk.com/en-gb/company/history-and-heritage/ 2026-03-05T09:37:19.683Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/ 2026-03-12T14:57:11.983Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/sir-jonathan-symonds/ 2026-03-26T14:41:38.477Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/luke-miels/ 2026-03-26T14:41:23.993Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/julie-brown/ 2026-03-26T14:41:09.337Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/elizabeth-liz-mckee-anderson/ 2026-03-26T14:40:51.32Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/charles-bancroft/ 2026-03-26T14:40:37.067Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/dr-hal-barron/ 2026-03-26T14:40:23.133Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/dr-anne-beal/ 2026-03-26T14:40:10.293Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/wendy-becker/ 2026-03-26T14:39:56.46Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/dr-harry-hal-c-dietz/ 2026-03-26T14:39:44.547Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/dr-jeannie-lee/ 2026-03-26T14:39:29.16Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/dr-gavin-screaton/ 2026-03-26T14:39:16.337Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/dr-vishal-sikka/ 2026-03-26T14:39:03.913Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/lynn-baxter/ 2026-03-26T14:38:49.847Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/diana-conrad/ 2026-03-26T14:38:35.487Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/mike-crichton/ 2026-03-26T14:38:22.987Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/james-ford/ 2026-03-26T14:38:09.177Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/mondher-mahjoubi/ 2026-03-26T14:37:51.41Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/maya-martinez-davis/ 2026-03-26T14:37:38.47Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/nina-mojas/ 2026-03-26T14:37:25.367Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/shobie-ramakrishnan/ 2026-03-26T14:37:09.667Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/david-redfern/ 2026-03-26T14:36:55.277Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/regis-simard/ 2026-03-26T14:36:43.71Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/phil-thomson/ 2026-03-26T14:36:32.46Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/deborah-waterhouse/ 2026-03-26T14:36:17.41Z https://www.gsk.com/en-gb/company/board-of-directors-and-leadership-team/tony-wood/ 2026-03-26T14:36:01.633Z https://www.gsk.com/en-gb/company/board-information/ 2026-03-05T09:30:20.163Z https://www.gsk.com/en-gb/company/governance/ 2026-03-05T09:29:38.423Z https://www.gsk.com/en-gb/company/governance/committees/ 2026-03-10T15:17:26.157Z https://www.gsk.com/en-gb/company/governance/shareholders/ 2026-01-15T15:30:27.347Z https://www.gsk.com/en-gb/company/governance/sarbanes-oxley-act-2002/ 2026-02-02T16:18:10.623Z https://www.gsk.com/en-gb/company/governance/compliance/ 2026-03-06T14:29:48.88Z https://www.gsk.com/en-gb/company/policy-positions/ 2025-09-29T14:22:58.833Z https://www.gsk.com/en-gb/company/codes-standards-and-reports/ 2026-03-05T09:04:12.697Z https://www.gsk.com/en-gb/locations/ 2026-03-05T11:28:43.597Z https://www.gsk.com/en-gb/locations/albania/ 2026-03-05T11:14:37.49Z https://www.gsk.com/en-gb/locations/algeria/ 2026-03-05T11:14:37.837Z https://www.gsk.com/en-gb/locations/angola/ 2026-03-05T11:14:38.18Z https://www.gsk.com/en-gb/locations/armenia/ 2026-03-05T11:14:38.97Z https://www.gsk.com/en-gb/locations/austria/ 2026-03-05T11:14:39.41Z https://www.gsk.com/en-gb/locations/austria/de-aut/ 2026-04-01T10:49:44.067Z https://www.gsk.com/en-gb/locations/azerbaijan/ 2026-03-05T11:14:39.743Z https://www.gsk.com/en-gb/locations/belarus/ 2026-03-05T11:14:40.24Z https://www.gsk.com/en-gb/locations/benin/ 2026-03-05T11:14:40.597Z https://www.gsk.com/en-gb/locations/bosnia-herz/ 2026-03-05T11:14:40.947Z https://www.gsk.com/en-gb/locations/botswana/ 2026-03-05T11:14:41.27Z https://www.gsk.com/en-gb/locations/bulgaria/ 2026-03-05T11:14:41.6Z https://www.gsk.com/en-gb/locations/bulgaria/bg-bg/ 2025-11-12T14:10:21.293Z https://www.gsk.com/en-gb/locations/cambodia/ 2026-03-05T11:14:41.917Z https://www.gsk.com/en-gb/locations/cameroon/ 2026-03-05T11:14:42.26Z https://www.gsk.com/en-gb/locations/caribbean-islands/ 2026-03-05T11:14:42.58Z https://www.gsk.com/en-gb/locations/chile/ 2026-03-05T11:14:42.95Z https://www.gsk.com/en-gb/locations/chile/es-cl/ 2026-04-02T08:01:05.207Z https://www.gsk.com/en-gb/locations/colombia/ 2026-03-05T11:14:43.273Z https://www.gsk.com/en-gb/locations/colombia/politica-ambiental-y-politica-de-proteccion-de-datos-de-gsk-colombia/ 2025-10-15T09:02:33.743Z https://www.gsk.com/en-gb/locations/congo/ 2026-03-05T11:14:43.59Z https://www.gsk.com/en-gb/locations/costa-rica/ 2026-03-05T11:14:43.943Z https://www.gsk.com/en-gb/locations/cote-d-ivoire/ 2026-03-05T11:14:44.293Z https://www.gsk.com/en-gb/locations/croatia/ 2026-03-05T11:14:44.65Z https://www.gsk.com/en-gb/locations/cyprus/ 2026-03-05T11:14:45.007Z https://www.gsk.com/en-gb/locations/czech-republic/ 2026-03-05T11:14:45.353Z https://www.gsk.com/en-gb/locations/czech-republic/cs-cze/ 2026-03-05T11:15:13.747Z https://www.gsk.com/en-gb/locations/democratic-republic-of-congo/ 2026-03-05T11:14:45.68Z https://www.gsk.com/en-gb/locations/denmark/ 2026-03-05T11:14:46.017Z https://www.gsk.com/en-gb/locations/denmark/da-dk/ 2025-10-08T11:51:53.79Z https://www.gsk.com/en-gb/locations/djibouti/ 2026-03-05T11:14:46.347Z https://www.gsk.com/en-gb/locations/dominican-republic/ 2026-03-05T11:14:46.693Z https://www.gsk.com/en-gb/locations/ethiopia/ 2026-03-05T11:14:47.017Z https://www.gsk.com/en-gb/locations/ecuador/ 2026-03-05T11:14:47.373Z https://www.gsk.com/en-gb/locations/ecuador/es-ec/ 2026-04-02T08:01:46.65Z https://www.gsk.com/en-gb/locations/egypt/ 2026-03-05T11:14:47.72Z https://www.gsk.com/en-gb/locations/el-salvador/ 2026-03-05T11:14:48.053Z https://www.gsk.com/en-gb/locations/estonia/ 2026-03-05T11:14:48.39Z https://www.gsk.com/en-gb/locations/georgia/ 2026-03-05T11:14:48.72Z https://www.gsk.com/en-gb/locations/gabon/ 2026-03-05T11:14:49.37Z https://www.gsk.com/en-gb/locations/guinea/ 2026-03-05T11:14:49.68Z https://www.gsk.com/en-gb/locations/ghana/ 2026-03-05T11:14:49.973Z https://www.gsk.com/en-gb/locations/greece/ 2026-03-05T11:14:50.303Z https://www.gsk.com/en-gb/locations/greece/gr-grc/ 2025-10-08T09:43:44.433Z https://www.gsk.com/en-gb/locations/guatemala/ 2026-03-05T11:14:50.657Z https://www.gsk.com/en-gb/locations/honduras/ 2026-03-05T11:14:51Z https://www.gsk.com/en-gb/locations/hong-kong-and-macau/ 2026-03-05T11:14:51.383Z https://www.gsk.com/en-gb/locations/hong-kong-and-macau/zh-hk/ 2026-03-05T11:15:12.983Z https://www.gsk.com/en-gb/locations/hungary/ 2026-03-05T11:14:51.76Z https://www.gsk.com/en-gb/locations/hungary/hu-hu/ 2025-11-12T14:11:15.673Z https://www.gsk.com/en-gb/locations/indonesia/ 2026-03-05T11:14:52.087Z https://www.gsk.com/en-gb/locations/ireland/ 2026-03-05T11:14:52.44Z https://www.gsk.com/en-gb/locations/ireland/gsk-mother-and-baby-home-information-service/ 2025-04-01T16:21:57.977Z https://www.gsk.com/en-gb/locations/israel/ 2026-03-05T11:14:52.777Z https://www.gsk.com/en-gb/locations/jamaica/ 2026-03-05T11:14:53.117Z https://www.gsk.com/en-gb/locations/jordan/ 2026-03-05T11:14:53.433Z https://www.gsk.com/en-gb/locations/kazakhstan/ 2026-03-05T11:14:53.737Z https://www.gsk.com/en-gb/locations/kazakhstan/ru-kz/ 2026-03-05T11:15:12.54Z https://www.gsk.com/en-gb/locations/kenya/ 2026-03-05T11:14:54.05Z https://www.gsk.com/en-gb/locations/latvia/ 2026-03-05T11:14:54.39Z https://www.gsk.com/en-gb/locations/latvia/lv-lv/ 2025-11-12T14:12:34.103Z https://www.gsk.com/en-gb/locations/lebanon/ 2026-03-05T11:14:54.737Z https://www.gsk.com/en-gb/locations/lithuania/ 2026-03-05T11:14:55.063Z https://www.gsk.com/en-gb/locations/madagascar/ 2026-03-05T11:14:55.393Z https://www.gsk.com/en-gb/locations/malawi/ 2026-03-05T11:14:55.703Z https://www.gsk.com/en-gb/locations/malaysia/ 2026-03-05T11:14:56.03Z https://www.gsk.com/en-gb/locations/maldives/ 2026-03-05T11:14:56.353Z https://www.gsk.com/en-gb/locations/malta/ 2026-03-05T11:14:56.68Z https://www.gsk.com/en-gb/locations/mauritius/ 2026-03-05T11:14:56.99Z https://www.gsk.com/en-gb/locations/mexico/ 2026-03-05T11:14:57.313Z https://www.gsk.com/en-gb/locations/moldova/ 2026-03-05T11:14:57.633Z https://www.gsk.com/en-gb/locations/montenegro/ 2026-03-05T11:14:57.957Z https://www.gsk.com/en-gb/locations/morocco/ 2026-03-05T11:14:58.277Z https://www.gsk.com/en-gb/locations/mozambique/ 2026-03-05T11:14:58.607Z https://www.gsk.com/en-gb/locations/namibia/ 2026-03-05T11:14:58.947Z https://www.gsk.com/en-gb/locations/netherlands/ 2026-03-05T11:14:59.277Z https://www.gsk.com/en-gb/locations/netherlands/nl-nl/ 2025-10-08T09:46:47.413Z https://www.gsk.com/en-gb/locations/new-zealand/ 2026-03-05T11:14:59.66Z https://www.gsk.com/en-gb/locations/nicaragua/ 2026-03-05T11:14:59.993Z https://www.gsk.com/en-gb/locations/nigeria/ 2026-03-05T11:15:00.317Z https://www.gsk.com/en-gb/locations/north-macedonia/ 2026-03-05T11:15:00.647Z https://www.gsk.com/en-gb/locations/norway/ 2026-03-05T11:15:00.99Z https://www.gsk.com/en-gb/locations/norway/nb-nor/ 2025-10-08T09:48:00.95Z https://www.gsk.com/en-gb/locations/panama/ 2026-03-05T11:15:01.34Z https://www.gsk.com/en-gb/locations/peru/ 2026-03-05T11:15:01.71Z https://www.gsk.com/en-gb/locations/peru/es-pe/ 2026-04-02T08:02:30.41Z https://www.gsk.com/en-gb/locations/philippines/ 2026-03-05T11:15:02.037Z https://www.gsk.com/en-gb/locations/romania/ 2026-03-05T11:15:02.4Z https://www.gsk.com/en-gb/locations/romania/ro-ro/ 2025-11-12T14:14:40.833Z https://www.gsk.com/en-gb/locations/rwanda/ 2026-03-05T11:15:02.747Z https://www.gsk.com/en-gb/locations/saudi-arabia/ 2026-03-05T11:15:03.097Z https://www.gsk.com/en-gb/locations/saudi-arabia/ar-sa/ 2026-03-05T11:15:12.11Z https://www.gsk.com/en-gb/locations/senegal/ 2026-03-05T11:15:03.433Z https://www.gsk.com/en-gb/locations/serbia/ 2026-03-05T11:15:03.797Z https://www.gsk.com/en-gb/locations/serbia/sr-rs/ 2026-01-08T10:39:41.767Z https://www.gsk.com/en-gb/locations/seychelles/ 2026-03-05T11:15:04.127Z https://www.gsk.com/en-gb/locations/singapore/ 2026-03-05T11:15:04.537Z https://www.gsk.com/en-gb/locations/slovakia/ 2026-03-05T11:15:04.91Z https://www.gsk.com/en-gb/locations/slovakia/sk-sk/ 2025-11-12T15:07:55.153Z https://www.gsk.com/en-gb/locations/slovenia/ 2026-03-05T11:15:05.267Z https://www.gsk.com/en-gb/locations/south-africa/ 2026-03-26T12:10:52.817Z https://www.gsk.com/en-gb/locations/sri-lanka/ 2026-03-05T11:15:05.943Z https://www.gsk.com/en-gb/locations/sweden/ 2026-03-17T10:31:27.1Z https://www.gsk.com/en-gb/locations/sweden/sv-se/ 2026-03-17T10:30:54.673Z https://www.gsk.com/en-gb/locations/switzerland/ 2026-03-05T11:15:06.673Z https://www.gsk.com/en-gb/locations/switzerland/de-ch/ 2026-03-05T11:15:14.147Z https://www.gsk.com/en-gb/locations/switzerland/fr-ch/ 2026-03-05T11:15:15.23Z https://www.gsk.com/en-gb/locations/tanzania/ 2026-03-05T11:15:07.01Z https://www.gsk.com/en-gb/locations/thailand/ 2026-03-05T11:15:07.34Z https://www.gsk.com/en-gb/locations/togo/ 2026-03-05T11:15:07.717Z https://www.gsk.com/en-gb/locations/trinidad-tobago/ 2026-03-05T11:15:08.047Z https://www.gsk.com/en-gb/locations/tunisia/ 2026-03-05T11:15:08.387Z https://www.gsk.com/en-gb/locations/uganda/ 2026-03-05T11:15:08.79Z https://www.gsk.com/en-gb/locations/ukraine/ 2026-03-05T11:15:09.16Z https://www.gsk.com/en-gb/locations/ukraine/uk-ukr/ 2025-10-09T09:26:46.907Z https://www.gsk.com/en-gb/locations/united-arab-emirates/ 2026-03-05T11:15:09.493Z https://www.gsk.com/en-gb/locations/united-kingdom/ 2026-03-16T13:42:26.363Z https://www.gsk.com/en-gb/locations/uruguay/ 2026-03-05T11:15:10.357Z https://www.gsk.com/en-gb/locations/uzbekistan/ 2026-03-05T11:15:10.733Z https://www.gsk.com/en-gb/locations/venezuela/ 2026-03-05T11:15:11.043Z https://www.gsk.com/en-gb/locations/vietnam/ 2026-03-05T11:15:11.373Z https://www.gsk.com/en-gb/locations/zambia/ 2026-03-05T11:15:11.767Z https://www.gsk.com/en-gb/innovation/ 2026-03-05T09:48:12.393Z https://www.gsk.com/en-gb/innovation/our-leading-scientists/ 2026-03-05T09:47:18.707Z https://www.gsk.com/en-gb/innovation/our-leading-scientists/tony-wood/ 2026-03-26T14:42:31.983Z https://www.gsk.com/en-gb/innovation/our-leading-scientists/sabine-luik/ 2026-03-26T14:42:53.397Z https://www.gsk.com/en-gb/innovation/our-leading-scientists/hesham-abdullah/ 2026-03-26T14:43:12.057Z https://www.gsk.com/en-gb/innovation/our-leading-scientists/kaivan-khavandi/ 2026-03-26T14:43:30.763Z https://www.gsk.com/en-gb/innovation/research-and-development-approach/ 2026-03-09T16:36:06.273Z https://www.gsk.com/en-gb/innovation/pipeline/ 2026-02-06T14:05:54.847Z https://www.gsk.com/en-gb/innovation/therapeutic-areas/ 2026-03-05T09:44:38.31Z https://www.gsk.com/en-gb/innovation/therapeutic-areas/respiratory-immunology-and-inflammation/ 2026-03-05T09:43:59.747Z https://www.gsk.com/en-gb/innovation/therapeutic-areas/oncology/ 2026-01-15T15:58:04.677Z https://www.gsk.com/en-gb/innovation/therapeutic-areas/hiv/ 2026-03-05T09:43:09.597Z https://www.gsk.com/en-gb/innovation/therapeutic-areas/infectious-diseases/ 2026-03-05T09:42:36.15Z https://www.gsk.com/en-gb/innovation/technologies/ 2026-03-26T11:21:09.693Z https://www.gsk.com/en-gb/innovation/trials/ 2026-01-15T16:01:23.883Z https://www.gsk.com/en-gb/innovation/trials/provision-of-unlicensed-medicines-for-unmet-medical-needs/ 2025-09-29T14:26:16.427Z https://www.gsk.com/en-gb/innovation/trials/data-transparency/ 2026-03-05T09:41:55.99Z https://www.gsk.com/en-gb/innovation/trials/representative-clinical-studies/ 2026-03-05T09:41:19.587Z https://www.gsk.com/en-gb/innovation/partnerships/ 2025-10-01T08:34:29.297Z https://www.gsk.com/en-gb/innovation/partnerships/supported-studies/ 2025-09-29T14:27:09.04Z https://www.gsk.com/en-gb/innovation/rd-locations/ 2026-03-24T15:29:59.18Z https://www.gsk.com/en-gb/products/ 2026-03-05T09:53:03.883Z https://www.gsk.com/en-gb/products/our-product-areas/ 2026-03-05T09:52:23.877Z https://www.gsk.com/en-gb/products/products-a-z/ 2026-03-05T09:51:43.973Z https://www.gsk.com/en-gb/responsibility/ 2026-03-05T09:27:47.123Z https://www.gsk.com/en-gb/responsibility/access/ 2026-03-05T09:26:55.01Z https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/ 2026-03-05T09:25:59.357Z https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/global-health/ 2026-03-05T09:25:21.107Z https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/health-security/ 2025-09-29T14:29:04.72Z https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/using-our-science-for-global-health/ 2026-03-05T09:24:30.787Z https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/improving-access-to-healthcare/ 2026-03-05T09:23:52.63Z https://www.gsk.com/en-gb/responsibility/global-health-and-health-security/africa-open-lab/ 2026-02-23T16:18:09.113Z https://www.gsk.com/en-gb/responsibility/environment/ 2026-03-25T09:04:14.397Z https://www.gsk.com/en-gb/responsibility/environment/climate/ 2026-03-25T09:38:25.9Z https://www.gsk.com/en-gb/responsibility/environment/freshwater/ 2026-03-05T09:20:37.063Z https://www.gsk.com/en-gb/responsibility/environment/land/ 2026-03-05T09:20:02.9Z https://www.gsk.com/en-gb/responsibility/environment/oceans/ 2026-03-05T09:19:19.41Z https://www.gsk.com/en-gb/responsibility/environment/materials-and-waste/ 2026-03-05T09:18:39.257Z https://www.gsk.com/en-gb/responsibility/environment/health-system-sustainability/ 2026-03-05T09:17:59.643Z https://www.gsk.com/en-gb/responsibility/inclusion/ 2026-04-01T15:44:07.25Z https://www.gsk.com/en-gb/responsibility/ethical-standards/ 2026-02-02T16:20:03.383Z https://www.gsk.com/en-gb/responsibility/ethical-standards/working-with-third-parties/ 2025-12-15T09:52:47.137Z https://www.gsk.com/en-gb/responsibility/ethical-standards/public-policy-and-patient-advocacy/ 2026-03-05T09:15:31.523Z https://www.gsk.com/en-gb/responsibility/ethical-standards/human-rights/ 2026-03-05T09:14:52.713Z https://www.gsk.com/en-gb/responsibility/ethical-standards/use-of-animals/ 2026-03-05T09:14:10.19Z https://www.gsk.com/en-gb/responsibility/ethical-standards/engaging-with-healthcare-professionals/ 2026-03-20T12:09:45.727Z https://www.gsk.com/en-gb/responsibility/product-governance/ 2026-01-20T15:39:32.15Z https://www.gsk.com/en-gb/responsibility/grants-and-donations/ 2026-01-20T15:40:11.843Z https://www.gsk.com/en-gb/responsibility/charitable-investments/ 2026-03-12T09:30:56.03Z https://www.gsk.com/en-gb/responsibility/responsibility-reports/ 2026-03-16T11:04:47.843Z https://www.gsk.com/en-gb/responsibility/responsibility-reports/responsibility-reports-archive/ 2025-09-30T10:34:00.143Z https://www.gsk.com/en-gb/investors/ 2026-03-24T15:13:59.703Z https://www.gsk.com/en-gb/investors/why-invest-in-gsk/ 2026-03-09T15:06:49.907Z https://www.gsk.com/en-gb/investors/quarterly-results/ 2026-03-25T10:22:36.057Z https://www.gsk.com/en-gb/investors/financial-reports/ 2026-03-06T14:28:40.053Z https://www.gsk.com/en-gb/investors/financial-reports/annual-report-2025/ 2026-03-06T14:27:43.743Z https://www.gsk.com/en-gb/investors/financial-reports/corporate-reports-archive/ 2026-01-22T16:38:44.887Z https://www.gsk.com/en-gb/investors/responsible-business/ 2026-03-16T11:05:44.163Z https://www.gsk.com/en-gb/investors/speeches-and-presentations/ 2026-01-22T16:40:26.997Z https://www.gsk.com/en-gb/investors/science-publications/ 2026-01-22T16:41:30.927Z https://www.gsk.com/en-gb/investors/events-calendar/ 2026-03-24T15:12:39.183Z https://www.gsk.com/en-gb/investors/dividend-and-share-price/ 2025-09-29T14:36:35.77Z https://www.gsk.com/en-gb/investors/dividend-and-share-price/gsk-share-price/ 2025-10-01T08:49:20.2Z https://www.gsk.com/en-gb/investors/dividend-and-share-price/share-price-calculators-gbpusd/ 2025-10-01T08:52:28.903Z https://www.gsk.com/en-gb/investors/dividend-and-share-price/dividend-calculators-gbpusd/ 2025-10-01T08:54:04.493Z https://www.gsk.com/en-gb/investors/dividend-and-share-price/dividend-calendar/ 2026-01-08T13:24:13.453Z https://www.gsk.com/en-gb/investors/analyst-consensus/ 2025-09-29T15:53:57.423Z https://www.gsk.com/en-gb/investors/analyst-consensus/analyst-consensus/ 2026-03-09T15:12:09.397Z https://www.gsk.com/en-gb/investors/stock-exchange-announcements/ 2025-09-29T14:39:20.237Z https://www.gsk.com/en-gb/investors/stock-exchange-announcements/london-rns/ 2025-10-01T08:55:20.513Z https://www.gsk.com/en-gb/investors/stock-exchange-announcements/london-rns-inside-information/ 2025-09-29T14:40:28.097Z https://www.gsk.com/en-gb/investors/stock-exchange-announcements/new-york-sec/ 2025-10-01T08:56:44.917Z https://www.gsk.com/en-gb/investors/stock-exchange-announcements/sign-up-for-announcements/ 2025-10-01T08:57:50.36Z https://www.gsk.com/en-gb/investors/shareholder-information/ 2025-09-29T14:41:28.51Z https://www.gsk.com/en-gb/investors/shareholder-information/manage-your-shares/ 2025-09-29T14:41:38.74Z https://www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/ 2026-03-25T12:23:43.187Z https://www.gsk.com/en-gb/investors/shareholder-information/general-meeting/ 2025-09-29T15:55:14.037Z https://www.gsk.com/en-gb/investors/shareholder-information/annual-governance-meeting/ 2025-09-29T14:07:41.96Z https://www.gsk.com/en-gb/investors/shareholder-information/corporate-sponsored-nominee-service/ 2026-01-22T16:43:12.44Z https://www.gsk.com/en-gb/investors/shareholder-information/adr-programme/ 2026-03-09T15:49:12.13Z https://www.gsk.com/en-gb/investors/shareholder-information/asset-reunification-georgeson/ 2025-09-29T14:42:53.58Z https://www.gsk.com/en-gb/investors/shareholder-information/share-scam-alert/ 2025-09-29T14:43:04.077Z https://www.gsk.com/en-gb/investors/shareholder-information/privacy-notice-for-ordinary-shareholders/ 2025-09-29T15:55:50.877Z https://www.gsk.com/en-gb/investors/shareholder-information/shareholder-faqs/ 2026-01-22T16:44:12.423Z https://www.gsk.com/en-gb/investors/corporate-actions/ 2026-01-22T16:45:29.673Z https://www.gsk.com/en-gb/investors/corporate-actions/consumer-healthcare-demerger/ 2025-09-29T15:56:24.85Z https://www.gsk.com/en-gb/investors/corporate-actions/consumer-healthcare-joint-venture/ 2025-09-29T14:43:59.453Z https://www.gsk.com/en-gb/investors/corporate-actions/agreement-to-acquire-tesaro/ 2025-09-29T14:44:09.847Z https://www.gsk.com/en-gb/investors/debt-investors/ 2026-04-02T10:42:47.167Z https://www.gsk.com/en-gb/investors/investor-contacts/ 2026-03-09T15:50:26.383Z https://www.gsk.com/en-gb/investors/cautionary-statement/ 2026-03-05T09:05:08.713Z https://www.gsk.com/en-gb/media/ 2026-03-05T09:10:45.93Z https://www.gsk.com/en-gb/media/press-releases/ 2026-03-06T08:47:00.647Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-board-changes/ 2025-04-01T16:36:38.25Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-results-from-first-phase-iii-studies-of-two-drug-hiv-treatment-regimen/ 2025-04-01T16:36:38.887Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-months-and-older/ 2025-04-01T16:36:39.617Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-in-fourth-consecutive-pivotal-trial-of-benlysta-belimumab-in-sle/ 2025-04-01T16:36:32.297Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-new-york-times-article-on-china/ 2025-04-01T16:36:32.843Z https://www.gsk.com/en-gb/media/press-releases/new-data-published-for-gsk-s-nucala-investigating-hospitalisation-reduction-in-severe-asthma-patients-with-an-eosinophilic-phenotype/ 2025-04-01T16:36:33.62Z https://www.gsk.com/en-gb/media/press-releases/gsk-sets-out-further-steps-to-address-emerging-global-health-security-challenges/ 2025-04-01T16:36:35.19Z https://www.gsk.com/en-gb/media/press-releases/gsk-announce-positive-results-from-the-copd-salford-lung-study-published-in-the-nejm-and-presented-at-european-respiratory-congress/ 2025-04-01T16:36:35.997Z https://www.gsk.com/en-gb/media/press-releases/nejm-publishes-results-of-gsk-s-long-term-laba-safety-study-of-advair-diskus-in-children-aged-4-11-years-with-asthma/ 2025-04-01T16:36:36.743Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-continued-commitment-to-innovative-respiratory-research-demonstrated-in-european-respiratory-society-congress-data-presentations/ 2025-04-01T16:36:37.54Z https://www.gsk.com/en-gb/media/press-releases/gsk-in-licenses-anti-il-33r-monoclonal-antibody-for-severe-asthma-from-janssen/ 2025-04-01T16:36:27.497Z https://www.gsk.com/en-gb/media/press-releases/executive-director-change/ 2025-04-01T16:36:27.937Z https://www.gsk.com/en-gb/media/press-releases/new-phase-iii-data-shows-greater-treatment-response-with-gsk-s-benlysta-belimumab-vs-placebo-in-patients-with-highly-active-sle/ 2025-04-01T16:36:28.37Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/ 2025-04-01T16:36:28.877Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-us-filing-plans-for-closed-triple-combination-therapy-ffumecvi-in-patients-with-copd/ 2025-04-01T16:36:29.417Z https://www.gsk.com/en-gb/media/press-releases/board-and-committee-changes/ 2025-04-01T16:36:30.003Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-phase-ii-study-results-for-first-two-drug-long-acting-injectable-regimen-for-hiv-1-treatment/ 2025-04-01T16:36:30.66Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv-1-infection/ 2025-04-01T16:36:31.27Z https://www.gsk.com/en-gb/media/press-releases/gsk-confronts-copd-to-deliver-new-insights-from-across-the-globe-to-promote-improved-management-of-chronic-lung-disease/ 2025-04-01T16:36:31.777Z https://www.gsk.com/en-gb/media/press-releases/major-milestone-for-gsknih-candidate-ebola-vaccine-as-first-doses-shipped-to-liberia-for-use-in-phase-iii-clinical-trial/ 2025-04-01T16:36:21.417Z https://www.gsk.com/en-gb/media/press-releases/gsk-extends-its-price-freeze-commitment-to-ten-years-for-countries-graduating-from-gavi-support/ 2025-04-01T16:36:22.18Z https://www.gsk.com/en-gb/media/press-releases/board-committee-change/ 2025-04-01T16:36:22.757Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-three-part-transaction-with-novartis/ 2025-04-01T16:36:23.37Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-oxford-university-phase-i-trial-results-of-an-ebola-candidate-vaccine/ 2025-04-01T16:36:23.983Z https://www.gsk.com/en-gb/media/press-releases/four-initiatives-from-across-africa-win-share-of-global-us-1-million-healthcare-innovation-award/ 2025-04-01T16:36:24.54Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-overall-survival-results-from-phase-iii-combi-d-study-of-dabrafenib-tafinlar-and-trametinib-mekinist-combination/ 2025-04-01T16:36:25.133Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-seeking-additional-indication-for-eltrombopag-revolade/ 2025-04-01T16:36:25.68Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-start-of-phase-iii-lung-function-study-with-closed-triple-combination-treatment-ffumecvi-for-copd/ 2025-04-01T16:36:26.473Z https://www.gsk.com/en-gb/media/press-releases/gsk-strengthens-early-stage-vaccine-pipeline-with-acquisition-of-glycovaxyn-ag/ 2025-04-01T16:36:26.987Z https://www.gsk.com/en-gb/media/press-releases/update-on-three-part-transaction-with-novartis/ 2025-04-01T16:36:14.743Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-changes-to-its-board/ 2025-04-01T16:36:15.267Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-major-three-part-transaction-with-novartis/ 2025-04-01T16:36:15.69Z https://www.gsk.com/en-gb/media/press-releases/gsk-transaction-launch/ 2025-04-01T16:36:16.85Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-major-new-commitment-to-asia/ 2025-04-01T16:36:17.437Z https://www.gsk.com/en-gb/media/press-releases/gsk-transaction/ 2025-04-01T16:36:18.047Z https://www.gsk.com/en-gb/media/press-releases/gsk-becomes-partner-in-new-global-fund-to-accelerate-dementia-research/ 2025-04-01T16:36:18.9Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-programme-to-evaluate-retosiban-for-spontaneous-preterm-labour/ 2025-04-01T16:36:19.92Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-outcome-of-us-fda-advisory-committee-on-breo-ellipta-in-asthma/ 2025-04-01T16:36:09.96Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-2015-discovery-fast-track-challenge-seeks-early-drug-discovery-partnerships-with-academics-in-europe-canada-and-us/ 2025-04-01T16:36:10.62Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-encruse-ellipta-in-japan-for-the-treatment-of-copd/ 2025-04-01T16:36:11.2Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-meningitis-vaccination-in-the-uk/ 2025-04-01T16:36:11.733Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-establish-global-vaccines-rd-centre-in-the-us/ 2025-04-01T16:36:12.253Z https://www.gsk.com/en-gb/media/press-releases/malaria-vaccine-candidate-has-demonstrated-efficacy-over-3-4-years-of-follow-up/ 2025-04-01T16:36:12.72Z https://www.gsk.com/en-gb/media/press-releases/gsk-candidate-vaccine-for-the-prevention-of-shingles-demonstrates-overall-efficacy-of-972-which-does-not-diminish-in-the-age-groups-studied/ 2025-04-01T16:36:13.27Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-breo-ellipta-for-the-treatment-of-adults-with-asthma-in-the-us/ 2025-04-01T16:36:13.753Z https://www.gsk.com/en-gb/media/press-releases/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-eu-regulatory-submission-for-gene-therapy-to-treat-rare-disease-ada-scid/ 2025-04-01T16:36:14.227Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/ 2025-04-01T16:36:05.4Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-board-and-committee-changes/ 2025-04-01T16:36:05.863Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-unc-chapel-hill-announce-novel-partnership-to-accelerate-search-for-hiv-cure/ 2025-04-01T16:36:06.29Z https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-latest-report-from-the-o-neill-review-on-antibiotic-resistance/ 2025-04-01T16:36:06.79Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-eclipse-study-shows-association-between-improving-health-status-and-reduced-morbidity-and-mortality-in-patients-with-copd/ 2025-04-01T16:36:07.2Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-at-ats-on-the-role-of-blood-eosinophil-levels-as-a-potential-biomarker-in-the-treatment-of-copd/ 2025-04-01T16:36:07.657Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-japan-regulatory-application-for-mepolizumab-in-severe-eosinophilic-asthma/ 2025-04-01T16:36:08.22Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-support-training-of-frontline-health-workers-across-ghana-kenya-and-nigeria/ 2025-04-01T16:36:08.763Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-outcome-of-us-fda-advisory-committee-recommending-approval-of-mepolizumab-for-the-treatment-of-adults-with-severe-asthma/ 2025-04-01T16:36:09.367Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-create-independent-research-institute-with-goal-of-radically-changing-and-improving-medicines-development/ 2025-04-01T16:36:00.157Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-divestment-of-nimenrix-and-mencevax/ 2025-04-01T16:36:00.653Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-the-francis-crick-institute-join-forces-in-collaboration-to-forge-new-scientific-discoveries/ 2025-04-01T16:36:01.177Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-launch-2015-call-for-developing-country-healthcare-innovations-to-reduce-child-deaths/ 2025-04-01T16:36:01.69Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-malaria-candidate-vaccine-mosquirix-rts-s-receives-positive-opinion-from-european-regulators-for-the-prevention-of-malaria-in-young-children-in-sub-saharan-africa/ 2025-04-01T16:36:02.213Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-synflorix-receives-chmp-positive-opinion-for-major-label-extension/ 2025-04-01T16:36:02.787Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2015/ 2025-04-01T16:36:03.383Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-divest-ofatumumab-for-auto-immune-indications-to-novartis-for-up-to-1-billion-plus-royalties/ 2025-04-01T16:36:03.93Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-nejm-publication-of-phase-3b4-study-of-ambrisentan-and-tadalafil-as-first-line-combination-treatment-in-patients-with-pulmonary-arterial-hypertension/ 2025-04-01T16:36:04.527Z https://www.gsk.com/en-gb/media/press-releases/gsk-starts-build-of-its-largest-indian-tablet-manufacturing-pharmaceutical-factory-in-vemgal-karnataka/ 2025-04-01T16:36:04.94Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-results-from-the-summit-copd-cv-survival-study/ 2025-04-01T16:35:54.06Z https://www.gsk.com/en-gb/media/press-releases/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/ 2025-04-01T16:35:54.587Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-theravance-announce-intention-to-file-relvar-ellipta-for-copd-in-japan/ 2025-04-01T16:35:55.1Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-in-europe-for-novel-anti-il5-biological-nucala-mepolizumab-for-the-treatment-of-patients-with-severe-refractory-eosinophilic-asthma/ 2025-04-01T16:35:55.74Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-post-hoc-analysis-of-anoro-ellipta-data-assessing-markers-of-copd-deterioration-compared-to-tiotropium-or-placebo-using-a-novel-composite-endpoint/ 2025-04-01T16:35:56.323Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-for-chlorhexidine-gel-for-the-prevention-of-umbilical-cord-infections-in-newborn-babies/ 2025-04-01T16:35:57.35Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-new-data-comparing-incruse-ellipta-to-tiotropium-and-glycopyrronium-in-patients-with-copd/ 2025-04-01T16:35:58.187Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-to-expand-indication-for-volibris-in-pulmonary-arterial-hypertension/ 2025-04-01T16:35:58.76Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-latitude-timi-60-losmapimod-cardiovascular-study/ 2025-04-01T16:35:59.527Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-candidate-shingles-vaccine-demonstrates-90-efficacy-against-shingles-in-people-70-years-of-age-and-over/ 2025-04-01T16:35:47.713Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-advair-diskus-achieves-primary-endpoint-in-laba-safety-study-of-patients-with-asthma/ 2025-04-01T16:35:48.687Z https://www.gsk.com/en-gb/media/press-releases/gsk-profiles-innovative-rd-portfolio-to-investors/ 2025-04-01T16:35:49.38Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-headline-results-from-a-study-of-two-drug-injectable-regimen-for-hiv-maintenance-therapy/ 2025-04-01T16:35:50.137Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment/ 2025-04-01T16:35:50.723Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-nucala-mepolizumab-receives-approval-from-us-fda/ 2025-04-01T16:35:51.39Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-bliss-sc-study-of-benlysta-belimumab-administered-subcutaneously-in-patients-with-systemic-lupus-erythematosus/ 2025-04-01T16:35:52.08Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-to-expand-indication-for-volibris-in-treatment-of-pulmonary-arterial-hypertension/ 2025-04-01T16:35:52.773Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-study-of-sirukumab-in-giant-cell-arteritis/ 2025-04-01T16:35:53.507Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-for-nucala-mepolizumab-in-31-countries/ 2025-04-01T16:35:38.973Z https://www.gsk.com/en-gb/media/press-releases/comic-relief-and-gsk-form-five-year-partnership-to-fight-malaria-and-strengthen-health-systems/ 2025-04-01T16:35:40.353Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-top-line-results-from-sirukumab-phase-iii-programme-supporting-regulatory-filings-for-rheumatoid-arthritis-in-2016/ 2025-04-01T16:35:41.973Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-global-hiv-business-viiv-healthcare-to-acquire-bristol-myers-squibb-s-rd-hiv-assets/ 2025-04-01T16:35:42.533Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-rights-to-ofatumumab-for-auto-immune-indications-to-novartis/ 2025-04-01T16:35:43.167Z https://www.gsk.com/en-gb/media/press-releases/anoro-umeclidinium-vilanterol-receives-positive-opinion-from-the-chmp-in-europe-for-the-treatment-of-copd/ 2025-04-01T16:35:43.92Z https://www.gsk.com/en-gb/media/press-releases/anoro-umeclidiniumvilanterol-gains-marketing-authorisation-in-europe-for-the-treatment-of-copd/ 2025-04-01T16:35:44.837Z https://www.gsk.com/en-gb/media/press-releases/anoro-ellipta-umeclidiniumvilanterol-gains-approval-in-japan-for-the-treatment-of-copd/ 2025-04-01T16:35:45.647Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-flonase-allergy-relief-for-sale-over-the-counter-in-the-united-states/ 2025-04-01T16:35:46.623Z https://www.gsk.com/en-gb/media/press-releases/gsk-acquires-full-ownership-of-its-indonesian-consumer-healthcare-business/ 2025-04-01T16:35:30.697Z https://www.gsk.com/en-gb/media/press-releases/gsk-adds-detailed-clinical-trial-data-to-multi-sponsor-request-system-as-part-of-continued-commitment-to-data-transparency/ 2025-04-01T16:35:31.473Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-positive-interim-result-for-phase-iii-study-of-ofatumumab-as-maintenance-therapy-for-relapsed-cll/ 2025-04-01T16:35:32.16Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-top-line-results-from-a-phase-iii-study-of-ofatumumab-versus-physicians-choice-for-bulky-fludarabine-refractory-cll/ 2025-04-01T16:35:32.787Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-eu-authorisation-for-arzerra/ 2025-04-01T16:35:33.687Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-fda-approval-for-arzerra/ 2025-04-01T16:35:34.47Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-fda-approval-for-arzerra-ofatumumab/ 2025-04-01T16:35:35.417Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-mmv-announce-start-of-phase-iii-programme-of-tafenoquine-for-plasmodium-vivax-malaria/ 2025-04-01T16:35:36.683Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-offer-1-million-award-for-healthcare-innovations-in-developing-countries-that-reduce-child-deaths/ 2025-04-01T16:35:37.333Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-initiation-of-phase-iii-programme-with-fixed-dose-triple-combination-treatment-ffumecvi-in-patients-with-copd/ 2025-04-01T16:35:38.03Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-phase-iii-study-of-fluticasone-furoatevilanterol-in-copd-commenced-to-support-potential-future-filing-in-japan/ 2025-04-01T16:35:24.417Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-data-from-two-studies-evaluating-the-efficacy-and-safety-of-incruse-ellipta-when-added-to-relvar-breo-ellipta-in-patients-with-copd/ 2025-04-01T16:35:25.373Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-results-from-studies-comparing-anoro-ellipta-with-seretide-diskus-and-advair-diskus-in-patients-with-copd/ 2025-04-01T16:35:25.96Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-submission-to-us-regulatory-authorities-for-fluticasone-furoatevilanterol-in-asthma/ 2025-04-01T16:35:26.633Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-approval-in-canada-for-incruse-ellipta-umeclidinium-as-a-treatment-for-copd/ 2025-04-01T16:35:27.193Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-for-malaria-vaccine-candidate-rts-s/ 2025-04-01T16:35:27.79Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-headline-results-for-phase-iii-study-of-the-combination-of-tafinlar-dabrafenib-and-mekinist-trametinib-in-metastatic-melanoma/ 2025-04-01T16:35:28.463Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-commitment-to-improve-access-to-vaccines-with-5-year-price-freeze-for-countries-graduating-from-gavi-alliance-support/ 2025-04-01T16:35:29.097Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-strategic-investments-in-africa-to-increase-access-to-medicines-build-capacity-and-deliver-sustainable-growth/ 2025-04-01T16:35:29.967Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-altto-results-for-anti-her2-therapy-combination-in-the-adjuvant-breast-cancer-treatment-setting/ 2025-04-01T16:35:17.527Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-study-with-darapladib-did-not-meet-primary-endpoint-in-patients-following-an-acute-coronary-syndrome/ 2025-04-01T16:35:18.6Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-studies-for-mepolizumab-in-severe-eosinophilic-asthma/ 2025-04-01T16:35:19.523Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submission-for-umeclidinium-monotherapy-for-copd-in-japan/ 2025-04-01T16:35:20.32Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-results-of-phase-iii-petit2-study-of-eltrombopag-promacta-revolade-in-paediatric-patients-with-chronic-immune-thrombocytopenia/ 2025-04-01T16:35:20.983Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-cardiovascular-outcomes-study-with-losmapimod-in-patients-with-acute-coronary-syndrome/ 2025-04-01T16:35:21.517Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-programme-for-mepolizumab-in-patients-with-copd/ 2025-04-01T16:35:22.513Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-lll-study-for-mepolizumab-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis/ 2025-04-01T16:35:23.143Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-submission-to-us-regulatory-authorities-for-promacta-eltrombopag-for-severe-aplastic-anaemia/ 2025-04-01T16:35:23.727Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-the-start-of-a-phase-iii-study-with-eltrombopag-in-patients-with-myelodysplastic-syndromes/ 2025-04-01T16:35:12.03Z https://www.gsk.com/en-gb/media/press-releases/gsk-comment-china-investigation/ 2025-04-01T16:35:12.463Z https://www.gsk.com/en-gb/media/press-releases/gsk-gains-accelerated-fda-approval-for-combination-use-of-mekinist-trametinib-and-tafinlar-dabrafenib/ 2025-04-01T16:35:12.903Z https://www.gsk.com/en-gb/media/press-releases/gsk-gains-fda-breakthrough-therapy-designation-for-promacta-revolade-eltrombopag-for-severe-aplastic-anaemia/ 2025-04-01T16:35:13.4Z https://www.gsk.com/en-gb/media/press-releases/gsk-increases-stake-in-indian-pharmaceuticals-subsidiary-to-75-per-cent-after-open-offer/ 2025-04-01T16:35:13.9Z https://www.gsk.com/en-gb/media/press-releases/gsk-kicks-off-2014-discovery-fast-track-challenge-for-academic-drug-hunters-in-europe-canada-and-usa/ 2025-04-01T16:35:14.417Z https://www.gsk.com/en-gb/media/press-releases/gsk-plc-announces-major-three-part-transaction-with-novartis-to-drive-sustainable-sales-growth-improve-long-term-earnings-and-deliver-increasing-returns-to-shareholders/ 2025-04-01T16:35:14.99Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-from-phase-iii-stability-study-of-darapladib-in-patients-with-chronic-coronary-heart-disease/ 2025-04-01T16:35:15.737Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-for-once-weekly-tanzeumeperzan-albiglutide-showing-blood-glucose-lowering-up-to-three-years-in-type-2-diabetes/ 2025-04-01T16:35:16.65Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-at-ats-2014-from-study-evaluating-efficacy-and-safety-of-incruse-ellipta-added-to-advair-diskus-in-patients-with-copd/ 2025-04-01T16:35:08.137Z https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-historical-quarterly-restated-financial-information/ 2025-04-01T16:35:08.617Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-incruse-ellipta-umeclidinium-in-the-us-for-the-treatment-of-copd/ 2025-04-01T16:35:09.093Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-eu-marketing-authorisation-for-incruse-umeclidinium-for-the-treatment-of-copd/ 2025-04-01T16:35:09.583Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-eu-marketing-authorisation-for-mekinist-trametinib-for-patients-with-unresectable-or-metastatic-melanoma-with-a-braf-v600-mutation/ 2025-04-01T16:35:10.013Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-authorisation-for-once-weekly-type-2-diabetes-treatment-eperzan-albiglutide/ 2025-04-01T16:35:10.623Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-arnuity-ellipta-fluticasone-furoate-in-the-usa-for-the-treatment-of-asthma/ 2025-04-02T13:56:14.687Z https://www.gsk.com/en-gb/media/press-releases/gsks-promacta-eltrombopag-receives-fda-approval-of-an-additional-indication/ 2025-04-01T16:35:11.55Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-incruse-umeclidinium-for-the-treatment-of-copd/ 2025-04-01T16:34:55.957Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-mekinist-trametinib-in-metastatic-melanoma-with-a-braf-v600-mutation/ 2025-04-01T16:34:56.563Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-opinion-from-the-chmp-in-europe-for-once-weekly-eperzantm-albiglutide-for-the-treatment-of-type-2-diabetes/ 2025-04-01T16:34:57.417Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-for-once-weekly-type-2-diabetes-treatment-tanzeum-albiglutide/ 2025-04-01T16:34:58Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-recent-media-coverage-related-to-our-china-business/ 2025-04-01T16:34:59.023Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-bbc-panorama-programme/ 2025-04-01T16:34:59.51Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-media-reports/ 2025-04-01T16:35:00.067Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-recent-media-coverage-related-to-our-china-business/ 2025-04-01T16:35:00.687Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-uk-government-initiated-review-of-antibiotic-resistance/ 2025-04-01T16:35:07.59Z https://www.gsk.com/en-gb/media/press-releases/investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-does-not-meet-first-co-primary-endpoints-in-magrit-a-phase-iii-non-small-cell-lung-cancer-clinical-trial/ 2025-04-01T16:34:48.437Z https://www.gsk.com/en-gb/media/press-releases/motherapy-for-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/ 2025-04-01T16:34:49.427Z https://www.gsk.com/en-gb/media/press-releases/patient-recruitment-completes-in-landmark-relvar-breo-ellipta-study-to-understand-mortality-and-morbidity-summit-in-copd/ 2025-04-01T16:34:49.997Z https://www.gsk.com/en-gb/media/press-releases/prosensa-regains-rights-to-drisapersen-from-gsk-and-retains-rights-to-all-other-programmes-for-the-treatment-of-duchenne-muscular-dystrophy-dmd/ 2025-04-01T16:34:50.56Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-combined-use-of-mekinist-trametinib-and-tafinlar-dabrafenib-in-europe/ 2025-04-01T16:34:51.04Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-votrient-pazopanib-as-maintenance-therapy-for-advanced-ovarian-cancer-in-the-eu/ 2025-04-01T16:34:51.723Z https://www.gsk.com/en-gb/media/press-releases/results-from-phase-iii-patient-preference-study-of-gsk-s-votrient-pazopanib-vs-sutent-sunitinib-in-advanced-renal-cell-carcinoma-published-in-journal-of-clinical-oncology/ 2025-04-01T16:34:52.327Z https://www.gsk.com/en-gb/media/press-releases/serious-fraud-office-investigation/ 2025-04-01T16:34:53.523Z https://www.gsk.com/en-gb/media/press-releases/tafinlar-receives-fda-breakthrough-therapy-designation-for-non-small-cell-lung-cancer-with-braf-mutation/ 2025-04-01T16:34:54.05Z https://www.gsk.com/en-gb/media/press-releases/trametinib-mekinist-and-dabrafenib-tafinlar-combination-demonstrated-overall-survival-benefit-compared-to-vemurafenib/ 2025-04-01T16:34:54.78Z https://www.gsk.com/en-gb/media/press-releases/triumeq-dolutegravirabacavirlamivudine-single-tablet-regimen-receives-positive-chmp-opinion-in-europe-for-the-treatment-of-hiv/ 2025-04-01T16:34:42.48Z https://www.gsk.com/en-gb/media/press-releases/update-on-phase-iii-clinical-trial-of-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-in-non-small-cell-lung-cancer/ 2025-04-01T16:34:42.9Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-new-collaboration-with-janssen-to-investigate-single-tablet-regimen-for-maintenance-treatment-of-hiv-1/ 2025-04-01T16:34:43.39Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool/ 2025-04-01T16:34:43.76Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-phase-iii-data/ 2025-04-01T16:34:44.167Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-fda-approval-for-triumeq-abacavir-dolutegravir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-1-infection/ 2025-04-01T16:34:44.61Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-s-new-hiv-medicine-tivicaytm-dolutegravir-is-approved-in-europe/ 2025-04-01T16:34:44.99Z https://www.gsk.com/en-gb/media/press-releases/where-do-you-start-when-developing-a-new-medicine/ 2025-04-01T16:34:45.753Z https://www.gsk.com/en-gb/media/press-releases/ebola-vaccine-trials-fast-tracked-by-international-consortium/ 2025-04-01T16:34:47.07Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq-dolutegravirabacavirlamivudine-a-new-once-daily-single-pill-regimen-for-the-treatment-of-hiv/ 2025-04-01T16:34:33.317Z https://www.gsk.com/en-gb/media/press-releases/gsk-data-presented-at-ers-demonstrate-potential-of-blood-eosinophil-levels-to-help-inform-copd-treatment-decisions/ 2025-04-01T16:34:33.947Z https://www.gsk.com/en-gb/media/press-releases/new-england-journal-of-medicine-and-ers-publish-positive-results-from-gsk-phase-iii-studies-of-mepolizumab-in-patients-with-severe-eosinophilic-asthma/ 2025-04-01T16:34:34.587Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-line-combination-of-ambrisentan-and-tadalafil-reduces-risk-of-clinical-failure-compared-to-monotherapy-in-pulmonary-arterial-hypertension-outcomes-study/ 2025-04-01T16:34:35.297Z https://www.gsk.com/en-gb/media/press-releases/gsk-gold-and-the-copd-foundation-announce-formation-of-a-new-external-expert-governance-board-for-the-copd-assessment-test-cat/ 2025-04-01T16:34:35.847Z https://www.gsk.com/en-gb/media/press-releases/gsk-joins-with-research-councils-in-uk-and-south-africa-to-tackle-non-communicable-diseases-in-africa/ 2025-04-01T16:34:36.53Z https://www.gsk.com/en-gb/media/press-releases/gsk-china-investigation-outcome/ 2025-04-01T16:34:37.153Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-sir-philip-hampton-to-the-board-of-directors/ 2025-04-01T16:34:37.707Z https://www.gsk.com/en-gb/media/press-releases/international-collaboration-to-develop-inhaled-form-of-oxytocin-to-manage-bleeding-after-childbirth-in-developing-countries/ 2025-04-01T16:34:38.247Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-overall-survival-results-from-phase-iii-break-3-study-of-tafinlar-dabrafenib-in-patients-with-braf-v600e-mutant-metastatic-melanoma/ 2025-04-01T16:34:26.377Z https://www.gsk.com/en-gb/media/press-releases/gsk-commits-further-funding-to-advance-bioelectronics-research-with-creation-of-5-million-innovation-challenge-fund/ 2025-04-01T16:34:26.873Z https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-mr-urs-rohner-to-its-board-as-a-non-executive-director/ 2025-04-01T16:34:27.62Z https://www.gsk.com/en-gb/media/press-releases/stiefel-a-gsk-company-announces-start-of-phase-iii-study-of-subcutaneous-ofatumumab-for-pemphigus-vulgaris/ 2025-04-01T16:34:28.437Z https://www.gsk.com/en-gb/media/press-releases/data-published-on-anoro-ellipta-demonstrate-improved-lung-function-compared-to-tiotropium/ 2025-04-01T16:34:29.277Z https://www.gsk.com/en-gb/media/press-releases/gsk-update-on-current-development-status-of-the-gsknih-ebola-vaccine-candidate/ 2025-04-01T16:34:30.043Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submissions-for-mepolizumab-in-severe-eosinophilic-asthma/ 2025-04-01T16:34:30.727Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-seeking-additional-indication-for-eltrombopag-revolade-1/ 2025-04-01T16:34:31.27Z https://www.gsk.com/en-gb/media/press-releases/gsk-launches-first-call-for-proposals-for-research-in-to-non-communicable-diseases-in-sub-saharan-africa/ 2025-04-01T16:34:32.12Z https://www.gsk.com/en-gb/media/press-releases/gsk-leads-access-to-medicine-index-2014/ 2025-04-01T16:34:32.743Z https://www.gsk.com/en-gb/media/press-releases/new-england-journal-of-medicine-publishes-positive-results-from-combi-v-study-of-trametinib-mekinist-and-dabrafenib-tafinlar-combination/ 2025-04-01T16:34:16.887Z https://www.gsk.com/en-gb/media/press-releases/publication-of-circular-and-notice-of-general-meeting-relating-to-the-proposed-major-transaction-with-novartis/ 2025-04-01T16:34:17.483Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-first-phase-1-trial-results-of-a-candidate-ebola-vaccine/ 2025-04-01T16:34:18.683Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-on-transaction-with-novartis/ 2025-04-01T16:34:19.34Z https://www.gsk.com/en-gb/media/press-releases/gsk-names-winners-of-2014-discovery-fast-track-challenge/ 2025-04-01T16:34:21.507Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-established-products-portfolio/ 2025-04-01T16:34:22.897Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-seeking-extended-indication-for-ambrisentan-volibris-in-pulmonary-arterial-hypertension/ 2025-04-01T16:34:23.553Z https://www.gsk.com/en-gb/media/press-releases/new-european-consortium-formed-to-help-further-advance-development-of-a-gsknih-ebola-candidate-vaccine/ 2025-04-01T16:34:24.21Z https://www.gsk.com/en-gb/media/press-releases/pivotal-phase-iii-study-of-gsk-shingles-candidate-vaccine-meets-its-primary-endpoint/ 2025-04-01T16:34:24.923Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-seeking-additional-indication-for-eltrombopag-promacta/ 2025-04-01T16:34:25.863Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-regulatory-submission-for-anoro-umecvi-in-europe/ 2025-04-01T16:34:11.173Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submission-of-albiglutide-bla-to-the-us-fda-for-the-treatment-of-type-2-diabetes/ 2025-04-01T16:34:11.733Z https://www.gsk.com/en-gb/media/press-releases/gsk-signs-up-to-uk-government-s-public-health-responsibility-deal/ 2025-04-01T16:34:12.32Z https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-hans-wijers-to-its-board-as-a-non-executive-director/ 2025-04-01T16:34:12.827Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-biological-e-announce-joint-venture-to-develop-combination-vaccine-for-india-and-other-developing-countries/ 2025-04-01T16:34:13.497Z https://www.gsk.com/en-gb/media/press-releases/gsk-response-to-news-article-in-the-guardian-on-uk-legal-proceedings-related-to-avandia-rosiglitazone/ 2025-04-01T16:34:14.423Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-starts-phase-iii-study-to-test-combined-brafmek-inhibition-in-patients-with-braf-positive-melanoma-following-surgery/ 2025-04-01T16:34:15.047Z https://www.gsk.com/en-gb/media/press-releases/gsk-increases-stake-in-its-publicly-listed-consumer-healthcare-subsidiary-in-india-to-725-per-cent/ 2025-04-01T16:34:15.633Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-support-for-alltrials-campaign-for-clinical-data-transparency/ 2025-04-01T16:34:16.293Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2012/ 2025-04-01T16:34:07.27Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-european-submission-for-mek-monotherapy-and-brafmek-combination-therapy-in-metastatic-melanoma/ 2025-04-01T16:34:07.697Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-priority-review-designation-for-dolutegravir-as-a-potential-treatment-for-hiv-infection/ 2025-04-01T16:34:08.123Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-fda-acceptance-of-new-drug-application-nda-submission-in-the-us-for-anoro-elliptatm-for-copd/ 2025-04-01T16:34:08.587Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the-medicines-patent-pool-to-increase-access-to-hiv-medicines-for-children/ 2025-04-01T16:34:09.02Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-data-from-phase-iii-study-of-dolutegravir-vs-raltegravir-in-treatment-experienced-adults-with-hiv-1/ 2025-04-01T16:34:09.453Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-regulatory-submission-for-albiglutide-in-europe/ 2025-04-01T16:34:09.897Z https://www.gsk.com/en-gb/media/press-releases/young-scientists-challenged-by-gsk-and-mclaren-to-help-drive-science-behind-formula-1/ 2025-04-01T16:34:10.31Z https://www.gsk.com/en-gb/media/press-releases/500-000-endowment-gift-from-the-glaxosmithkline-foundation-expands-program-to-help-patients-with-cancer-and-their-families-at-the-children-s-hospital-of-philadelphia/ 2025-04-01T16:34:10.697Z https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2012-corporate-responsibility-report/ 2025-04-01T16:34:02.25Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-glaxosmithkline-receives-complete-response-from-fda-for-candidate-pandemic-h5n1-adjuvanted-influenza-vaccine/ 2025-04-01T16:34:02.663Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-four-strain-seasonal-influenza-vaccine-granted-marketing-authorisation-in-germany-and-the-uk/ 2025-04-01T16:34:03.26Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-start-of-phase-iii-study-of-benlysta-belimumab-in-patients-with-vasculitis/ 2025-04-01T16:34:03.683Z https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-recommends-approval-of-breo-tm-ellipta-tm-for-the-treatment-of-copd/ 2025-04-01T16:34:04.093Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-oft-statement-of-objections/ 2025-04-01T16:34:04.533Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-regulatory-submission-for-anoro-ellipta-umecvi-in-japan/ 2025-04-01T16:34:05.703Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2013/ 2025-04-01T16:34:06.13Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submission-for-umeclidinium-monotherapy-in-european-union/ 2025-04-01T16:34:06.527Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-impax-pharmaceuticals-terminate-their-collaboration-on-ipx066/ 2025-04-01T16:34:06.883Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submission-for-umeclidinium-monotherapy-in-us/ 2025-04-01T16:33:57.99Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-trametinib-us-pdufa-date-extended-to-3-september-2013/ 2025-04-01T16:33:58.367Z https://www.gsk.com/en-gb/media/press-releases/funding-boost-for-gsk-s-open-innovation-research-into-diseases-affecting-the-developing-world/ 2025-04-01T16:33:58.79Z https://www.gsk.com/en-gb/media/press-releases/gsk-gives-update-on-plans-to-share-detailed-clinical-trial-data-as-part-of-its-commitment-to-transparency/ 2025-04-01T16:33:59.263Z https://www.gsk.com/en-gb/media/press-releases/gsk-enters-new-commitment-with-the-gavi-alliance-to-supply-cervical-cancer-vaccine-for-girls-in-the-world-s-poorest-countries/ 2025-04-01T16:33:59.697Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-form-unique-partnership-to-save-the-lives-of-one-million-children/ 2025-04-01T16:34:00.143Z https://www.gsk.com/en-gb/media/press-releases/breo-ellipta-gains-us-approval-for-the-treatment-of-copd/ 2025-04-01T16:34:00.587Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-awarded-up-to-200-million-by-us-government-to-develop-new-antibiotics/ 2025-04-01T16:34:01.02Z https://www.gsk.com/en-gb/media/press-releases/grant-to-help-coordinate-campaign-to-train-one-million-community-health-workers-in-sub-saharan-africa/ 2025-04-01T16:34:01.403Z https://www.gsk.com/en-gb/media/press-releases/gsk-strengthens-vaccines-business-with-acquisition-of-okairos/ 2025-04-01T16:34:01.793Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-positive-top-line-results-from-pivotal-trial-of-arzerra-ofatumumab-combined-with-chlorambucil-in-previously-untreated-chronic-lymphocytic-leukaemia/ 2025-04-01T16:33:53.957Z https://www.gsk.com/en-gb/media/press-releases/two-new-gsk-oral-oncology-treatments-braf-inhibitor-tafinlar-dabrafenib-capsules-and-the-first-mek-inhibitor-mekinist-trametinib-tablets-approved-by-fda-as-single-agent-therapies/ 2025-04-01T16:33:54.407Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-late-stage-clinical-data-for-votrient-pazopanib-following-chemotherapy-in-women-with-advanced-epithelial-ovarian-cancer/ 2025-04-01T16:33:54.82Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-data-for-tykerbtyverb-lapatinib-in-combination-with-chemotherapy-for-advanced-her2-positive-gastric-cancer/ 2025-04-01T16:33:55.327Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-fda-advisory-committee-s-vote-on-availability-of-avandia-rosiglitazone/ 2025-04-01T16:33:55.743Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-regarding-2010-nature-medicine-study/ 2025-04-01T16:33:56.157Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-offer-for-its-thrombosis-brands-and-related-manufacturing-site/ 2025-04-01T16:33:56.617Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-data-from-five-phase-iii-studies-of-albiglutide-an-investigational-once-weekly-treatment-for-type-2-diabetes/ 2025-04-01T16:33:57.047Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-launch-1-million-award-to-discover-new-healthcare-innovations-for-reducing-child-deaths/ 2025-04-01T16:33:57.457Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-s-drisapersen-previously-gsk2402968pro051-to-receive-food-and-drug-administration-breakthrough-therapy-designation/ 2025-04-01T16:33:49.51Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-receives-positive-chmp-opinions-for-tafinlar-dabrafenib-and-tyverb-lapatinib/ 2025-04-01T16:33:49.883Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-us-submission-for-dabrafenibtrametinib-combination-in-metastatic-melanoma/ 2025-04-01T16:33:50.303Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-fluticasone-furoatevilanterol-submission-in-japan/ 2025-04-01T16:33:50.75Z https://www.gsk.com/en-gb/media/press-releases/gsk-response-to-china-investigation/ 2025-04-01T16:33:51.173Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-regarding-recent-meeting-with-chinese-authorities/ 2025-04-01T16:33:51.54Z https://www.gsk.com/en-gb/media/press-releases/update-on-gsk-consumer-nigeria-plc-scheme-of-arrangement/ 2025-04-01T16:33:52.123Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2013/ 2025-04-01T16:33:52.557Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-revolade-in-thrombocytopenia-associated-with-chronic-hepatitis-c-infection/ 2025-04-01T16:33:53.127Z https://www.gsk.com/en-gb/media/press-releases/gsk-adds-to-its-commitment-to-gavi-alliance-to-help-protect-millions-more-children-against-infectious-diseases/ 2025-04-01T16:33:53.517Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-albiglutide-us-pdufa-date-extended-by-three-months/ 2025-04-01T16:33:45.71Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-eu-submission-seeking-additional-indication-for-votrient-as-maintenance-therapy-for-advanced-ovarian-cancer/ 2025-04-01T16:33:46.137Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-eu-submission-for-cervarix-two-dose-schedule/ 2025-04-01T16:33:46.513Z https://www.gsk.com/en-gb/media/press-releases/gsk-launches-50-million-venture-capital-fund-to-invest-in-pioneering-bioelectronic-medicines-and-technologies/ 2025-04-01T16:33:46.93Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-approval-of-tivicay-dolutegravir-for-the-treatment-of-hiv-1/ 2025-04-01T16:33:47.423Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-from-the-european-commission-for-additional-indication-tyverb-lapatinib/ 2025-04-01T16:33:47.837Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-study-of-vercirnon-in-patients-with-moderate-to-severe-crohn-s-disease-did-not-meet-its-primary-endpoint/ 2025-04-01T16:33:48.237Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-from-the-european-commission-for-tafinlar/ 2025-04-01T16:33:48.633Z https://www.gsk.com/en-gb/media/press-releases/the-investigational-mage-a3-antigen-specific-cancer-immunotherapeutic-does-not-meet-first-co-primary-endpoint-in-phase-iii-melanoma-clinical-trial/ 2025-04-01T16:33:49.067Z https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-divest-lucozade-and-ribena-for-135-billion/ 2025-04-01T16:33:41.967Z https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-recommends-approval-in-us-of-umeclidiniumvilanterol-for-the-treatment-of-copd/ 2025-04-01T16:33:42.333Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-of-dolutegravir-vs-darunavir-in-treatment-naive-adults-with-hiv-1/ 2025-04-01T16:33:42.767Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-patent-ruling-reversal-on-lovaza/ 2025-04-01T16:33:43.163Z https://www.gsk.com/en-gb/media/press-releases/fda-grants-gsk-and-genmab-s-arzerra-ofatumumab-breakthrough-therapy-designation-for-previously-untreated-chronic-lymphocytic-leukaemia/ 2025-04-01T16:33:43.543Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-priority-review-from-fda-for-dabrafenibtrametinib-combination-in-metastatic-melanoma/ 2025-04-01T16:33:43.963Z https://www.gsk.com/en-gb/media/press-releases/gsk-signs-a-multi-year-agreement-with-barda-to-supply-the-us-government-with-anthrax-treatment/ 2025-04-01T16:33:44.347Z https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-receives-positive-opinion-from-the-chmp-in-europe-for-the-treatment-of-asthma-and-copd/ 2025-04-01T16:33:44.797Z https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-gains-approval-in-japan-for-the-treatment-of-asthma/ 2025-04-01T16:33:45.263Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-prosensa-announce-primary-endpoint-not-met-in-phase-iii-study-of-drisapersen-in-patients-with-duchenne-muscular-dystrophy/ 2025-04-01T16:33:37.963Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-from-the-european-commission-for-additional-revolade/ 2025-04-01T16:33:38.46Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-barclays-form-partnership-to-increase-access-to-healthcare-and-promote-economic-development-in-zambia/ 2025-04-01T16:33:38.897Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-reaches-agreement-with-aspen-to-divest-thrombosis-brands-and-related-manufacturing-site-for-07-billion/ 2025-04-01T16:33:39.343Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-genmab-announce-european-submission-to-regulatory-authorities-for-arzerra-ofatumumab-as-1st-line-treatment-of-chronic-lymphocytic-leukaemia-cll/ 2025-04-01T16:33:39.78Z https://www.gsk.com/en-gb/media/press-releases/malaria-vaccine-candidate-reduces-disease-over-18-months-of-follow-up-in-late-stage-study-of-more-than-15-000-infants-and-young-children/ 2025-04-01T16:33:40.217Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-genmab-announce-submission-to-us-regulatory-authorities-for-arzerra-ofatumumab-as-1st-line-treatment-of-chronic-lymphocytic-leukaemia-cll/ 2025-04-01T16:33:40.69Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/ 2025-04-01T16:33:41.1Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-for-fluticasone-furoate-monotherapy-for-asthma/ 2025-04-01T16:33:41.533Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-create-a-new-centre-of-excellence-for-sustainable-chemistry-in-brazil/ 2025-04-01T16:33:33.737Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-european-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/ 2025-04-01T16:33:34.117Z https://www.gsk.com/en-gb/media/press-releases/synflorix-receives-positive-opinion-from-the-chmp-in-europe-for-additional-pneumonia-indication/ 2025-04-01T16:33:34.51Z https://www.gsk.com/en-gb/media/press-releases/new-partnership-between-gsk-and-the-bill-melinda-gates-foundation-to-accelerate-research-into-vaccines-for-global-health-needs/ 2025-04-01T16:33:34.907Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-data-to-support-cervarix-two-dose-schedule-for-the-prevention-of-cervical-cancer-in-9-14-year-old-girls/ 2025-04-01T16:33:35.437Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-apprentice-and-graduate-engineering-opportunities-in-the-uk-during-tomorrow-s-engineers-week/ 2025-04-01T16:33:35.89Z https://www.gsk.com/en-gb/media/press-releases/gsk-names-inaugural-winners-in-unique-competition-for-academic-drug-hunters/ 2025-04-01T16:33:36.28Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-top-line-results-from-pivotal-phase-iii-study-of-darapladib-in-chronic-coronary-heart-disease/ 2025-04-01T16:33:36.677Z https://www.gsk.com/en-gb/media/press-releases/five-inspirational-organisations-from-malawi-bangladesh-mali-kenya-and-colombia-recognised-by-gsk-and-save-the-children/ 2025-04-01T16:33:37.117Z https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-receives-european-marketing-authorisation-for-the-treatment-of-asthma-and-copd/ 2025-04-01T16:33:37.53Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-amicus-therapeutics-announce-revised-fabry-agreement/ 2025-04-01T16:33:30.07Z https://www.gsk.com/en-gb/media/press-releases/tivicay-dolutegravir-receives-positive-chmp-opinion-in-europe-for-the-treatment-of-hiv/ 2025-04-01T16:33:30.47Z https://www.gsk.com/en-gb/media/press-releases/h5n1-vaccine-approved-by-the-us-fda-as-pandemic-influenza-preparedness-measure/ 2025-04-01T16:33:30.847Z https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-fda-decision-on-avandia-rosiglitazone/ 2025-04-01T16:33:31.233Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-receives-positive-chmp-opinion-for-cervarix-two-dose-schedule/ 2025-04-01T16:33:31.647Z https://www.gsk.com/en-gb/media/press-releases/synflorix-receives-european-marketing-authorisation-for-additional-pneumonia-indication/ 2025-04-01T16:33:32.033Z https://www.gsk.com/en-gb/media/press-releases/gsk-launches-global-consortium-with-six-renowned-cancer-research-centres/ 2025-04-01T16:33:32.517Z https://www.gsk.com/en-gb/media/press-releases/update-regarding-2010-nature-medicine-study/ 2025-04-01T16:33:32.92Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-results-from-pivotal-phase-iii-study-for-fluticasone-furoatevilanterol-in-asthma/ 2025-04-01T16:33:33.32Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-200-million-investment-in-uk-advanced-manufacturing-and-science/ 2025-04-01T16:33:25.867Z https://www.gsk.com/en-gb/media/press-releases/gsk-initiates-voluntary-open-offer-to-increase-stake-in-its-pharmaceuticals-subsidiary-in-india/ 2025-04-01T16:33:26.283Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-changes-to-its-global-sales-and-marketing-practices-to-further-ensure-patient-interests-come-first/ 2025-04-01T16:33:26.713Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-priority-review-from-fda-for-arzerra-ofatumumab-as-1st-line-treatment-for-chronic-lymphocytic-leukaemia-cll/ 2025-04-01T16:33:27.157Z https://www.gsk.com/en-gb/media/press-releases/update-on-patent-ruling-on-viiv-healthcares-epzicom-and-trizivir/ 2025-04-01T16:33:27.577Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-1-million-innovation-prize-for-bioelectronics-research/ 2025-04-01T16:33:28.027Z https://www.gsk.com/en-gb/media/press-releases/anoro-ellipta-approved-as-first-once-daily-dual-bronchodilator-for-the-treatment-of-copd-in-the-us/ 2025-04-01T16:33:28.393Z https://www.gsk.com/en-gb/media/press-releases/gsk-cervarix-two-dose-schedule-receives-european-marketing-authorisation/ 2025-04-01T16:33:28.797Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-mmv-announce-fda-breakthrough-therapy-designation-for-tafenoquine-for-plasmodium-vivax-malaria/ 2025-04-01T16:33:29.24Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-thrombosis-brands-and-related-manufacturing-site-to-aspen/ 2025-04-01T16:33:29.65Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-lucozade-and-ribena-to-suntory/ 2025-04-01T16:33:23.717Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-positive-opinion-in-europe-from-the-chmp-for-nimenrixreg/ 2025-04-01T16:33:24.103Z https://www.gsk.com/en-gb/media/press-releases/eu-and-us-regulatory-update-tykerbtyverb-lapatinib/ 2025-04-01T16:33:24.527Z https://www.gsk.com/en-gb/media/press-releases/gsk-results-announcement-for-q4-and-full-year-2011/ 2025-04-01T16:33:24.973Z https://www.gsk.com/en-gb/media/press-releases/gsk-joins-new-global-partnership-to-help-defeat-ten-neglected-tropical-diseases-by-2020/ 2025-04-01T16:33:25.437Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-changes-to-the-board/ 2025-04-01T16:33:19.887Z https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-the-recent-court-ruling-on-the-compas-study-in-mendoza-argentina/ 2025-04-01T16:33:20.337Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-initial-outcomes-from-pivotal-phase-iii-studies-for-once-daily-relovair-star-in-copd-and-asthma/ 2025-04-01T16:33:20.787Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-daiichi-sankyo-vaccines-joint-venture-to-become-largest-vaccines-company-in-japan/ 2025-04-01T16:33:21.223Z https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-phase-iii-study-of-dolutegravir-in-hiv/ 2025-04-01T16:33:21.61Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submissions-for-two-influenza-vaccines/ 2025-04-01T16:33:22.027Z https://www.gsk.com/en-gb/media/press-releases/gsk-reinforces-commitment-to-youth-training-with-launch-of-new-uk-apprenticeship-programme/ 2025-04-01T16:33:22.43Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-provides-further-update-on-divestment-of-non-core-over-the-counter-otc-brands/ 2025-04-01T16:33:22.843Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-vote-from-fda-panel-for-pazopanib-in-certain-advanced-soft-tissue-sarcomas/ 2025-04-01T16:33:23.283Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-to-increase-its-ownership-in-theravance/ 2025-04-01T16:33:15.787Z https://www.gsk.com/en-gb/media/press-releases/gsk-confirms-significant-investments-in-uk-manufacturing-ulverston-in-cumbria-selected-as-site-of-new-biopharmaceutical-factory/ 2025-04-01T16:33:16.173Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-completion-of-the-relovair-star-registrational-programme-and-topline-results-from-relovair-vs-advair-phase-iii-studies-in-copd/ 2025-04-01T16:33:16.557Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-further-data-from-phase-lll-studies-of-albiglutide-in-type-2-diabetes/ 2025-04-01T16:33:16.98Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-corporate-responsibility-commitments-in-2011-report/ 2025-04-02T13:52:45.883Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-yale-university-establish-drug-discovery-collaboration-to-design-potential-new-class-of-medicines/ 2025-04-01T16:33:17.883Z https://www.gsk.com/en-gb/media/press-releases/gsk-confirms-offer-to-acquire-human-genome-sciences-for-us-1300-per-share-in-cash/ 2025-04-01T16:33:18.273Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-two-non-executive-directors-to-its-board/ 2025-04-01T16:33:18.687Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-reaches-agreement-to-divest-non-core-over-the-counter-otc-brands-in-international-markets-for-164-million/ 2025-04-01T16:33:19.113Z https://www.gsk.com/en-gb/media/press-releases/james-shannon-named-glaxosmithkline-chief-medical-officer/ 2025-04-01T16:33:19.477Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2012/ 2025-04-01T16:33:12.023Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-commence-tender-offer-to-acquire-human-genome-sciences-for-us-1300-per-share-in-cash/ 2025-04-01T16:33:12.45Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-university-of-nottingham-collaborate-to-create-centre-of-excellence-for-sustainable-chemistry/ 2025-04-01T16:33:12.863Z https://www.gsk.com/en-gb/media/press-releases/children-in-ghana-to-be-vaccinated-against-diarrhoeal-disease-with-the-introduction-of-gsk-s-rotarix-vaccine/ 2025-04-01T16:33:13.363Z https://www.gsk.com/en-gb/media/press-releases/gsk-commences-tender-offer-to-acquire-human-genome-sciences-for-us-1300-per-share-in-cash/ 2025-04-01T16:33:13.75Z https://www.gsk.com/en-gb/media/press-releases/stiefel-receives-us-fda-approval-of-fabior-foam-01/ 2025-04-01T16:33:14.153Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-bbc-panorama-broadcast-the-truth-about-tax/ 2025-04-01T16:33:14.573Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-to-fully-acquire-cellzome-for-61-million/ 2025-04-01T16:33:14.977Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-completes-transaction-to-increase-its-ownership-in-theravance/ 2025-04-01T16:33:15.377Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-tender-offer-to-acquire-human-genome-sciences/ 2025-04-01T16:33:07.753Z https://www.gsk.com/en-gb/media/press-releases/two-overall-winners-announced-at-prestigious-national-award-ceremony-in-london-s-science-museum/ 2025-04-01T16:33:08.157Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-votrient-for-treatment-of-patients-with-certain-types-of-advanced-soft-tissue-sarcoma/ 2025-04-01T16:33:08.587Z https://www.gsk.com/en-gb/media/press-releases/innovative-public-private-collaboration-launches-to-tackle-antibiotic-research/ 2025-04-01T16:33:09.05Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-opinion-from-european-chmp-for-pazopanib-in-the-treatment-of-patients-with-certain-advanced-soft-tissue-sarcomas/ 2025-04-01T16:33:09.473Z https://www.gsk.com/en-gb/media/press-releases/gsk-secures-future-of-local-playing-fields-with-fields-in-trust-as-part-of-london-2012-legacy/ 2025-04-01T16:33:09.923Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-european-authorisation-for-nimenrix-meningococcal-group-a-c-w-135-and-y-conjugate-vaccine/ 2025-04-01T16:33:10.3Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-programme-for-combination-of-dabrafenib-gsk2118436-and-trametinib-gsk1120212-in-braf-v600-mutation-positive-metastatic-cutaneous-melanoma/ 2025-04-01T16:33:10.707Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-confirms-us-district-court-ruling-in-pronova-biopharma-s-favour-on-lovaza-patents/ 2025-04-01T16:33:11.217Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-expiration-of-hart-scott-rodino-waiting-period-for-tender-offer-for-hgs/ 2025-04-01T16:33:11.627Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submissions-in-the-eu-us-for-new-indications-for-promacta-revolade/ 2025-04-01T16:33:03.693Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-epsrc-announce-creation-of-new-chair-in-sustainable-chemistry-at-the-university-of-nottingham/ 2025-04-01T16:33:04.087Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-xenoport-receive-fda-approval-for-horizant-for-postherpetic-neuralgia/ 2025-04-01T16:33:04.487Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-concludes-previously-announced-agreement-in-principle-to-resolve-multiple-investigations-with-us-government-and-numerous-states/ 2025-04-01T16:33:04.91Z https://www.gsk.com/en-gb/media/press-releases/gsk-extends-tender-offer-for-all-outstanding-shares-of-human-genome-sciences/ 2025-04-01T16:33:05.347Z https://www.gsk.com/en-gb/media/press-releases/gsk-sets-20-july-for-expiration-of-tender-offer-to-acquire-human-genome-sciences/ 2025-04-01T16:33:05.797Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-52-week-data-from-phase-iii-study-of-once-weekly-albiglutide-in-type-2-diabetes/ 2025-04-01T16:33:06.207Z https://www.gsk.com/en-gb/media/press-releases/gsk-continues-with-tender-offer-to-acquire-all-outstanding-shares-of-human-genome-sciences/ 2025-04-01T16:33:06.603Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-menhibrix/ 2025-04-01T16:33:06.973Z https://www.gsk.com/en-gb/media/press-releases/stiefel-signs-worldwide-acquisition-and-license-agreement-for-toctino/ 2025-04-01T16:33:07.353Z https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-positive-initial-data-from-phase-iii-study-of-dolutegravir-based-regimen-vs-atripla-in-hiv/ 2025-04-01T16:32:59.733Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-data-from-harmony-8-and-completion-of-clinical-registration-package-for-albiglutide-in-type-2-diabetes/ 2025-04-01T16:33:00.17Z https://www.gsk.com/en-gb/media/press-releases/us-regulatory-update-tykerb-lapatinib/ 2025-04-01T16:33:00.547Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-celebrates-its-role-in-supporting-the-biggest-anti-doping-operation-in-the-history-of-the-olympic-games/ 2025-04-01T16:33:01.037Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-human-genome-sciences-for-us-1425-per-share-in-cash/ 2025-04-01T16:33:01.437Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-amicus-therapeutics-expand-fabry-disease-collaboration/ 2025-04-01T16:33:01.9Z https://www.gsk.com/en-gb/media/press-releases/innovative-uk-research-project-to-study-the-value-medicines-bring-to-patients-in-the-real-world/ 2025-04-01T16:33:02.33Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-iii-programme-of-sirukumab-in-rheumatoid-arthritis/ 2025-04-01T16:33:02.733Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submissions-in-the-eu-and-us-for-dabrafenib-and-trametinib/ 2025-04-01T16:33:03.237Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-human-genome-sciences/ 2025-04-01T16:32:55.43Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-reaches-agreement-to-divest-majority-of-classic-brands-in-australia-for-172m/ 2025-04-01T16:32:55.797Z https://www.gsk.com/en-gb/media/press-releases/european-commission-grants-marketing-authorisation-for-pazopanib-votrient-in-the-treatment-of-certain-advanced-soft-tissue-sarcoma-subtypes/ 2025-04-01T16:32:56.257Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2012/ 2025-04-01T16:32:56.643Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-acquisition-of-79-of-human-genome-sciences-shares-commences-subsequent-offering-period/ 2025-04-01T16:32:57.147Z https://www.gsk.com/en-gb/media/press-releases/maximuscle-powers-vodafone-mclaren-mercedes-drivers-through-the-2012-formula-1-season/ 2025-04-01T16:32:57.713Z https://www.gsk.com/en-gb/media/press-releases/gsk-pre-broadcast-statement-on-bbc-panorama-the-truth-about-sports-products-19-july-2012/ 2025-04-01T16:32:58.103Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-announces-submission-for-a-new-indication-for-synflorix-in-europe/ 2025-04-01T16:32:58.487Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-five-million-shares-in-response-genetics-for-us-110-per-share-in-cash/ 2025-04-01T16:32:58.887Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-completion-of-the-phase-iii-programme-for-once-daily-lamalaba-umecvi-in-copd/ 2025-04-01T16:32:59.293Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-fda-acceptance-of-ffvi-new-drug-application-nda-submission-in-the-us-for-copd/ 2025-04-01T16:32:51.577Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-changes-to-its-board-and-committees/ 2025-04-01T16:32:51.97Z https://www.gsk.com/en-gb/media/press-releases/shionogi-viiv-healthcare-announces-completion-of-initial-clinical-registration-package-for-dolutegravir-in-hiv/ 2025-04-01T16:32:52.337Z https://www.gsk.com/en-gb/media/press-releases/millions-of-children-in-pakistan-to-be-protected-against-pneumococcal-disease-with-gsk-s-synflorix/ 2025-04-01T16:32:52.85Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-further-initiatives-to-advance-openness-and-collaboration-to-help-tackle-global-health-challenges/ 2025-04-01T16:32:53.293Z https://www.gsk.com/en-gb/media/press-releases/results-from-five-phase-iii-studies-presented-for-gsk-s-two-candidate-quadrivalent-influenza-vaccines/ 2025-04-01T16:32:53.693Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-glaxosmithkline-s-four-strain-seasonal-influenza-vaccine-for-use-in-the-us/ 2025-04-01T16:32:54.157Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-regulatory-submission-for-umecvi-lamalaba-in-the-us/ 2025-04-01T16:32:54.567Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-provides-update-on-divestment-of-non-core-over-the-counter-otc-brands/ 2025-04-01T16:32:55.033Z https://www.gsk.com/en-gb/media/press-releases/gsk-extends-pneumococcal-vaccine-agreement-with-gavi-alliance/ 2025-04-01T16:32:47.747Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-initiate-phase-iii-trial-of-belimumab-benlystareg-administered-subcutaneously-in-subjects-with-systemic-lupus-erythematosus/ 2025-04-01T16:32:48.177Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-phase-lll-data-for-lapatinib-at-san-antonio-breast-cancer-symposium/ 2025-04-01T16:32:48.593Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-help-for-heroes-partner-to-support-the-rehabilitation-of-wounded-servicemen-and-women-in-the-uk/ 2025-04-01T16:32:49.067Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-in-response-to-the-prime-minister-s-speech-on-life-sciences/ 2025-04-01T16:32:49.5Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-glaxosmithkline-submits-additional-information-for-candidate-meningococcal-and-hib-combination-vaccine/ 2025-04-01T16:32:49.933Z https://www.gsk.com/en-gb/media/press-releases/reporting-on-a-core-earnings-basis-will-begin-with-effect-from-q1-2012/ 2025-04-01T16:32:50.307Z https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-gavi-alliance-decision-to-introduce-vaccines-against-cervical-cancer-and-rubella-in-the-world-s-poorest-countries/ 2025-04-01T16:32:50.76Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-welcomes-innovative-knowledge-sharing-collaboration-to-break-deadlock-in-antibiotic-discovery-and-development/ 2025-04-01T16:32:51.19Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-initial-data-from-the-first-completed-phase-lll-study-of-albiglutide-in-type-2-diabetes/ 2025-04-01T16:32:43.653Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-phase-iii-results-for-eltrombopag-in-hepatitis-c-virus-related-thrombocytopenia/ 2025-04-01T16:32:44.043Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-reaches-agreement-in-principle-to-resolve-multiple-investigations-with-us-government/ 2025-04-01T16:32:44.463Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q3-performance-with-underlying-sales-growth-of-6-and-reported-sales-growth-of-3/ 2025-04-01T16:32:44.92Z https://www.gsk.com/en-gb/media/press-releases/gsk-joins-wipo-research-open-innovation-platform-as-part-of-its-commitment-to-tackling-diseases-of-the-developing-world/ 2025-04-01T16:32:45.3Z https://www.gsk.com/en-gb/media/press-releases/first-results-from-ongoing-phase-iii-trial-show-malaria-vaccine-candidate-rts-sstar-reduces-the-risk-of-malaria-by-half-in-african-children-aged-5-to-17-months/ 2025-04-01T16:32:45.697Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-glaxosmithkline-receives-complete-response-letter-from-fda-for-candidate-meningococcal-and-hib-combination-vaccine/ 2025-04-01T16:32:46.16Z https://www.gsk.com/en-gb/media/press-releases/lucozade-to-help-drive-vodafone-mclaren-mercedes-performance/ 2025-04-01T16:32:46.55Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-gsk-and-mclaren-group-announce-innovative-strategic-partnership/ 2025-04-01T16:32:46.943Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-gsk-commits-1-million-in-cervical-cancer-vaccine-to-new-cooperative-effort-aimed-at-reducing-deaths-from-womens-cancers/ 2025-04-01T16:32:47.357Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-amicus-therapeutics-commence-second-phase-iii-study-of-amigal-for-fabry-disease/ 2025-04-01T16:32:39.937Z https://www.gsk.com/en-gb/media/press-releases/gsk-gives-update-on-agreement-with-world-health-organization-to-support-de-worming-of-school-age-children-in-endemic-countries/ 2025-04-01T16:32:40.407Z https://www.gsk.com/en-gb/media/press-releases/lapatinib-clinical-trial-update/ 2025-04-01T16:32:40.787Z https://www.gsk.com/en-gb/media/press-releases/jens-eckstein-named-president-of-sr-one-gsk-s-venture-healthcare-group/ 2025-04-01T16:32:41.21Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-gsk-shows-sign-of-things-to-come-at-london-2012-olympic-and-paralympic-games/ 2025-04-01T16:32:41.69Z https://www.gsk.com/en-gb/media/press-releases/gsk-awarded-contract-by-barda-to-support-research-on-potential-novel-antibiotic/ 2025-04-01T16:32:42.083Z https://www.gsk.com/en-gb/media/press-releases/gsk-takes-minority-stake-in-new-spin-out-autifony-therapeutics/ 2025-04-01T16:32:42.457Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-impax-announce-positive-topline-results-of-ascend-pd-phase-iii-study-of-ipx066-in-advanced-parkinson-s-disease/ 2025-04-01T16:32:42.867Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-enigma-diagnostics-announce-collaboration-on-assay-development-and-commercialisation-of-enigma-s-ml-platform/ 2025-04-01T16:32:43.233Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-xenoport-submit-supplemental-new-drug-application-to-fda-for-horizant-in-postherpetic-neuralgia/ 2025-04-01T16:32:35.94Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-stiefel-a-gsk-company-files-nda-for-tazarotene-foam/ 2025-04-01T16:32:36.32Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-performance-with-underlying-sales-growthstar-of-5-increased-pipeline-visibility-and-dividend-of-16p-up-7/ 2025-04-01T16:32:36.73Z https://www.gsk.com/en-gb/media/press-releases/eu-and-us-regulatory-update-votrientreg-pazopanib/ 2025-04-01T16:32:37.167Z https://www.gsk.com/en-gb/media/press-releases/london-2012-partner-glaxosmithkline-shares-scientific-expertise-with-world-anti-doping-agency-to-help-fight-against-abuse-of-drugs-in-sport/ 2025-04-01T16:32:37.57Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-new-approval-for-rotarix-and-significant-new-indication-for-lamictalreg-lamotrigine-in-japan/ 2025-04-01T16:32:38.02Z https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-external-scientists-to-diseases-of-the-developing-world-research-campus/ 2025-04-01T16:32:38.46Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-university-of-east-anglia-study-examining-health-impacts-of-anticholinergic-medicines-for-over-65s/ 2025-04-01T16:32:39.147Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-agreements-with-state-attorneys-general-on-former-cidra-manufacturing-facility/ 2025-04-01T16:32:39.507Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-purchase-shenzhen-neptunus-stake-in-previously-formed-joint-venture-for-influenza-vaccines-in-china/ 2025-04-01T16:32:31.633Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-valeant-announce-us-fda-approval-of-potiga-ezogabine/ 2025-04-01T16:32:32.047Z https://www.gsk.com/en-gb/media/press-releases/millions-of-children-in-the-world-s-poorest-countries-could-receive-vaccination-against-rotavirus-diarrhoeal-disease-under-new-offer-made-by-gsk-to-the-gavi-alliance/ 2025-04-01T16:32:32.497Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-s-pazopanib-improved-progression-free-survival-in-adults-with-certain-soft-tissue-sarcomas/ 2025-04-01T16:32:32.913Z https://www.gsk.com/en-gb/media/press-releases/gsk-forms-partnership-with-three-leading-ngos-to-address-shortage-of-frontline-healthcare-workers-in-least-developed-countries-ldcs/ 2025-04-01T16:32:33.283Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-receive-positive-opinion-in-europe-from-the-chmp-for-benlysta-belimumab/ 2025-04-01T16:32:33.747Z https://www.gsk.com/en-gb/media/press-releases/young-peoples-health-charity-steps-forward-to-claim-top-accolade-and-35-000/ 2025-04-01T16:32:34.157Z https://www.gsk.com/en-gb/media/press-releases/pharmaceutical-industry-and-university-create-manchester-collaborative-centre-for-inflammation-research/ 2025-04-01T16:32:34.613Z https://www.gsk.com/en-gb/media/press-releases/gsk-q1-performance-demonstrates-continued-progress-with-delivery-of-underlying-sales-growth-cash-generation-and-pipeline-visibility/ 2025-04-01T16:32:34.983Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-valeant-respond-to-fda-on-ezogabine/ 2025-04-01T16:32:35.38Z https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-key-agreement-to-support-global-preparedness-against-pandemic-influenza/ 2025-04-01T16:32:27.943Z https://www.gsk.com/en-gb/media/press-releases/gsk-european-regulatory-update-on-pandemrix/ 2025-04-01T16:32:28.31Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-tyverbreg-lapatinib/ 2025-04-01T16:32:28.69Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-non-core-otc-products-to-be-divested/ 2025-04-01T16:32:29.107Z https://www.gsk.com/en-gb/media/press-releases/unique-research-alliance-expands-collaboration-opportunities-at-state-of-the-art-medical-imaging-centre/ 2025-04-01T16:32:29.523Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-xenoport-receive-fda-approval-for-horizant/ 2025-04-01T16:32:30.057Z https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-payments-for-research-consulting-and-advising-by-us-healthcare-professionals/ 2025-04-01T16:32:30.433Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-confirms-pronova-biopharma-reaches-agreement-with-apotex-regarding-lovaza-us-patent-litigation/ 2025-04-01T16:32:30.83Z https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2010-corporate-responsibility-report/ 2025-04-02T13:54:08.417Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-avodart-dutasteride-for-prostate-cancer-risk-reduction/ 2025-04-01T16:32:24.087Z https://www.gsk.com/en-gb/media/press-releases/gsk-launches-london-2012-initiative-with-king-s-college-london-to-inspire-young-people-into-science-careers/ 2025-04-01T16:32:24.523Z https://www.gsk.com/en-gb/media/press-releases/gsk-supports-recovery-efforts-to-help-those-affected-by-the-japan-earthquake/ 2025-04-01T16:32:24.943Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-topline-results-of-phase-lll-study-of-ipx066-in-advanced-parkinson-s-disease/ 2025-04-01T16:32:25.36Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-tolerx-announce-phase-iii-defend-1-study-of-otelixizumab-in-type-1-diabetes-did-not-meet-its-primary-endpoint/ 2025-04-01T16:32:25.797Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-fda-approval-of-benlystareg-belimumab-for-the-treatment-of-systemic-lupus-erythematosus/ 2025-04-01T16:32:26.277Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-two-non-executive-directors-to-its-board-1/ 2025-04-01T16:32:26.733Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-nimenrixreg-menacwy-vaccine/ 2025-04-01T16:32:27.14Z https://www.gsk.com/en-gb/media/press-releases/gsk-outlines-new-plan-to-drive-recruitment-and-attract-graduate-talent-in-the-uk/ 2025-04-01T16:32:27.517Z https://www.gsk.com/en-gb/media/press-releases/reward-for-charities-bridging-gaps-in-health-care-provision/ 2025-04-01T16:32:19.833Z https://www.gsk.com/en-gb/media/press-releases/david-redfern-appointed-as-new-chairman-of-viiv-healthcare/ 2025-04-01T16:32:20.25Z https://www.gsk.com/en-gb/media/press-releases/first-african-country-introduces-gsk-s-pneumococcal-vaccine-through-innovative-financing-mechanism/ 2025-04-01T16:32:20.69Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-moving-to-new-building-at-philadelphia-navy-yard/ 2025-04-01T16:32:21.137Z https://www.gsk.com/en-gb/media/press-releases/gsk-revises-us-avandia-label-to-include-new-restrictions-on-use/ 2025-04-01T16:32:21.527Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-publication-of-bliss-52-phase-lll-study-results-for-benlysta-in-the-lancet/ 2025-04-01T16:32:21.913Z https://www.gsk.com/en-gb/media/press-releases/gsk-results-announcement-for-the-fourth-quarter/ 2025-04-01T16:32:22.333Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-the-sale-of-its-entire-shareholding-in-quest-diagnostics/ 2025-04-01T16:32:22.707Z https://www.gsk.com/en-gb/media/press-releases/update-on-pandemrix-and-interim-finnish-report-on-narcolepsy/ 2025-04-01T16:32:23.17Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-actelion-discontinue-clinical-development-of-almorexant/ 2025-04-01T16:32:23.657Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-complete-response-letter-for-avodart-for-prostate-cancer-risk-reduction-supplemental-indication/ 2025-04-01T16:32:15.947Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-start-of-two-phase-iii-studies-in-advancedmetastatic-melanoma/ 2025-04-01T16:32:16.347Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-and-valeant-receive-positive-opinion-in-europe-from-the-chmp-for-trobalt-retigabine/ 2025-04-01T16:32:16.723Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-prosensa-announce-start-of-phase-iii-study-of-investigational-duchenne-muscular-dystrophy-medication/ 2025-04-01T16:32:17.11Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-commences-phase-iii-study-of-intravenous-zanamivir-for-hospitalised-patients-with-influenza/ 2025-04-01T16:32:17.683Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-q4-2010-legal-charge/ 2025-04-01T16:32:18.09Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-chemocentryx-announce-initiation-of-phase-iii-study-of-gsk-786-formerly-traficet-en-for-the-treatment-of-crohn-s-disease/ 2025-04-01T16:32:18.52Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-dentsply-international-sign-global-agreement-to-create-a-portfolio-of-co-branded-professional-oral-care-products/ 2025-04-01T16:32:18.973Z https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-60-minutes/ 2025-04-01T16:32:19.36Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-european-regulatory-update-on-pandemrix/ 2025-04-01T16:32:11.747Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-receive-european-authorisation-for-benlysta-belimumab/ 2025-04-01T16:32:12.16Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-valeant-receive-european-authorisation-for-trobalt-retigabine/ 2025-04-01T16:32:12.58Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-progression-of-lamalaba-combination-treatment-into-phase-iii-development-for-copd/ 2025-04-01T16:32:13.01Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-results-of-two-pivotal-phase-iii-studies-for-relovair-in-copd/ 2025-04-01T16:32:13.383Z https://www.gsk.com/en-gb/media/press-releases/gsk-european-regulatory-update-on-pandemrix-1/ 2025-04-01T16:32:13.823Z https://www.gsk.com/en-gb/media/press-releases/data-published-in-the-lancet-oncology-support-high-efficacy-previously-demonstrated-by-cervarixreg-hpv-16-and-18-vaccine-against-precancerous-cervical-lesions/ 2025-04-01T16:32:14.317Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-theravance-commence-maba-phase-iib-copd-study/ 2025-04-01T16:32:14.713Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-impax-pharmaceuticals-enter-global-agreement-to-develop-and-commercialise-a-late-stage-compound-for-parkinson-s-disease/ 2025-04-01T16:32:15.123Z https://www.gsk.com/en-gb/media/press-releases/andrew-witty-appointed-lead-non-executive-board-member-for-the-department-for-business-innovation-and-skills-bis/ 2025-04-01T16:32:15.55Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-strengthen-nutritional-healthcare-business-with-acquisition-of-maxinutrition/ 2025-04-01T16:32:07.907Z https://www.gsk.com/en-gb/media/press-releases/phase-iii-study-in-her2-positive-advanced-breast-cancer-shows-overall-survival-benefit-when-tykerb-is-combined-with-paclitaxel/ 2025-04-01T16:32:08.337Z https://www.gsk.com/en-gb/media/press-releases/data-from-tykerb-investigational-phase-iii-studies-in-neo-adjuvant-her2-positive-breast-cancer-presented-at-breast-cancer-symposium/ 2025-04-01T16:32:08.78Z https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-to-acquire-nanjing-meirui-pharmaceuticals-in-china/ 2025-04-01T16:32:09.19Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-fda-extension-of-benlysta-pdufa-target-date-to-10th-march-2011/ 2025-04-01T16:32:09.587Z https://www.gsk.com/en-gb/media/press-releases/avodart-reviewed-by-fda-advisory-committee-for-prostate-cancer-risk-reduction/ 2025-04-01T16:32:09.967Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-valeant-announce-receipt-of-us-fda-complete-response-letter-for-ezogabine/ 2025-04-01T16:32:10.393Z https://www.gsk.com/en-gb/media/press-releases/government-patent-box-proposals-transform-uk-attractiveness-for-investment/ 2025-04-01T16:32:10.82Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-to-increase-its-shareholding-in-theravance/ 2025-04-01T16:32:11.263Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-jsc-binnopharm-enter-vaccine-production-alliance-in-russia/ 2025-04-01T16:32:03.897Z https://www.gsk.com/en-gb/media/press-releases/human-genome-sciences-and-glaxosmithkline-announce-vote-of-fda-advisory-committee-to-recommend-approval-of-benlysta-for-systemic-lupus-erythematosus/ 2025-04-01T16:32:04.283Z https://www.gsk.com/en-gb/media/press-releases/new-study-findings-show-no-benefit-of-prescription-omega-3-fatty-acids-in-prevention-of-recurrent-symptomatic-atrial-fibrillation-in-affected-patients/ 2025-04-01T16:32:04.653Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-fiocruz-extend-innovative-collaboration-to-research-and-develop-new-medicines-for-neglected-tropical-diseases/ 2025-04-01T16:32:05.077Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-approval-in-japan-for-two-medicines-revolade-and-xyzal/ 2025-04-01T16:32:05.453Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-amicus-therapeutics-enter-exclusive-worldwide-agreement-to-develop-and-commercialise-amigal-for-fabry-disease/ 2025-04-01T16:32:05.88Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-previously-reported-settlement-with-us-department-of-justice-regarding-former-manufacturing-plant/ 2025-04-01T16:32:06.3Z https://www.gsk.com/en-gb/media/press-releases/gsk-outlines-approach-to-delivering-advances-in-the-treatment-of-rare-diseases/ 2025-04-01T16:32:06.677Z https://www.gsk.com/en-gb/media/press-releases/gsk-fondazione-telethon-and-fondazione-san-raffaele-to-collaborate-on-gene-therapy-for-rare-diseases/ 2025-04-01T16:32:07.127Z https://www.gsk.com/en-gb/media/press-releases/gsk-increases-support-for-who-strategy-to-improve-children-s-health-with-new-5-year-commitment-to-expand-donations-of-albendazole-medicine/ 2025-04-01T16:32:07.5Z https://www.gsk.com/en-gb/media/press-releases/gsk-takes-minority-stake-in-newly-formed-convergence-pharmaceuticals/ 2025-04-01T16:32:00.027Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-herpevac-trial-for-women-evaluating-simplirix-herpes-simplex-vaccine/ 2025-04-01T16:32:00.5Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-eu-approval-for-a-new-therapeutic-indication-for-arixtra-fondaparinux/ 2025-04-01T16:32:00.89Z https://www.gsk.com/en-gb/media/press-releases/gsk-regulatory-update-on-avandia-following-ema-and-fda-reviews/ 2025-04-01T16:32:01.267Z https://www.gsk.com/en-gb/media/press-releases/gsk-eu-regulatory-update-on-pandemrix/ 2025-04-01T16:32:01.747Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-combination-icslaba-phase-ii-results-in-the-relovair-development-programme/ 2025-04-01T16:32:02.18Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-refocus-development-programme-for-ofatumumab-in-autoimmune-indications/ 2025-04-01T16:32:02.627Z https://www.gsk.com/en-gb/media/press-releases/three-year-results-from-eclipse-study-indicate-that-copd-patients-may-require-prevention-strategies-to-manage-exacerbations-regardless-of-disease-severity/ 2025-04-01T16:32:03.06Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-bjd-collaborate-on-a-new-educational-programme-to-reduce-global-burden-of-joint-pain/ 2025-04-01T16:32:03.467Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-announce-start-of-ofatumumab-phase-iii-combination-study-in-non-hodgkin-s-lymphoma/ 2025-04-01T16:31:55.87Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-succession-plan-for-chief-financial-officer/ 2025-04-01T16:31:56.287Z https://www.gsk.com/en-gb/media/press-releases/galapagos-reaches-agreement-to-acquire-glaxosmithkline-research-centre-in-zagreb-croatia/ 2025-04-01T16:31:57.067Z https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-with-lonza-to-secure-capacity-and-expertise-in-biological-manufacturing-to-support-ongoing-development-of-gsk-s-biopharmaceuticals-portfolio/ 2025-04-01T16:31:57.44Z https://www.gsk.com/en-gb/media/press-releases/bbc-panorama-6-september-2010/ 2025-04-01T16:31:57.843Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-pre-broadcast-statement-bbc-panorama-6-september-2010/ 2025-04-01T16:31:58.257Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-responds-to-british-medical-journal-article-regarding-avandia-rosiglitazone/ 2025-04-01T16:31:58.667Z https://www.gsk.com/en-gb/media/press-releases/reports-of-narcolepsy-in-europe-following-vaccination-with-pandemrix/ 2025-04-01T16:31:59.1Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-valeant-announce-new-us-fda-pdufa-goal-date-for-ezogabine/ 2025-04-01T16:31:59.54Z https://www.gsk.com/en-gb/media/press-releases/gsk-commences-phase-iii-clinical-trials-to-develop-herpes-zoster-vaccine-for-the-prevention-of-shingles/ 2025-04-01T16:31:51.213Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-fda-priority-review-designation-for-benlysta-belimumab-as-a-potential-treatment-for-systemic-lupus-erythematosus/ 2025-04-01T16:31:51.63Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-announce-topline-results-from-the-concluded-pivotal-trial-of-arzerra-ofatumumab-in-fludarabine-and-alemtuzumab-refractory-chronic-lymphocytic-leukemia/ 2025-04-01T16:31:52.08Z https://www.gsk.com/en-gb/media/press-releases/image-of-new-antibiotic-in-action-opens-up-new-opportunities-to-combat-antibacterial-resistance/ 2025-04-01T16:31:52.483Z https://www.gsk.com/en-gb/media/press-releases/gsk-exercises-option-on-anacor-s-novel-antibiotic-for-the-treatment-of-gram-negative-infections/ 2025-04-01T16:31:53.08Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-for-a-new-indication-for-arixtra/ 2025-04-01T16:31:53.6Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-statement-in-response-to-fda-announcement-on-tide-trial/ 2025-04-01T16:31:54.133Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-legal-update/ 2025-04-01T16:31:54.6Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-statement-in-response-to-fda-advisory-committees-vote-on-safety-of-avandia-rosiglitazone/ 2025-04-01T16:31:55.037Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-gsk-responds-to-senate-finance-committee-letter-of-12-july-to-fda/ 2025-04-01T16:31:55.463Z https://www.gsk.com/en-gb/media/press-releases/data-support-avandia-rosiglitazone-maleate-cardiovascular-safety-profile/ 2025-04-01T16:31:46.983Z https://www.gsk.com/en-gb/media/press-releases/gsk-eu-regulatory-update-on-avandia-rosiglitazone/ 2025-04-01T16:31:47.377Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-edb-commit-35-million-usd-in-funding-to-support-research-in-green-and-sustainable-manufacturing-in-singapore/ 2025-04-01T16:31:47.9Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-announce-amendment-to-ofatumumab-agreement/ 2025-04-01T16:31:48.29Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-creates-a-new-operating-unit-dedicated-to-expanding-access-to-medicines-for-people-living-in-the-world-s-poorest-countries/ 2025-04-01T16:31:48.7Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-aptuit-finalise-agreement-for-aptuit-to-acquire-gsk-s-research-operations-in-italy/ 2025-04-01T16:31:49.107Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-eu-authorisation-for-a-new-therapeutic-indication-for-tyverb-lapatinib/ 2025-04-01T16:31:49.56Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-enters-agreement-with-medivir-for-exclusive-rights-to-cold-sore-treatment-xerclear/ 2025-04-01T16:31:49.963Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-conditional-marketing-authorisation-in-the-eu-for-votrient-pazopanib/ 2025-04-01T16:31:50.38Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-jalyn-a-fixed-dose-combination-of-dutasteride-and-tamsulosin-for-symptomatic-bph-in-men-with-an-enlarged-prostate/ 2025-04-01T16:31:50.8Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-complete-response-from-fda-for-candidate-meningococcal-and-hib-combination-vaccine/ 2025-04-01T16:31:43.313Z https://www.gsk.com/en-gb/media/press-releases/gsk-drives-latin-america-growth-strategy-with-acquisition-of-laboratorios-phoenix/ 2025-04-01T16:31:43.7Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-bla-filed-for-benlysta-belimumab/ 2025-04-01T16:31:44.087Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-benlysta-belimumab/ 2025-04-01T16:31:44.507Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-revised-product-labels-for-serevent-and-advair/ 2025-04-01T16:31:44.907Z https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-maintains-position-on-the-continued-use-of-rotarix-rotavirus-vaccine/ 2025-04-01T16:31:45.343Z https://www.gsk.com/en-gb/media/press-releases/viani-seretide-german-patent-litigation-update/ 2025-04-01T16:31:45.797Z https://www.gsk.com/en-gb/media/press-releases/new-research-identifies-promising-leads-to-follow-in-search-for-medicines-to-fight-malaria/ 2025-04-01T16:31:46.177Z https://www.gsk.com/en-gb/media/press-releases/fda-says-healthcare-providers-can-resume-use-of-rotarix-rotavirus-vaccine-live-oral/ 2025-04-01T16:31:46.55Z https://www.gsk.com/en-gb/media/press-releases/patrick-vallance-appointed-to-gsk-executive-leadership-team/ 2025-04-01T16:31:39.057Z https://www.gsk.com/en-gb/media/press-releases/gsk-extends-presence-in-asia-with-new-strategic-alliance-in-south-korea/ 2025-04-01T16:31:39.427Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-fda-advisory-committee-meeting-on-rotavirus-vaccines/ 2025-04-01T16:31:39.913Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-topline-76-week-results-of-phase-3-trial-of-benlysta-in-systemic-lupus-erythematosus/ 2025-04-01T16:31:40.327Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-conditional-marketing-authorisation-in-the-eu-for-arzerra-ofatumumab/ 2025-04-01T16:31:40.723Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-isis-pharmaceuticals-collaborate-on-rna-therapeutics-for-rare-and-infectious-diseases/ 2025-04-01T16:31:41.2Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-approval-for-duodart/ 2025-04-01T16:31:41.643Z https://www.gsk.com/en-gb/media/press-releases/gsk-regulatory-update-avodart-dutasteride/ 2025-04-01T16:31:42.063Z https://www.gsk.com/en-gb/media/press-releases/updated-glaxosmithkline-statement-on-european-regulatory-guidance-relating-to-manufacture-of-rotarix-rotavirus-vaccine/ 2025-04-01T16:31:42.48Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-government-orders-for-pandemic-h1n1-vaccine/ 2025-04-01T16:31:42.897Z https://www.gsk.com/en-gb/media/press-releases/gsk-joins-global-vaccine-alliance-to-help-prevent-millions-of-children-from-contracting-pneumococcal-disease-in-the-world-s-poorest-countries/ 2025-04-01T16:31:34.52Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-succession-plan-for-leadership-of-consumer-healthcare-business/ 2025-04-01T16:31:34.9Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-statement-on-new-information-relating-to-manufacture-of-rotarix-rotavirus-vaccine/ 2025-04-01T16:31:35.367Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-swiss-approval-of-duodart/ 2025-04-01T16:31:35.993Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-commences-relovair-phase-iii-asthma-programme/ 2025-04-01T16:31:36.363Z https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2009-corporate-responsibility-report/ 2025-04-01T16:31:36.777Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-marketing-authorisation-in-the-eu-for-revolade-eltrombopag/ 2025-04-01T16:31:37.233Z https://www.gsk.com/en-gb/media/press-releases/gsk-commences-succession-plan-for-management-of-vaccines-business/ 2025-04-01T16:31:37.703Z https://www.gsk.com/en-gb/media/press-releases/gsk-ceo-andrew-witty-dedicates-albendazole-facility-in-nashik-to-who-s-global-programme-to-eliminate-lf/ 2025-04-01T16:31:38.083Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-responds-to-us-senate-committee-on-finance-report-on-avandia/ 2025-04-01T16:31:38.57Z https://www.gsk.com/en-gb/media/press-releases/gsk-rejects-conclusions-of-senate-committee-on-finance-staff-report-on-avandia/ 2025-04-01T16:31:30.92Z https://www.gsk.com/en-gb/media/press-releases/gsk-rejects-conclusions-reported-in-the-new-york-times-story-on-avandia/ 2025-04-01T16:31:31.277Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-opinions-in-europe-for-tyverb-lapatinib-and-votrient-pazopanib/ 2025-04-01T16:31:31.707Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-fda-s-proposed-label-revisions-for-some-asthma-medicines/ 2025-04-01T16:31:32.11Z https://www.gsk.com/en-gb/media/press-releases/gsk-consumer-healthcare-warns-consumers-of-potential-health-risks-associated-with-long-term-excessive-use-of-zinc-containing-denture-adhesives/ 2025-04-01T16:31:32.503Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-xenoport-receive-fda-complete-response-letter-for-horizant-gsk1838262xp13512-for-rls/ 2025-04-01T16:31:32.933Z https://www.gsk.com/en-gb/media/press-releases/gsk-launches-new-specialist-unit-to-research-and-develop-medicines-for-rare-diseases/ 2025-04-01T16:31:33.357Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-appointment-of-philippe-fauchet-as-president-of-gsk-japan/ 2025-04-01T16:31:33.753Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2009/ 2025-04-01T16:31:34.127Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-tykerb-receives-accelerated-approval-for-first-line-combination-treatment-of-hormone-receptor-positive-her2pluserbb2plus-metastatic-breast-cancer/ 2025-04-01T16:31:27.167Z https://www.gsk.com/en-gb/media/press-releases/rotarix-significantly-reduced-severe-rotavirus-gastroenteritis-in-african-babies-during-their-first-year-of-life/ 2025-04-01T16:31:27.59Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-open-innovation-strategy-to-help-deliver-new-and-better-medicines-for-people-living-in-the-world-s-poorest-countries/ 2025-04-01T16:31:28.013Z https://www.gsk.com/en-gb/media/press-releases/gsk-contributes-to-haiti-relief-efforts/ 2025-04-01T16:31:28.39Z https://www.gsk.com/en-gb/media/press-releases/gsk-exercises-option-to-progress-development-of-chemocentryx-s-traficet-en-for-the-treatment-of-inflammatory-bowel-diseases/ 2025-04-01T16:31:28.827Z https://www.gsk.com/en-gb/media/press-releases/audio-recording-of-meeting-between-gsk-and-dr-nissen-to-discuss-avandia/ 2025-04-01T16:31:29.273Z https://www.gsk.com/en-gb/media/press-releases/revolade-eltrombopag-receives-positive-opinion-in-europe-for-chronic-immune-thrombocytopenic-purpura/ 2025-04-01T16:31:29.723Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-nanobio-announce-otc-licensing-agreement-for-cold-sore-treatment/ 2025-04-01T16:31:30.113Z https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-speaking-consulting-fees-paid-to-us-healthcare-professionals/ 2025-04-01T16:31:30.507Z https://www.gsk.com/en-gb/media/press-releases/gsk-study-showed-targeted-therapy-combination-achieved-14-month-overall-survival-in-patients-with-advanced-breast-cancer/ 2025-04-01T16:31:21.35Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-intercell-form-strategic-alliance-to-develop-and-commercialise-innovative-needle-free-patch-based-vaccines/ 2025-04-01T16:31:21.903Z https://www.gsk.com/en-gb/media/press-releases/pre-budget-report-response-gsk-comments-on-patent-box/ 2025-04-01T16:31:22.357Z https://www.gsk.com/en-gb/media/press-releases/gsk-initiates-second-pivotal-phase-iii-trial-for-investigational-cardiovascular-medication-darapladib/ 2025-04-01T16:31:22.85Z https://www.gsk.com/en-gb/media/press-releases/gsk-update-gsk-s-arepanrix-h1n1-pandemic-vaccine-prequalified-by-the-world-health-organization/ 2025-04-01T16:31:23.403Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-extension-of-strategic-collaboration-with-aspen/ 2025-04-01T16:31:24.793Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announced-as-tier-3-sponsor-as-london-2012-anti-doping-plans-confirmed/ 2025-04-01T16:31:25.463Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-gsk-files-rotarix-for-prevention-of-rotavirus-in-japan/ 2025-04-01T16:31:25.893Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-gilead-announce-agreement-to-commercialise-viread-for-chronic-hepatitis-b-in-key-asian-countries/ 2025-04-01T16:31:26.343Z https://www.gsk.com/en-gb/media/press-releases/gsk-regulatory-update-avodart/ 2025-04-01T16:31:26.753Z https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-in-children-and-adolescents-from-3-to-17-years-of-age/ 2025-04-01T16:31:17.063Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-nabi-announce-agreement-for-nicvax-a-vaccine-for-nicotine-addiction/ 2025-04-01T16:31:17.627Z https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-us-fda-approves-gsk-s-pandemic-h1n1-vaccine/ 2025-04-01T16:31:18.073Z https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-with-the-who-to-donate-50-million-doses-of-pandemic-h1n1-vaccine-for-distribution-to-developing-countries/ 2025-04-01T16:31:18.513Z https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-on-co-administration-with-annual-seasonal-influenza-vaccine-fluarix/ 2025-04-01T16:31:18.94Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-xenoport-announce-extension-of-gsk1838262-xp13512-fda-review-date-to-9-february-2010/ 2025-04-01T16:31:19.347Z https://www.gsk.com/en-gb/media/press-releases/world-health-organization-grants-prequalification-for-global-use-to-gsk-s-10-valent-synflorix-vaccine/ 2025-04-01T16:31:19.823Z https://www.gsk.com/en-gb/media/press-releases/world-s-largest-malaria-vaccine-trial-now-underway-in-seven-african-countries/ 2025-04-01T16:31:20.27Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-a-new-specialist-hiv-company-dedicated-to-delivering-advances-in-hiv-treatment-and-care/ 2025-04-01T16:31:20.907Z https://www.gsk.com/en-gb/media/press-releases/retigabine-regulatory-update/ 2025-04-01T16:31:13.27Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-positive-results-in-second-of-two-phase-3-trials-of-benlysta-in-systemic-lupus-erythematosus/ 2025-04-01T16:31:13.65Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2009/ 2025-04-01T16:31:14.043Z https://www.gsk.com/en-gb/media/press-releases/pandemic-2009-influenza-update-pandemrix-data-in-an-elderly-population/ 2025-04-01T16:31:14.447Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-theravance-commence-phase-iii-horizon-programme-to-develop-a-next-generation-treatment-for-copd/ 2025-04-01T16:31:14.897Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-genmab-receive-accelerated-approval-for-arzerra/ 2025-04-01T16:31:15.27Z https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-experience-of-gsk-s-h1n1-adjuvanted-vaccine-pandemrix-and-preliminary-paediatric-results/ 2025-04-01T16:31:15.657Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-human-genome-sciences-announce-full-presentation-at-acr-of-positive-phase-3-study-results-for-benlysta-in-systemic-lupus-erythematosus/ 2025-04-01T16:31:16.12Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-glaxosmithkline-s-votrient-for-advanced-renal-cell-cancer/ 2025-04-01T16:31:16.563Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-cervarix-glaxosmithkline-s-cervical-cancer-vaccine/ 2025-04-01T16:31:08.797Z https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-results-from-second-clinical-trial-of-gsk-s-h1n1-adjuvanted-vaccine-confirm-immune-response-and-tolerability/ 2025-04-01T16:31:09.28Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-cervarix-becomes-the-first-cervical-cancer-vaccine-to-gain-approval-in-japan/ 2025-04-01T16:31:09.663Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-us-patent-and-trademark-office-file-a-motion-to-dismiss-litigation-over-final-regulations/ 2025-04-01T16:31:10.043Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-prosensa-form-alliance-to-fight-duchenne-muscular-dystrophy/ 2025-04-01T16:31:10.457Z https://www.gsk.com/en-gb/media/press-releases/gsk-expands-presence-in-china-through-strategic-cooperation-to-form-a-joint-venture-on-paediatric-vaccines/ 2025-04-01T16:31:10.887Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-government-orders-for-pandemic-h1n1-2009-vaccine/ 2025-04-01T16:31:11.287Z https://www.gsk.com/en-gb/media/press-releases/positive-phase-ii-results-for-gsk1838262-xp13512-reported-for-subjects-with-post-herpetic-neuralgia-and-a-history-of-inadequate-response-to-gabapentin/ 2025-04-01T16:31:11.71Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-unanimous-fda-panel-approval-recommendation-for-votrient/ 2025-04-01T16:31:12.13Z https://www.gsk.com/en-gb/media/press-releases/gsk-partners-with-uk-government-and-wellcome-trust-to-stimulate-innovation-through-the-creation-of-a-world-class-science-park/ 2025-04-01T16:31:12.867Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-avodart-tamsulosin-combination-showed-benefits-for-men-with-prostate-enlargement/ 2025-04-01T16:31:05.193Z https://www.gsk.com/en-gb/media/press-releases/avodart-dutasteride-regulatory-update/ 2025-04-01T16:31:05.58Z https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-gsk-s-h1n1-pandemrix-vaccine-receives-european-commission-approval/ 2025-04-01T16:31:06.03Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-on-fda-review-of-cervarix/ 2025-04-01T16:31:06.413Z https://www.gsk.com/en-gb/media/press-releases/fatality-reported-in-uk-hpv-vaccine-immunisation-programme/ 2025-04-01T16:31:06.79Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-upch-to-launch-lucozade-across-china/ 2025-04-01T16:31:07.173Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-regulatory-filings-for-zunrisarezonic/ 2025-04-01T16:31:07.54Z https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-gsk-s-h1n1-pandemrix-vaccine-receives-positive-opinion-from-european-regulators/ 2025-04-01T16:31:07.927Z https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update-initial-results-from-first-clinical-trial-of-gsk-s-h1n1-adjuvanted-vaccine/ 2025-04-01T16:31:08.373Z https://www.gsk.com/en-gb/media/press-releases/antiviral-activity-of-sgsk1265744-a-once-daily-unboosted-integrase-inhibitor-in-clinical-development-evaluated-in-phase-1-2a-study-in-healthy-and-hiv-infected-subjects/ 2025-04-01T16:31:01.47Z https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-makes-favorable-recommendation-for-cervarix-glaxosmithkline-s-candidate-cervical-cancer-vaccine/ 2025-04-01T16:31:01.853Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-announce-results-from-a-study-of-arzerra-in-rituximab-refractory-follicular-nhl/ 2025-04-01T16:31:02.253Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-brazil-s-fiocruz-form-partnership-for-new-rd-effort-and-increased-vaccine-access/ 2025-04-01T16:31:02.727Z https://www.gsk.com/en-gb/media/press-releases/pandemic-h1n1-2009-influenza-update/ 2025-04-01T16:31:03.117Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-announce-top-line-results-for-ofatumumab-in-rheumatoid-arthritis/ 2025-04-01T16:31:03.523Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-mepolizumab-for-the-treatment-of-hypereosinophilic-syndrome-hes/ 2025-04-01T16:31:03.933Z https://www.gsk.com/en-gb/media/press-releases/amgen-to-collaborate-with-gsk-to-commercialize-denosumab-in-europe-for-postmenopausal-osteoporosis-pmo/ 2025-04-01T16:31:04.373Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-completes-acquisition-of-stiefel/ 2025-04-01T16:31:04.81Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2009/ 2025-04-01T16:30:57.57Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-enigma-diagnostics-announce-commercial-partnership-to-develop-point-of-care-influenza-diagnostics/ 2025-04-01T16:30:57.98Z https://www.gsk.com/en-gb/media/press-releases/antiviral-activity-of-sgsk1349572-the-only-once-daily-unboosted-integrase-inhibitor-in-clinical-development-evaluated-in-phase-2-study/ 2025-04-01T16:30:58.38Z https://www.gsk.com/en-gb/media/press-releases/human-genome-sciences-and-glaxosmithkline-announce-positive-phase-3-study-results-for-benlysta-in-systemic-lupus-erythematosus/ 2025-04-01T16:30:58.807Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-commitments-to-fight-hivaids-in-sub-saharan-africa-special-focus-on-care-and-treatment-of-children/ 2025-04-01T16:30:59.23Z https://www.gsk.com/en-gb/media/press-releases/who-grants-prequalification-to-cervarix-gsk-s-vaccine-to-help-combat-cervical-cancer-in-developing-nations/ 2025-04-01T16:30:59.67Z https://www.gsk.com/en-gb/media/press-releases/alnylam-joins-gsk-in-donating-intellectual-property-to-patent-pool-for-neglected-tropical-diseases/ 2025-04-01T16:31:00.237Z https://www.gsk.com/en-gb/media/press-releases/gsk-further-extends-its-product-portfolio-in-the-middle-east-and-north-africa/ 2025-04-01T16:31:00.683Z https://www.gsk.com/en-gb/media/press-releases/seretide-irish-patent-litigation-update/ 2025-04-01T16:31:01.06Z https://www.gsk.com/en-gb/media/press-releases/regulatory-update-for-rezonic-casopitant-mesylate/ 2025-04-01T16:30:52.87Z https://www.gsk.com/en-gb/media/press-releases/landmark-study-for-gsk-s-cervical-cancer-vaccine-published-in-the-lancet/ 2025-04-01T16:30:53.277Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-chroma-therapeutics-form-alliance-to-develop-novel-macrophage-targeted-drugs/ 2025-04-01T16:30:53.773Z https://www.gsk.com/en-gb/media/press-releases/fda-extends-review-of-arzerra-ofatumumab/ 2025-04-01T16:30:54.2Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-a-h1n1-influenza/ 2025-04-01T16:30:54.63Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-shenzhen-neptunus-create-new-alliance-to-develop-and-manufacture-influenza-vaccines-in-china/ 2025-04-01T16:30:55.04Z https://www.gsk.com/en-gb/media/press-releases/large-long-term-study-shows-avandia-has-no-increased-overall-cardiovascular-risk-compared-to-other-commonly-used-diabetes-medicines/ 2025-04-01T16:30:55.453Z https://www.gsk.com/en-gb/media/press-releases/world-health-organization-grants-global-prequalification-to-gsk-s-rotarix-vaccine/ 2025-04-01T16:30:56.207Z https://www.gsk.com/en-gb/media/press-releases/positive-results-with-revolade-and-arzerra-for-difficult-to-treat-blood-disorders/ 2025-04-01T16:30:56.807Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-concert-pharmaceuticals-form-alliance-to-develop-novel-deuterium-modified-drugs/ 2025-04-01T16:30:57.203Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-pazopanib-significantly-delayed-tumor-progression-in-patients-with-advanced-kidney-cancer/ 2025-04-01T16:30:49.063Z https://www.gsk.com/en-gb/media/press-releases/fda-advisory-panel-makes-favorable-recommendation-for-arzerra-ofatumumab/ 2025-04-01T16:30:49.45Z https://www.gsk.com/en-gb/media/press-releases/us-department-of-health-and-human-services-hhs-purchases-gsk-s-a-h1n1-influenza-antigen-and-proprietary-adjuvant-system/ 2025-04-01T16:30:49.853Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-a-h1n1-influenza-vaccine-development/ 2025-04-01T16:30:50.293Z https://www.gsk.com/en-gb/media/press-releases/gsk-extends-strategic-collaboration-with-aspen/ 2025-04-01T16:30:50.737Z https://www.gsk.com/en-gb/media/press-releases/community-healthcare-charities-receive-300-000-from-glaxosmithkline-in-recognition-of-their-work/ 2025-04-01T16:30:51.18Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-to-divest-us-rights-for-wellbutrin-xl-to-biovail-for-510-million/ 2025-04-01T16:30:51.603Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-influenza-a-h1n1/ 2025-04-01T16:30:51.987Z https://www.gsk.com/en-gb/media/press-releases/large-long-term-study-shows-dutasteride-reduced-prostate-cancer-risk-in-men-at-increased-risk-of-the-disease/ 2025-04-01T16:30:52.397Z https://www.gsk.com/en-gb/media/press-releases/emergence-of-a-new-h1n1-influenza-a-strain-swine-influenza/ 2025-04-01T16:30:45.3Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-launches-alli-orlistat-60-mg/ 2025-04-01T16:30:45.693Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-stiefel-to-create-new-world-leading-specialist-dermatology-business/ 2025-04-01T16:30:46.107Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-pfizer-announce-innovative-agreement-to-create-a-new-world-leading-specialist-hiv-company/ 2025-04-01T16:30:46.52Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-idenix-pharmaceuticals-sign-worldwide-license-agreement-for-idx899-a-novel-nnrti-for-the-treatment-of-hiv/ 2025-04-01T16:30:46.913Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-tyverb-tykerb-lapatinib-for-first-line-treatment-of-metastatic-breast-cancer-in-europe-us/ 2025-04-01T16:30:47.31Z https://www.gsk.com/en-gb/media/press-releases/cervarix-us-regulatory-update/ 2025-04-01T16:30:47.813Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-phase-2b-results-for-once-daily-fluticasone-furoate-in-the-treatment-of-asthma/ 2025-04-01T16:30:48.247Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-announces-board-changes/ 2025-04-01T16:30:48.64Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-submit-arzerra-ofatumumab-application-to-fda-for-the-treatment-of-advanced-stage-blood-cancer/ 2025-04-01T16:30:41.61Z https://www.gsk.com/en-gb/media/press-releases/deirdre-connelly-to-join-gsk-as-president-north-american-pharmaceuticals/ 2025-04-01T16:30:42.063Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-charges-for-legal-matters/ 2025-04-01T16:30:42.437Z https://www.gsk.com/en-gb/media/press-releases/the-uk-government-signs-influenza-pandemic-contract-with-glaxosmithkline-for-relenza/ 2025-04-01T16:30:42.807Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-drive-growth-in-emerging-markets-with-acquisition-of-ucb-products/ 2025-04-01T16:30:43.227Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-paediatric-pneumococcal-candidate-vaccine-synflorix-receives-positive-opinion-in-europe/ 2025-04-01T16:30:43.603Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-receives-european-commission-approval-to-market-alli-orlistat-60mg/ 2025-04-01T16:30:44.027Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-xenoport-resubmit-new-drug-application-for-solzira-in-restless-legs-syndrome/ 2025-04-01T16:30:44.487Z https://www.gsk.com/en-gb/media/press-releases/synflorix-glaxosmithkline-s-pneumococcal-vaccine-receives-european-authorisation/ 2025-04-01T16:30:44.91Z https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-2008-corporate-responsibility-report/ 2025-04-01T16:30:38.257Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-and-genmab-seek-european-marketing-authorisation-of-arzerra-ofatumumab-in-advanced-stage-blood-cancer/ 2025-04-01T16:30:38.7Z https://www.gsk.com/en-gb/media/press-releases/gsk-initiates-phase-iii-programme-for-novel-type-2-diabetes-medication-syncria-albiglutide/ 2025-04-01T16:30:39.117Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-submits-european-marketing-authorisation-application-for-pazopanib-in-advanced-kidney-cancer/ 2025-04-01T16:30:39.513Z https://www.gsk.com/en-gb/media/press-releases/nice-refuses-funding-for-advanced-breast-cancer-treatment-tyverb-lapatinib/ 2025-04-01T16:30:39.96Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-sale-of-shares-in-quest-diagnostics-inc/ 2025-04-01T16:30:40.37Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-a-strategic-alliance-with-dr-reddy-s-to-further-accelerate-sales-growth-in-emerging-markets/ 2025-04-01T16:30:40.767Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2008/ 2025-04-01T16:30:41.19Z https://www.gsk.com/en-gb/media/press-releases/shionogi-glaxosmithkline-pharmaceuticals-acknowledges-position-of-the-european-aids-treatment-group/ 2025-04-01T16:30:34.277Z https://www.gsk.com/en-gb/media/press-releases/positive-results-for-relvar-ellipta-lung-function-study-in-patients-with-well-controlled-asthma/ 2025-04-01T16:30:34.67Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment/ 2025-04-01T16:30:35.097Z https://www.gsk.com/en-gb/media/press-releases/gsk-confirms-closure-of-agreement-to-divest-anaesthesia-portfolio-to-aspen/ 2025-04-01T16:30:35.617Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-musca-study-shows-nucala-mepolizumab-significantly-improves-quality-of-life-and-lung-function-in-severe-asthma-patients-with-an-eosinophilic-phenotype/ 2025-04-01T16:30:36.03Z https://www.gsk.com/en-gb/media/press-releases/gsk-makes-change-to-financial-reporting-framework/ 2025-04-01T16:30:36.493Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-another-quarter-of-continued-progress/ 2025-04-01T16:30:36.973Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare/ 2025-04-01T16:30:37.337Z https://www.gsk.com/en-gb/media/press-releases/four-innovations-to-tackle-under-five-deaths-win-us-1-million-healthcare-innovation-award-from-gsk-and-save-the-children/ 2025-04-01T16:30:37.867Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017/ 2025-04-01T16:30:31.027Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-board-and-committee-changes/ 2025-04-01T16:30:31.433Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-versus-lopinavirritonavir-in-second-line-hiv-treatment-in-resource-limited-settings/ 2025-04-01T16:30:31.877Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-respiratory-data-from-pipeline-to-clinical-practice-at-ers/ 2025-04-01T16:30:32.373Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-world-health-organization-prequalification-for-synflorix-pneumococcal-vaccine-four-dose-vial/ 2025-04-01T16:30:33.067Z https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-the-us-for-prevention-of-shingles-in-adults-aged-50-and-over/ 2025-04-01T16:30:33.44Z https://www.gsk.com/en-gb/media/press-releases/cdc-s-advisory-committee-on-immunization-practices-recommends-shingrix-as-the-preferred-vaccine-for-the-prevention-of-shingles-for-adults-aged-50-and-up/ 2025-04-01T16:30:33.847Z https://www.gsk.com/en-gb/media/press-releases/dr-hal-barron-appointed-chief-scientific-officer-and-president-research-development-gsk/ 2025-04-01T16:30:27.167Z https://www.gsk.com/en-gb/media/press-releases/juluca-approved-in-us-as-first-2-drug-regimen-once-daily-single-pill/ 2025-04-01T16:30:27.563Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-landmark-impact-data-to-us-regulatory-authority-to-support-expanded-label-for-trelegy-ellipta/ 2025-04-01T16:30:28.37Z https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-uk-industrial-strategy/ 2025-04-01T16:30:28.797Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/ 2025-04-01T16:30:29.233Z https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-launch-of-the-uk-government-s-life-sciences-sector-deal/ 2025-04-01T16:30:29.787Z https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-the-amr-benchmark/ 2025-04-01T16:30:30.17Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-receives-positive-opinion-from-the-chmp-in-europe-for-the-prevention-of-shingles-in-adults-aged-50-and-over/ 2025-04-01T16:30:30.557Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-approval-for-expanded-indication-for-fluarix-tetra-influenza-vaccine-for-ages-six-months-and-older/ 2025-04-01T16:30:23.487Z https://www.gsk.com/en-gb/media/press-releases/new-clinical-data-demonstrate-high-vaccine-efficacy-of-fluarix-tetra-influenza-vaccine-in-children-6-35-months-of-age/ 2025-04-01T16:30:23.993Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-eu-approval-for-labelling-update-to-relvar-ellipta-in-patients-with-asthma/ 2025-04-01T16:30:24.413Z https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-europe-and-japan-for-the-prevention-of-shingles-in-adults-aged-50-and-over/ 2025-04-01T16:30:24.87Z https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-with-novartis-to-acquire-full-ownership-of-consumer-healthcare-business/ 2025-04-01T16:30:25.353Z https://www.gsk.com/en-gb/media/press-releases/once-daily-trelegy-ellipta-gains-expanded-indication-in-the-us-for-the-treatment-of-patients-with-copd/ 2025-04-01T16:30:25.773Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-industry-leading-respiratory-research-and-scientific-innovation-showcased-at-ats-conference/ 2025-04-02T13:57:28.293Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine-demonstrating-the-ability-to-control-hiv-with-a-two-drug-regimen-in-treatment-naive-patients/ 2025-04-01T16:30:26.687Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018/ 2025-04-01T16:30:20.037Z https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-krintafel-tafenoquine-for-the-radical-cure-of-p-vivax-malaria/ 2025-04-01T16:30:20.607Z https://www.gsk.com/en-gb/media/press-releases/chmp-recommend-nucala-mepolizumab-for-the-treatment-of-severe-eosinophilic-asthma-paediatric-patients-in-europe/ 2025-04-02T13:48:11.973Z https://www.gsk.com/en-gb/media/press-releases/iain-mackay-appointed-gsk-chief-financial-officer/ 2025-04-01T16:30:21.55Z https://www.gsk.com/en-gb/media/press-releases/gsk-data-presented-at-ers-further-supports-its-industry-leading-respiratory-medicines-portfolio/ 2025-04-01T16:30:22.04Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv/ 2025-04-01T16:30:22.48Z https://www.gsk.com/en-gb/media/press-releases/gsk-candidate-vaccine-helps-prevent-active-pulmonary-tuberculosis-in-hiv-negative-adults-in-phase-ii-study/ 2025-04-01T16:30:22.983Z https://www.gsk.com/en-gb/media/press-releases/positive-results-from-harmony-outcomes-study-of-albiglutide-published-in-the-lancet/ 2025-04-01T16:30:16.247Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-efficacy-and-safety-data-of-an-anti-gm-csf-antibody-in-patients-with-rheumatoid-arthritis/ 2025-04-01T16:30:16.65Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-phase-3-results-for-daprodustat-in-patients-with-anaemia-associated-with-chronic-kidney-disease/ 2025-04-01T16:30:17.083Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen/ 2025-04-01T16:30:17.563Z https://www.gsk.com/en-gb/media/press-releases/access-to-medicine-index-2018-media-statement/ 2025-04-01T16:30:18.197Z https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-tesaro-an-oncology-focused-biopharmaceutical-company/ 2025-04-01T16:30:18.617Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-succession-plan-to-appoint-new-chairman/ 2025-04-01T16:30:19.027Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-further-positive-data-from-dreamm-1-study-of-anti-bcma-antibody-drug-conjugate/ 2025-04-01T16:30:19.5Z https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-product-sales-reporting-changes-and-the-impact-of-ifrs-16-leases/ 2025-04-01T16:30:12.617Z https://www.gsk.com/en-gb/media/press-releases/phase-iii-captain-study-of-trelegy-ellipta-in-patients-with-asthma-meets-primary-endpoint/ 2025-04-01T16:30:13.04Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-strong-science-prominent-at-ats-2019/ 2025-05-14T15:13:52.17Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-first-ever-study-to-identify-and-evaluate-approaches-to-implementing-its-once-monthly-injectable-hiv-treatment-in-clinical-practice/ 2025-04-01T16:30:13.92Z https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-the-uk-trial-of-subscription-style-payment-system-for-pharma-companies-to-incentivise-creation-of-new-antibiotics/ 2025-04-01T16:30:14.357Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-in-phase-3-prima-study-of-zejula-niraparib-for-patients-with-ovarian-cancer-in-the-first-line-maintenance-setting/ 2025-04-01T16:30:14.873Z https://www.gsk.com/en-gb/media/press-releases/ias-2019-viiv-healthcare-showcasing-innovation-in-hiv-science/ 2025-04-01T16:30:15.333Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-96-week-data-from-phase-iii-study-of-investigational-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv-at-ias-2019/ 2025-04-01T16:30:15.843Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-week-48-results-in-first-study-to-evaluate-treatment-switch-from-taf-containing-regimen/ 2025-04-01T16:30:09.84Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-gemini-1-2-studies-through-week-96-showing-2-drug-regimen-of-dolutegravir-plus-lamivudine-continues-to-demonstrate-high-efficacy-rates/ 2025-04-01T16:30:10.32Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-jonathan-symonds-as-non-executive-chairman-of-the-board-of-directors/ 2025-04-01T16:30:10.777Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-investigational-cabotegravir-to-be-used-in-combination-with-rilpivirine/ 2025-04-01T16:30:11.253Z https://www.gsk.com/en-gb/media/press-releases/five-years-on-39-million-people-in-the-developing-world-have-access-to-hiv-treatment-dolutegravir-thanks-to-access-oriented-voluntary-licensing-agreements/ 2025-04-01T16:30:11.727Z https://www.gsk.com/en-gb/media/press-releases/nucala-receives-eu-approval-for-self-administration-by-patients-with-severe-eosinophilic-asthma/ 2025-04-01T16:30:12.17Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-first-regulatory-application-for-daprodustat-in-japan-for-patients-with-renal-anaemia-due-to-chronic-kidney-disease/ 2025-04-01T16:30:06.557Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-from-the-pivotal-dreamm-2-study-for-multiple-myeloma/ 2025-04-01T16:30:06.96Z https://www.gsk.com/en-gb/media/press-releases/real-world-effectiveness-evidence-among-gsk-data-presented-at-ers-2019/ 2025-04-01T16:30:07.403Z https://www.gsk.com/en-gb/media/press-releases/idweek-2019-viiv-healthcare-to-present-20-abstracts-from-its-innovative-rd-portfolio-with-focus-on-2-drug-and-long-acting-regimens-and-mental-health-impact-of-hiv/ 2025-04-01T16:30:07.927Z https://www.gsk.com/en-gb/media/press-releases/global-fund-replenishment-2019-media-statement/ 2025-04-01T16:30:08.357Z https://www.gsk.com/en-gb/media/press-releases/eacs-2019-viiv-healthcare-to-present-17-abstracts-from-its-portfolio-addressing-the-diverse-needs-of-people-living-with-hiv/ 2025-04-01T16:30:08.867Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-files-submissions-to-the-fda-and-ema-for-the-first-ever-dispersible-formulation-of-dolutegravir-dtg-for-children-living-with-hiv/ 2025-04-01T16:30:09.387Z https://www.gsk.com/en-gb/media/press-releases/gsk-consumer-healthcare-nutritional-products-divestment/ 2025-04-01T16:30:03.147Z https://www.gsk.com/en-gb/media/press-releases/pivotal-dreamm-2-study-demonstrated-a-clinically-meaningful-overall-response-rate-with-belantamab-mafodotin-gsk2857916-for-patients-with-relapsedrefractory-multiple-myeloma/ 2025-04-01T16:30:03.563Z https://www.gsk.com/en-gb/media/press-releases/us-food-and-drug-administration-fda-grants-priority-review-of-belantamab-mafodotin-for-patients-with-relapsed-or-refractory-multiple-myeloma/ 2025-04-01T16:30:03.977Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-european-medicines-agency-ema-accepted-marketing-authorisation-application-for-belantamab-mafodotin-for-the-treatment-of-relapsed-or-refractory-multiple-myeloma/ 2025-04-01T16:30:04.397Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-ec-approval-for-the-sale-of-thermacare/ 2025-04-01T16:30:04.807Z https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-charles-bancroft-to-the-board-as-a-non-executive-director/ 2025-04-01T16:30:05.213Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-horlicks-and-other-consumer-healthcare-nutrition-products-in-india-and-certain-other-markets/ 2025-04-01T16:30:05.697Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer-regardless-of-biomarker-status/ 2025-04-01T16:30:06.097Z https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-scientific-innovation-and-advances-in-its-growing-oncology-portfolio-at-asco-2020/ 2025-04-01T16:29:59.477Z https://www.gsk.com/en-gb/media/press-releases/dreamm-2-and-dreamm-6-data-at-asco-reinforce-the-potential-of-gsk-s-investigational-belantamab-mafodotin/ 2025-04-01T16:30:00.037Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-data-presentations-from-the-dreamm-programme/ 2025-04-01T16:30:00.47Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-the-first-ever-dispersible-tablet-formulation-of-dolutegravir/ 2025-04-01T16:30:00.93Z https://www.gsk.com/en-gb/media/press-releases/gsk-prices-280-336-000-senior-notes-due-2023-exchangeable-into-theravance-biopharma-ordinary-shares/ 2025-04-01T16:30:01.333Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-data-on-long-acting-regimens-for-hiv-prevention-and-treatment-at-aids-2020-virtual/ 2025-04-01T16:30:01.743Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-implementation-research-study-on-how-best-to-integrate-an-investigational-once-monthly-injectable-hiv-treatment-in-us-healthcare-practices/ 2025-04-01T16:30:02.217Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-medicago-announce-collaboration-to-develop-a-novel-adjuvanted-covid-19-candidate-vaccine/ 2025-04-01T16:30:02.667Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-superior-efficacy-of-investigational-long-acting-injectable-formulation-of-cabotegravir-dosed-every-two-months-over-daily-oral-prep/ 2025-04-01T16:29:56.087Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-fda-advisory-committee-votes-in-favour-of-positive-benefitrisk-profile-for-belantamab-mafodotin-for-patients-with-relapsedrefractory-multiple-myeloma/ 2025-04-01T16:29:56.533Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-announce-strategic-mrna-technology-collaboration/ 2025-04-01T16:29:56.973Z https://www.gsk.com/en-gb/media/press-releases/covid-19-prompts-increased-focus-on-self-care-with-europeans-taking-their-health-more-seriously-to-relieve-pressure-on-healthcare-systems/ 2025-04-01T16:29:57.403Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-recommending-approval-of-belantamab-mafodotin-for-the-treatment-of-relapsed-and-refractory-multiple-myeloma/ 2025-04-01T16:29:57.807Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-agree-with-the-uk-government-to-supply-up-to-60-million-doses-of-covid-19-vaccine/ 2025-04-01T16:29:58.24Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-selected-for-operation-warp-speed-to-supply-united-states-government-with-100-million-doses-of-covid-19-vaccine/ 2025-04-01T16:29:58.697Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-supply-european-union-with-up-to-300-million-doses-of-covid-19-vaccine/ 2025-04-01T16:29:59.08Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-blenrep-belantamab-mafodotin-blmf-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/ 2025-04-01T16:29:52.877Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-participant-vaccinated-in-phase-3-clinical-trials-of-its-5-in-1-meningitis-abcwy-vaccine-candidate/ 2025-04-01T16:29:53.33Z https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-blenrep-belantamab-mafodotin-for-the-treatment-of-patients-with-relapsed-and-refractory-multiple-myeloma/ 2025-04-01T16:29:53.757Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-promising-phase-2a-data-for-chronic-hepatitis-b-treatment/ 2025-04-01T16:29:54.233Z https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-start-phase-23-study-of-covid-19-antibody-treatment/ 2025-04-01T16:29:54.63Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-trelegy-ellipta-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-both-asthma-and-copd-in-the-us/ 2025-04-01T16:29:55.04Z https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-scientific-advances-across-its-growing-oncology-portfolio-at-esmo-virtual-congress-2020/ 2025-04-01T16:29:55.513Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-recommending-approval-of-zejula/ 2025-04-01T16:29:49.09Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-implementation-science-study/ 2025-04-01T16:29:49.58Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-nucala-as-the-first-and-only-biologic-treatment-for-hypereosinophilic-syndrome-hes/ 2025-04-01T16:29:50.02Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-long-term-safety-and-efficacy-data-for-2-drug-regimen/ 2025-04-01T16:29:50.51Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-dolutegravir-plus-lamivudine-three-year-data-confirming-long-term-viral-suppression/ 2025-04-01T16:29:51.007Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-long-term-switch-data-for-dovato/ 2025-04-01T16:29:51.417Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-positive-chmp-opinion-for-long-acting-regimen-for-the-treatment-of-hiv/ 2025-04-01T16:29:51.917Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-clinical-data-on-maternal-and-older-adults-rsv-candidate-vaccines/ 2025-04-01T16:29:52.343Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-analysis-showing-no-antiretroviral-therapy-interruptions-due-to-covid-19/ 2025-04-01T16:29:45.483Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-continued-positive-findings-from-first-ever-implementation-science-study/ 2025-04-01T16:29:46.003Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-new-findings-from-two-studies-of-its-investigational-long-acting-regimen-of-cabotegravir-and-rilpivirine/ 2025-04-01T16:29:46.447Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-resilient-performance-strong-commercial-execution-and-further-strategic-progress-in-q3/ 2025-04-23T14:19:25.687Z https://www.gsk.com/en-gb/media/press-releases/gsk-sets-new-environmental-goals-of-net-zero-impact-on-climate-and-net-positive-impact-on-nature-by-2030/ 2025-04-01T16:29:47.623Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-investigational-injectable-cabotegravir-is-superior-to-oral-standard-of-care-for-hiv-prevention-in-women/ 2025-04-01T16:29:48.08Z https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-progress-from-the-blenrep-belantamab-mafodotin-blmf-development-programme-in-multiple-myeloma-at-ash-annual-meeting/ 2025-04-01T16:29:48.6Z https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-start-of-phase-23-clinical-trials-of-adjuvanted-covid-19-vaccine-candidate/ 2025-04-01T16:29:41.867Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-for-the-first-ever-dispersible-tablet-formulation-of-dolutegravir-tivicay-a-treatment-for-children-living-with-hiv-in-europe/ 2025-04-01T16:29:42.247Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-phase-2b-data-on-linerixibat-for-the-treatment-of-cholestatic-pruritus-in-primary-biliary-cholangitis-pbc/ 2025-04-01T16:29:42.663Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-fda-breakthrough-therapy-designation-for-investigational-long-acting-cabotegravir-for-hiv-prevention/ 2025-04-01T16:29:43.07Z https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-3-study-of-rsv-maternal-candidate-vaccine/ 2025-04-01T16:29:43.483Z https://www.gsk.com/en-gb/media/press-releases/fda-accepts-gsk-s-filing-of-nucala-mepolizumab-for-use-in-chronic-rhinosinusitis-with-nasal-polyps/ 2025-04-01T16:29:43.93Z https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-start-of-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/ 2025-04-01T16:29:44.37Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-chmp-opinion-for-rukobia-fostemsavir/ 2025-04-01T16:29:44.887Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-the-marketing-authorisation-of-the-first-complete-long-acting-injectable-hiv-treatment-in-europe/ 2025-04-01T16:29:38.457Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-the-first-ever-dispersible-tablet-formulation-of-dolutegravir-tivicay-a-treatment-for-children-living-with-hiv-in-europe/ 2025-04-01T16:29:39.06Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-efficacy-data-of-dostarlimab-in-mismatch-repair-deficient-dmmr-solid-cancers-at-asco-gastrointestinal-cancers-symposium/ 2025-04-01T16:29:39.473Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-approval-of-cabenuva-cabotegravir-rilpivirine-the-first-and-only-complete-long-acting-regimen-for-hiv-treatment/ 2025-04-01T16:29:39.91Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-fy-2020-reported-sales-of-34-billion/ 2025-04-25T15:38:46.9Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-marketing-authorisation-for-rukobia-fostemsavir-a-first-in-class-attachment-inhibitor-in-combination-with-other-antiretrovirals/ 2025-04-01T16:29:40.847Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-sell-cephalosporin-antibiotics-business-to-sandoz/ 2025-04-01T16:29:41.44Z https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-rsv-candidate-vaccine-programme-for-older-adults/ 2025-04-01T16:29:34.74Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-recommending-approval-of-dostarlimab-for-women-with-recurrent-or-advanced-endometrial-cancer/ 2025-04-01T16:29:35.133Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-data-on-long-acting-regimens-for-hiv-prevention-and-treatment-alongside-pipeline-advances-at-croi-2021/ 2025-04-01T16:29:35.66Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-data-for-long-acting-cabotegravir-and-rilpivirine-for-the-treatment-of-hiv-showing-continued-virologic-suppression-to-96-weeks/ 2025-04-01T16:29:36.087Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-gsk3640254-a-novel-investigational-maturation-inhibitor-for-the-treatment-of-hiv/ 2025-04-01T16:29:36.667Z https://www.gsk.com/en-gb/media/press-releases/gsk-starts-the-first-phase-3-study-with-a-long-acting-anti-il-5-treatment-for-patients-with-severe-asthma/ 2025-04-01T16:29:37.187Z https://www.gsk.com/en-gb/media/press-releases/back-to-the-dentist-new-study-highlights-urgent-need-to-tackle-oral-healthcare-habits-post-covid-19/ 2025-04-01T16:29:37.61Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-highlight-scientific-research-in-ovarian-and-endometrial-cancer-at-sgo-2021-annual-meeting-on-women-s-cancer/ 2025-04-01T16:29:38.01Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-recommending-approval-of-benlysta-for-adult-patients-with-active-lupus-nephritis/ 2025-04-01T16:29:31.647Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-dr-anne-beal-to-join-the-board-as-non-executive-director/ 2025-04-01T16:29:32.07Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-feladilimab-an-investigational-inducible-t-cell-co-stimulatory-icos-agonist/ 2025-04-01T16:29:32.523Z https://www.gsk.com/en-gb/media/press-releases/fda-grants-accelerated-approval-for-gsk-s-jemperli-dostarlimab-gxly-for-women-with-recurrent-or-advanced-dmmr-endometrial-cancer/ 2025-04-01T16:29:32.953Z https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-gsk-s-jemperli-dostarlimab-the-first-anti-pd-1-therapy-approved-for-recurrent-or-advanced-endometrial-cancer/ 2025-04-01T16:29:33.387Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-q1-sales-of-74-billion-18-aer-15-cer/ 2025-04-23T14:21:49.36Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-initiates-rolling-submission-of-new-drug-application-with-us-fda-for-long-acting-cabotegravir-for-prevention-of-hiv/ 2025-04-01T16:29:34.36Z https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-benlysta-for-adult-patients-with-active-lupus-nephritis/ 2025-04-01T16:29:28.253Z https://www.gsk.com/en-gb/media/press-releases/gsk-consumer-healthcare-commits-to-make-over-a-billion-toothpaste-tubes-recyclable-by-2025-as-part-of-its-ongoing-sustainability-journey/ 2025-04-01T16:29:28.677Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-sale-of-stake-in-innoviva-inc/ 2025-04-01T16:29:29.097Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-sotrovimab-vir-7831-receives-emergency-use-authorization-from-the-us-fda/ 2025-04-01T16:29:29.527Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-showcase-scientific-advances-and-progress-in-oncology-at-asco-and-eha/ 2025-04-01T16:29:29.997Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-iteos-therapeutics-announce-development/ 2025-04-01T16:29:30.4Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-and-halozyme-enter-global-collaboration-and-license-agreement-for-enhanze-drug-delivery-technology-to-enable-development-of-ultra-long-acting-medicines-for-hiv/ 2025-04-01T16:29:30.79Z https://www.gsk.com/en-gb/media/press-releases/new-study-shows-more-needs-to-be-done-to-raise-public-awareness-on-the-impact-of-good-oral-health-habits-on-overall-health/ 2025-04-01T16:29:31.213Z https://www.gsk.com/en-gb/media/press-releases/gsk-unveils-plan-for-one-of-europe-s-largest-life-science-campuses-in-stevenage/ 2025-04-01T16:29:25.15Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-data-from-diverse-portfolio-and-pipeline/ 2025-04-01T16:29:25.603Z https://www.gsk.com/en-gb/media/press-releases/brian-mcnamara-appointed-ceo-designate-of-new-independent-consumer-healthcare-company/ 2025-04-01T16:29:26.007Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-sales-of-81-billion-plus6-aer-plus15-cer/ 2025-04-23T14:16:31.573Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-joint-procurement-agreement-with-european-commission-for-covid-19-treatment-sotrovimab/ 2025-04-01T16:29:26.97Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-fda-approval-for-nucala-mepolizumab-for-use-in-adults-with-chronic-rhinosinusitis-with-nasal-polyps/ 2025-04-01T16:29:27.353Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-accelerated-approval-for-jemperli-dostarlimab-gxly-for-adult-patients-with-mismatch-repair-deficient-dmmr-recurrent-or-advanced-solid-tumours/ 2025-04-01T16:29:27.83Z https://www.gsk.com/en-gb/media/press-releases/gsk-consumer-healthcare-leads-oral-care-industry-with-launch-of-its-first-carbon-neutral-toothbrush/ 2025-04-01T16:29:21.647Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-highlight-continued-progress-in-oncology-pipeline-and-portfolio-with-data-presented-at-esmo/ 2025-04-01T16:29:22.093Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinions-recommending-approval-of-nucala-mepolizumab-in-three-additional-eosinophil-driven-diseases/ 2025-04-01T16:29:22.49Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-key-data-that-provides-further-support-for-the-use-of-2-drug-regimens/ 2025-04-01T16:29:22.89Z https://www.gsk.com/en-gb/media/press-releases/changing-attitudes-to-vaccination-after-the-covid-19-pandemic-could-increase-adult-vaccination-rates-improving-health-outcomes-over-the-longer-term/ 2025-04-01T16:29:23.343Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-exclusive-license-agreement-with-shionogi-to-develop-third-generation-hiv-integrase-inhibitor-with-potential-for-ultra-long-acting-dosing-intervals/ 2025-04-01T16:29:23.8Z https://www.gsk.com/en-gb/media/press-releases/viiv-presents-three-year-switch-data-for-dovato/ 2025-04-01T16:29:24.267Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-showcase-significant-scientific-advances-in-renal-care-at-the-american-society-of-nephrology-kidney-week-2021/ 2025-04-01T16:29:24.7Z https://www.gsk.com/en-gb/media/press-releases/votes-unanimously-to-recommend-shingrix-for-immunocompromised-adults-aged-19-and-up/ 2025-04-01T16:29:18.13Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q3-sales-of-91-billion-plus5-aer-plus10-cer/ 2025-04-23T14:15:29.683Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-dr-harry-hal-c-dietz-md-to-join-the-board-as-non-executive-director/ 2025-04-01T16:29:19.12Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-interim-data-showing-vocabria-cabotegravir-and-rekambys-rilpivirine-can-be-implemented-successfully-in-a-variety-of-european-healthcare-settings/ 2025-04-01T16:29:19.563Z https://www.gsk.com/en-gb/media/press-releases/gsk-showcases-progress-from-the-dreamm-clinical-trial-programme-in-multiple-myeloma-at-the-2021-ash-annual-meeting/ 2025-04-01T16:29:20.133Z https://www.gsk.com/en-gb/media/press-releases/gsk-unveils-target-the-future-a-global-multi-year-programme-to-help-address-key-challenges-affecting-the-multiple-myeloma-community/ 2025-04-01T16:29:20.6Z https://www.gsk.com/en-gb/media/press-releases/mhra-grants-conditional-marketing-authorisation1-for-covid-19-treatment-xevudy-sotrovimab/ 2025-04-01T16:29:21.063Z https://www.gsk.com/en-gb/media/press-releases/xevudy-sotrovimab-granted-marketing-authorisation-by-the-european-commission-for-the-early-treatment-of-covid-19/ 2025-04-01T16:29:14.95Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-sir-dave-lewis-appointed-non-executive-chair-designate-of-independent-consumer-healthcare-company/ 2025-04-01T16:29:15.417Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-apretude-cabotegravir-extended-release-injectable-suspension-the-first-and-only-long-acting-injectable-option-for-hiv-prevention/ 2025-04-01T16:29:15.853Z https://www.gsk.com/en-gb/media/press-releases/tony-wood-appointed-chief-scientific-officer-designate-gsk/ 2025-04-01T16:29:16.29Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-settlement-between-viiv-healthcare-and-gilead-sciences/ 2025-04-01T16:29:16.76Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-long-term-findings-from-its-innovative-2-drug-and-long-acting-hiv-medicines-portfolio-at-croi-2022/ 2025-04-01T16:29:17.157Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-fy-2021-reported-sales-of-34-billion-stable-at-aer-plus5-cer/ 2025-04-23T14:14:53.45Z https://www.gsk.com/en-gb/media/press-releases/china-s-national-medical-products-administration-approves-benlysta-belimumab-for-adult-patients-with-active-lupus-nephritis/ 2025-04-01T16:29:11.82Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-phase-iii-rsv-maternal-vaccine-candidate-programme/ 2025-04-01T16:29:12.22Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-independent-consumer-healthcare-company-is-to-be-called-haleon/ 2025-04-01T16:29:12.653Z https://www.gsk.com/en-gb/media/press-releases/gsk-introduces-haleon-to-investors/ 2025-04-01T16:29:13.107Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-appointments-to-designate-haleon-board/ 2025-04-01T16:29:13.537Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-demonstrate-its-commitment-to-improving-outcomes-for-patients-with-gynaecologic-cancer-at-the-2022-sgo-annual-meeting/ 2025-04-01T16:29:13.97Z https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-sierra-oncology-for-19bn/ 2025-04-01T16:29:14.423Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q1-2022-sales-of-98-billion/ 2025-04-23T14:13:04.937Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-dr-vishal-sikka-to-join-the-board-as-non-executive-director/ 2025-04-01T16:29:09.023Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-seeking-expanded-indication-for-flulaval-quadrivalent-influenza-vaccine-for-infants-6-mosplus/ 2025-04-01T16:29:09.563Z https://www.gsk.com/en-gb/media/press-releases/gsk-confirms-closure-of-agreement-to-divest-non-core-assets-to-aspen/ 2025-04-01T16:29:09.973Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/ 2025-04-01T16:29:10.357Z https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-study-of-once-daily-closed-triple-combination-therapy-ffumecvi-in-patients-with-asthma/ 2025-04-01T16:29:10.86Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-tivicay-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/ 2025-04-01T16:29:11.29Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-in-japan-for-belimumab-in-systemic-lupus-erythematosus/ 2025-04-01T16:29:05.483Z https://www.gsk.com/en-gb/media/press-releases/gsk-opens-new-global-vaccines-rd-center-in-rockville-md-usa/ 2025-04-01T16:29:05.943Z https://www.gsk.com/en-gb/media/press-releases/dominique-limet-to-step-down-as-ceo-of-viiv-healthcare-deborah-waterhouse-to-succeed-him/ 2025-04-01T16:29:06.33Z https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-10025-mcg-gains-approval-in-japan-for-use-in-patients-with-copd/ 2025-04-01T16:29:06.717Z https://www.gsk.com/en-gb/media/press-releases/gsk-files-eu-regulatory-submission-for-once-daily-closed-triple-combination-therapy-ffumecvi-for-patients-with-copd/ 2025-04-01T16:29:07.153Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-of-candidate-vaccine-for-prevention-of-shingles-follows-regulatory-submissions-in-us-and-canada/ 2025-04-01T16:29:07.583Z https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-programme-with-daprodustat-for-anaemia-associated-with-chronic-kidney-disease/ 2025-04-01T16:29:07.997Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-lll-study-of-mepolizumab-meets-co-primary-endpoints-and-all-secondary-endpoints-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis/ 2025-04-01T16:29:02.34Z https://www.gsk.com/en-gb/media/press-releases/gsk-files-regulatory-submission-in-us-for-once-daily-closed-triple-combination-therapy-ffumecvi-for-patients-with-copd/ 2025-04-01T16:29:02.807Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen/ 2025-04-01T16:29:03.273Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-data-from-phase-iii-studies-of-sirukumab-in-adult-patients-with-moderately-to-severely-active-rheumatoid-arthritis/ 2025-04-01T16:29:03.747Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-benlysta-belimumab-shows-sustained-benefits-in-patients-with-sle/ 2025-04-01T16:29:04.157Z https://www.gsk.com/en-gb/media/press-releases/gsk-leads-access-to-medicine-index-2016/ 2025-04-01T16:29:04.557Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-for-shingles-candidate-vaccine-at-idweek-scientific-conference/ 2025-04-01T16:29:04.983Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2016/ 2025-04-01T16:28:58.77Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-of-candidate-vaccine-for-prevention-of-shingles/ 2025-04-01T16:28:59.197Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-appoints-brian-mcnamara-as-ceo-of-gsk-consumer-healthcare/ 2025-04-01T16:28:59.683Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-completes-sale-of-remaining-aspen-shares/ 2025-04-01T16:29:00.12Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-announces-intention-to-sell-remaining-holding-in-aspen/ 2025-04-01T16:29:00.66Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-for-sirukumab-in-rheumatoid-arthritis/ 2025-04-01T16:29:01.047Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submissions-for-subcutaneous-formulation-of-benlysta-belimumab-for-patients-with-systemic-lupus-disease/ 2025-04-01T16:29:01.467Z https://www.gsk.com/en-gb/media/press-releases/emma-walmsley-to-succeed-andrew-witty-as-chief-executive-officer-of-glaxosmithkline/ 2025-04-01T16:29:01.893Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-candidate-shingles-vaccine-shows-high-efficacy-against-shingles-and-its-complications-in-adults-aged-70-years-and-over-in-phase-iii-study-published-in-nejm/ 2025-04-01T16:28:55.643Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-for-sirukumab-in-rheumatoid-arthritis/ 2025-04-01T16:28:56.11Z https://www.gsk.com/en-gb/media/press-releases/gsk-divests-non-core-assets-to-aspen/ 2025-04-01T16:28:56.56Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-results-from-phase-iii-fulfil-study-of-closed-triple-combination-therapy-ffumecvi-versus-symbicort-turbohaler-in-copd-at-ers-international-congress/ 2025-04-01T16:28:57.063Z https://www.gsk.com/en-gb/media/press-releases/real-world-data-shows-83-percent-effectiveness-for-bexsero-in-infants-in-first-year-of-uk-national-meningitis-b-immunisation-programme/ 2025-04-01T16:28:57.5Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/ 2025-04-01T16:28:57.893Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-verily-to-establish-galvani-bioelectronics-a-new-company-dedicated-to-the-development-of-bioelectronic-medicines/ 2025-04-01T16:28:58.313Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2016-and-half-yearly-financial-report-for-the-half-year-2016/ 2025-04-01T16:28:52.187Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-significant-new-investment-in-uk-manufacturing-network/ 2025-04-01T16:28:52.657Z https://www.gsk.com/en-gb/media/press-releases/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%C3%AFve-women-living-with-hiv/ 2025-04-01T16:28:53.173Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-call-for-developing-country-innovations-to-enter-1-million-award/ 2025-04-01T16:28:53.64Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-phase-i-oncology-study-with-its-icos-agonist-antibody/ 2025-04-01T16:28:54.07Z https://www.gsk.com/en-gb/media/press-releases/fulfil-study-shows-superiority-of-closed-triple-combination-therapy/ 2025-04-01T16:28:54.467Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/ 2025-04-01T16:28:54.933Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-study-of-sirukumab-meets-both-co-primary-endpoints-in-patients-with-rheumatoid-arthritis/ 2025-04-01T16:28:48.66Z https://www.gsk.com/en-gb/media/press-releases/strimvelistm-receives-european-marketing-authorisation-to-treat-very-rare-disease-ada-scid/ 2025-04-01T16:28:49.143Z https://www.gsk.com/en-gb/media/press-releases/gsk-fondazione-telethon-and-ospedale-san-raffaele-announce-publication-of-pivotal-safety-and-efficacy-of-gene-therapy-for-children-with-ada-scid/ 2025-04-01T16:28:49.6Z https://www.gsk.com/en-gb/media/press-releases/salford-lung-study-results-show-copd-patients-treated-with-relvar-ellipta-achieve-superior-reduction-in-exacerbations-compared-with-usual-care/ 2025-04-01T16:28:50.013Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-from-breo-ellipta-summit-study-in-patients-with-copd-at-ats-conference/ 2025-04-01T16:28:50.483Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-efficacy-data-for-anoro-ellipta-in-copd-patients-who-remained-symptomatic-on-tiotropium/ 2025-04-01T16:28:50.927Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-bexsero-achieves-primary-and-secondary-endpoints-with-reduced-3-dose-schedule-2plus1-in-safety-and-immunogenicity-study-in-infants-and-children/ 2025-04-01T16:28:51.363Z https://www.gsk.com/en-gb/media/press-releases/european-agency-endorses-antiseptic-gel-developed-through-gsk-and-save-the-children-partnership-for-newborn-umbilical-cord-infections-in-developing-countries/ 2025-04-01T16:28:51.78Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2016/ 2025-04-01T16:28:45.66Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-extends-medicines-patent-pool-licence-agreement-for-dolutegravir-to-cover-all-lower-middle-income-countries/ 2025-04-01T16:28:46.03Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-start-of-a-phase-ii-study-to-evaluate-an-anti-gm-csf-antibody-for-inflammatory-hand-osteoarthritis/ 2025-04-01T16:28:46.46Z https://www.gsk.com/en-gb/media/press-releases/gsk-opens-new-state-of-the-art-respiratory-manufacturing-facility-in-ware-uk/ 2025-04-01T16:28:46.883Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-in-europe-for-strimvelis-the-first-gene-therapy-to-treat-very-rare-disease-ada-scid/ 2025-04-01T16:28:47.323Z https://www.gsk.com/en-gb/media/press-releases/gsk-expands-graduated-approach-to-patents-and-intellectual-property-to-widen-access-to-medicines-in-the-world-s-poorest-countries/ 2025-04-01T16:28:47.793Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-marketing-authorisation-for-nucala-mepolizumab-in-japan/ 2025-04-01T16:28:48.203Z https://www.gsk.com/en-gb/media/press-releases/sir-andrew-witty-to-retire-from-gsk-in-march-2017/ 2025-04-01T16:28:42.07Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-the-company-directorate-changes/ 2025-04-01T16:28:42.49Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-advair-diskus-achieves-primary-endpoint-in-laba-safety-study-of-children-aged-4-11-years-with-asthma/ 2025-04-01T16:28:42.863Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-miltenyi-biotec-establish-cell-and-gene-therapy-collaboration/ 2025-04-01T16:28:43.367Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-at-aaaai-on-efficacy-of-nucala-mepolizumab-in-severe-asthma-patients-stratified-by-eosinophil-levels/ 2025-04-01T16:28:43.79Z https://www.gsk.com/en-gb/media/press-releases/nejm-publishes-results-of-gsk-s-long-term-laba-safety-study-of-advair-diskus-in-adults-and-adolescents-with-asthma/ 2025-04-01T16:28:44.21Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-on-the-long-term-efficacy-safety-of-nucala-for-the-treatment-of-severe-asthma-with-an-eosinophilic-phenotype/ 2025-04-01T16:28:44.77Z https://www.gsk.com/en-gb/media/press-releases/gsk-names-winners-of-2015-discovery-fast-track-challenge/ 2025-04-01T16:28:45.22Z https://www.gsk.com/en-gb/media/press-releases/new-long-term-organ-damage-analysis-published-for-gsk-s-benlysta-belimumab/ 2025-04-01T16:28:38.893Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-results-for-investigational-long-acting-injectable-cabotegravir/ 2025-04-01T16:28:39.333Z https://www.gsk.com/en-gb/media/press-releases/four-inspiring-innovations-which-help-reduce-child-deaths-in-developing-countries-share-1-million-prize-from-gsk-and-save-the-children/ 2025-04-01T16:28:39.79Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-global-hiv-business-viiv-healthcare-completes-transactions-to-acquire-bristol-myers-squibb-s-rd-hiv-assets/ 2025-04-01T16:28:40.253Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2015/ 2025-06-02T13:19:04.537Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-adaptimmune-expand-strategic-immunotherapy-collaboration/ 2025-04-01T16:28:41.083Z https://www.gsk.com/en-gb/media/press-releases/update-on-gsk-s-response-to-the-zika-virus-disease-outbreak/ 2025-04-01T16:28:41.513Z https://www.gsk.com/en-gb/media/press-releases/gsk-statement-on-pneumococcal-vaccine-pricing/ 2025-04-01T16:28:35.643Z https://www.gsk.com/en-gb/media/press-releases/global-pharmaceutical-industry-calls-on-governments-to-work-with-them-to-beat-the-rising-threat-of-drug-resistance/ 2025-04-01T16:28:36.057Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2014/ 2025-04-01T16:28:36.51Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2015/ 2025-04-01T16:28:36.897Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2015/ 2025-04-01T16:28:37.26Z https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-dr-jesse-goodman-to-the-board-as-a-non-executive-director/ 2025-04-01T16:28:37.67Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-fourth-quarter-2013/ 2025-04-01T16:28:38.04Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-first-quarter-2014/ 2025-04-01T16:28:38.463Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-second-quarter-2014/ 2025-04-01T16:28:31.703Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2014/ 2025-04-01T16:28:32.167Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-third-quarter-2013/ 2025-04-01T16:28:32.647Z https://www.gsk.com/en-gb/media/press-releases/world-s-first-everyday-fluoride-toothpaste-with-novamin-technology-that-can-repair-sensitive-teeth/ 2025-04-01T16:28:33.097Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-q3-results-for-2010/ 2025-04-01T16:28:33.493Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-q2-results-for-2010/ 2025-04-01T16:28:33.86Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-q1-results-for-2010/ 2025-04-01T16:28:34.303Z https://www.gsk.com/en-gb/media/press-releases/abbas-hussain-to-leave-gsk/ 2025-04-01T16:28:34.723Z https://www.gsk.com/en-gb/media/press-releases/luke-miels-appointed-president-global-pharmaceuticals-gsk/ 2025-04-01T16:28:35.17Z https://www.gsk.com/en-gb/media/press-releases/results-announcement-for-the-fourth-quarter-2016/ 2025-06-02T13:06:58.25Z https://www.gsk.com/en-gb/media/press-releases/uk-biobank-gsk-and-regeneron-announce-largest-gene-sequencing-initiative-on-world-s-most-detailed-health-database-to-improve-drug-discovery-and-disease-diagnosis/ 2025-04-01T16:28:29.52Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-scholarships-to-recognise-retiring-ceo-sir-andrew-witty-s-contribution-to-global-health/ 2025-04-01T16:28:29.97Z https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-study-with-mepolizumab-in-patients-with-severe-hypereosinophilic-syndrome/ 2025-04-01T16:28:30.453Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-regulatory-submission-in-japan-of-its-candidate-vaccine-for-prevention-of-shingles/ 2025-04-01T16:28:30.903Z https://www.gsk.com/en-gb/media/press-releases/togo-becomes-first-country-in-africa-to-validate-the-elimination-of-lymphatic-filariasis-as-a-public-health-problem/ 2025-04-01T16:28:31.33Z https://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-significantly-improved-asthma-control-in-salford-lung-study-patients-compared-with-their-usual-care/ 2025-04-01T16:28:26.087Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-headline-phase-iii-results-of-mepolizumab-in-patients-with-severe-chronic-obstructive-pulmonary-disease/ 2025-04-01T16:28:26.557Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-nejm-publication-of-positive-phase-iii-study-investigating-mepolizumab-in-patients-with-eosinophilic-granulomatosis-with-polyangiitis-egpa/ 2025-04-01T16:28:26.987Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-at-ats-on-treatment-effect-of-nucala-mepolizumab-in-severe-asthma-according-to-blood-eosinophil-level/ 2025-04-01T16:28:27.417Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines/ 2025-04-01T16:28:27.847Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-mmv-announce-positive-headline-phase-iii-results-showing-single-dose-tafenoquine-reduces-risk-of-relapse-in-patients-with-plasmodium-vivax-malaria/ 2025-04-01T16:28:28.277Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-results-from-10-year-continuation-study-showing-sustained-disease-control-with-benlysta-belimumab-in-sle/ 2025-04-01T16:28:28.703Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-results-from-phase-iii-revaccination-study-of-its-candidate-shingles-vaccine-shingrix-at-cdc-s-advisory-meeting/ 2025-04-01T16:28:22.85Z https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-study-with-mepolizumab-in-patients-with-nasal-polyps/ 2025-04-01T16:28:23.263Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-for-synflorix-pneumococcal-vaccine-four-dose-vial/ 2025-04-01T16:28:23.697Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-regulatory-submission-for-mepolizumab-in-eosinophilic-granulomatosis-with-polyangiitis-egpa/ 2025-04-01T16:28:24.253Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-further-progress-in-q2-and-sets-out-new-priorities-for-the-group/ 2025-04-25T15:39:17.033Z https://www.gsk.com/en-gb/media/press-releases/gsk-updates-on-uk-manufacturing-network/ 2025-04-01T16:28:25.233Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-eu-filing-for-extended-use-of-relvar-ellipta-in-patients-with-controlled-asthma-on-an-icslaba-combination/ 2025-04-01T16:28:25.657Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-fda-approval-for-a-new-self-injectable-formulation-of-benlysta-belimumab-for-systemic-lupus-erythematosus/ 2025-04-01T16:28:19.72Z https://www.gsk.com/en-gb/media/press-releases/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks/ 2025-04-01T16:28:20.183Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-filing-of-arnuity-ellipta-in-children-with-asthma/ 2025-04-01T16:28:20.727Z https://www.gsk.com/en-gb/media/press-releases/karenann-terrell-appointed-chief-digital-technology-officer-gsk/ 2025-04-01T16:28:21.15Z https://www.gsk.com/en-gb/media/press-releases/switching-to-a-dolutegravir-regimen-from-a-boosted-protease-inhibitor-regimen-maintained-viral-suppression-and-improved-lipid-fractions/ 2025-04-01T16:28:21.65Z https://www.gsk.com/en-gb/media/press-releases/gsk-responds-to-uk-life-sciences-industrial-strategy/ 2025-04-01T16:28:22.027Z https://www.gsk.com/en-gb/media/press-releases/gsk-exercises-option-on-phase-iii-ny-eso-t-cell-therapy-gsk3377794/ 2025-04-01T16:28:22.427Z https://www.gsk.com/en-gb/media/press-releases/positive-results-from-pioneering-salford-lung-study-in-asthma-published-in-the-lancet-and-presented-at-european-respiratory-congress/ 2025-04-01T16:28:16.3Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-results-published-in-nejm-of-mepolizumab-in-patients-with-eosinophilic-copd-at-risk-of-exacerbations/ 2025-04-01T16:28:16.787Z https://www.gsk.com/en-gb/media/press-releases/fda-advisory-committee-votes-unanimously-for-shingrix-hzsu-in-the-us-for-prevention-of-herpes-zoster-shingles-in-adults-ages-50-and-over/ 2025-04-01T16:28:17.287Z https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-once-daily-single-inhaler-triple-therapy-receives-positive-opinion-from-the-chmp-in-europe-for-appropriate-patients-with-copd/ 2025-04-01T16:28:17.75Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-for-self-injectable-formulation-of-benlysta-for-systemic-lupus-erythematosus/ 2025-04-01T16:28:18.18Z https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-approved-as-the-first-once-daily-single-inhaler-triple-therapy-for-the-treatment-of-appropriate-patients-with-copd-in-the-us/ 2025-04-01T16:28:18.823Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-innoviva-report-positive-headline-results-from-impact-study-showing-single-inhaler-triple-therapy-trelegy-ellipta-reduced-copd-exacerbations/ 2025-04-01T16:28:19.243Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-approval-for-benlysta-in-japan-for-the-treatment-of-systemic-lupus-erythematosus/ 2025-04-01T16:28:12.99Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-approval-of-shingrix-in-canada/ 2025-04-01T16:28:13.413Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-q3-sales-of-78-billion-plus4-aer-plus2-cer/ 2025-04-23T14:54:19.65Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/ 2025-04-01T16:28:14.37Z https://www.gsk.com/en-gb/media/press-releases/public-private-consortium-aims-to-cut-preclinical-cancer-drug-discovery-from-six-years-to-just-one/ 2025-04-01T16:28:14.82Z https://www.gsk.com/en-gb/media/press-releases/gsk-study-demonstrates-superiority-of-anoro-ellipta-to-stiolto-respimat-in-improving-lung-function-in-chronic-obstructive-pulmonary-disease/ 2025-04-01T16:28:15.267Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-investigational-bcma-antibody-drug-conjugate-receives-breakthrough-therapy-designation-from-us-fda-for-relapsed-and-refractory-multiple-myeloma/ 2025-04-01T16:28:15.79Z https://www.gsk.com/en-gb/media/press-releases/new-multi-country-survey-reveals-need-for-improved-awareness-around-long-term-impact-and-appropriate-use-of-corticosteroids-in-sle-management/ 2025-04-01T16:28:09.77Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-application-for-mepolizumab-in-eosinophilic-chronic-obstructive-pulmonary-disease-copd/ 2025-04-01T16:28:10.25Z https://www.gsk.com/en-gb/media/press-releases/first-long-term-efficacy-analysis-on-the-effect-of-gsk-s-benlysta-on-rate-of-organ-damage-progression-in-sle-versus-standard-therapy-alone/ 2025-04-01T16:28:10.707Z https://www.gsk.com/en-gb/media/press-releases/patrick-vallance-president-rd-gsk-to-become-uk-governments-chief-scientific-adviser/ 2025-04-16T12:56:13.33Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-for-self-injectable-formulation-of-benlysta-for-the-treatment-of-systemic-lupus-erythematosus/ 2025-04-01T16:28:11.747Z https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-once-daily-single-inhaler-triple-therapy-gains-marketing-authorisation-in-europe-for-the-treatment-of-copd/ 2025-04-01T16:28:12.15Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-application-for-single-dose-tafenoquine-for-plasmodium-vivax-malaria/ 2025-04-01T16:28:12.603Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-start-of-phase-iii-study-of-long-acting-cabotegravir-for-hiv-prevention-in-women/ 2025-04-01T16:28:06.513Z https://www.gsk.com/en-gb/media/press-releases/new-data-supports-the-safety-and-efficacy-of-gsk-s-shingrix-in-preventing-shingles-in-autologous-haematopoietic-stem-cell-transplant-patients/ 2025-04-01T16:28:06.983Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-promising-new-data-for-priority-bcma-asset-from-its-emerging-oncology-pipeline-at-59th-ash-meeting/ 2025-04-01T16:28:07.46Z https://www.gsk.com/en-gb/media/press-releases/gsk-achieves-approval-for-nucala-mepolizumab-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-egpa-for-adults-in-the-us/ 2025-04-01T16:28:07.937Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-for-single-dose-tafenoquine-for-the-treatment-of-plasmodium-vivax-malaria-to-australia-s-therapeutic-goods-administration/ 2025-04-01T16:28:08.4Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-us-label-update-on-icslaba-combinations-in-asthma-based-on-review-of-safety-data/ 2025-04-01T16:28:08.883Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-chmp-positive-opinion-for-labelling-update-to-relvar-ellipta-in-patients-with-asthma/ 2025-04-01T16:28:09.347Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-improvements-in-sales-margins-and-cash-flow-in-2017/ 2025-04-23T14:53:54.363Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-meningitis-b-vaccine-bexsero-receives-breakthrough-therapy-designation-from-us-fda-for-prevention-of-invasive-meningococcal-disease-in-children-2-10-years-of-age/ 2025-04-01T16:28:03.747Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/ 2025-04-01T16:28:04.17Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-files-patent-infringement-litigation-against-gilead-sciences-inc-over-bictegravir/ 2025-04-01T16:28:04.657Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-landmark-impact-data-to-european-medicines-agency-to-support-expanded-label-for-trelegy-ellipta/ 2025-04-01T16:28:05.1Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-improved-asthma-control-in-patients-uncontrolled-on-xolair-omalizumab/ 2025-04-01T16:28:05.57Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/ 2025-04-01T16:28:06.047Z https://www.gsk.com/en-gb/media/press-releases/gsk-starts-phase-iii-study-of-benlysta-and-rituximab-combination-in-systemic-lupus-erythematosus/ 2025-04-01T16:28:00.273Z https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-plc-and-pfizer-inc-to-form-new-world-leading-consumer-healthcare-joint-venture/ 2025-04-01T16:28:00.69Z https://www.gsk.com/en-gb/media/press-releases/gsk-update-regarding-pfizer-inc-consumer-healthcare/ 2025-04-01T16:28:01.117Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/ 2025-04-16T12:54:20.873Z https://www.gsk.com/en-gb/media/press-releases/gsk-signs-strategic-agreement-to-transfer-rare-disease-gene-therapy-portfolio-to-orchard-therapeutics/ 2025-04-01T16:28:01.947Z https://www.gsk.com/en-gb/media/press-releases/landmark-impact-study-published-in-nejm-shows-significant-benefits-of-trelegy-ellipta-for-patients-with-copd/ 2025-04-01T16:28:02.6Z https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-kevin-sin-as-new-svp-and-head-of-worldwide-business-development-for-rd/ 2025-04-01T16:27:57.45Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-q1-sales-of-72-billion-2-aer-plus4-cer/ 2025-04-23T14:53:27.867Z https://www.gsk.com/en-gb/media/press-releases/simon-dingemans-chief-financial-officer-to-retire-from-gsk/ 2025-04-01T16:27:58.383Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-study-reports-long-term-safety-data-consistent-exacerbation-reduction-and-improved-asthma-control/ 2025-04-01T16:27:58.883Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/ 2025-04-01T16:27:59.31Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-of-arnuity-ellipta-for-use-in-children-from-5-years-old-who-suffer-from-asthma/ 2025-04-01T16:27:59.807Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-in-japan-for-once-daily-single-inhaler-triple-therapy-ffumecvi-for-patients-with-copd/ 2025-04-01T16:27:54.01Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-consumer-healthcare-buyout/ 2025-04-01T16:27:54.52Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-changes-to-vaccines-and-global-manufacturing-supply-leadership/ 2025-04-01T16:27:55.127Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-results-showing-low-rates-of-organ-damage-with-long-term-use-of-benlysta/ 2025-04-01T16:27:55.653Z https://www.gsk.com/en-gb/media/press-releases/infants-may-now-be-protected-against-meningitis-b-with-fewer-doses-adding-flexibility-to-vaccination-schedules/ 2025-04-01T16:27:56.09Z https://www.gsk.com/en-gb/media/press-releases/roivant-subsidiary-dermavant-sciences-signs-agreement-with-gsk-to-purchase-rights-to-tapinarof/ 2025-04-01T16:27:57.027Z https://www.gsk.com/en-gb/media/press-releases/james-ford-appointed-gsk-general-counsel/ 2025-04-01T16:27:50.66Z https://www.gsk.com/en-gb/media/press-releases/us-fda-advisory-committee-endorses-the-effectiveness-and-safety-of-single-dose-tafenoquine-for-the-radical-cure-of-p-vivax-malaria/ 2025-04-01T16:27:51.11Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-phase-iii-data-at-aids-2018-from-landmark-gemini-studies/ 2025-04-01T16:27:51.54Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/ 2025-04-01T16:27:52.003Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-improvements-in-sales-margins-and-cash-flow-in-q2-2018/ 2025-04-23T14:52:55.497Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-adaptimmune-complete-transition-of-ny-eso-spear-t-cell-therapy-programme-to-gsk/ 2025-04-01T16:27:53.007Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-23andme-sign-agreement-to-leverage-genetic-insights-for-the-development-of-novel-medicines/ 2025-04-01T16:27:53.533Z https://www.gsk.com/en-gb/media/press-releases/gsk-reports-on-outcome-of-the-fda-advisory-committee-on-mepolizumab-for-the-treatment-of-copd-patients-on-maximum-inhaled-therapy/ 2025-04-01T16:27:47.63Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/ 2025-04-01T16:27:48.04Z https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-nucala-mepolizumab-for-the-treatment-of-children-with-severe-asthma/ 2025-04-16T13:36:57.9Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-complete-response-letter-from-us-fda-for-use-of-mepolizumab-in-copd-patients/ 2025-04-01T16:27:48.903Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-results-of-indirect-treatment-comparisons-of-nucala-to-benralizumab-and-reslizumab-for-severe-eosinophilic-asthma/ 2025-04-01T16:27:49.35Z https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-receives-positive-chmp-opinion-supporting-expanded-copd-indication-in-europe/ 2025-04-01T16:27:49.803Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-tres-cantos-open-lab-foundation-announce-additional-5m-funding-for-open-innovation-research-in-diseases-impacting-the-developing-world/ 2025-04-01T16:27:50.237Z https://www.gsk.com/en-gb/media/press-releases/gsk-updates-policy-for-working-with-healthcare-professionals/ 2025-04-01T16:27:44.27Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv/ 2025-04-01T16:27:44.707Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-q3-sales-of-81-billion-plus3-aer-plus6-cer/ 2025-04-23T14:52:20.027Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/ 2025-04-01T16:27:45.72Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-at-48-weeks-in-heavily-treatment-experienced-patients-with-hiv/ 2025-04-01T16:27:46.373Z https://www.gsk.com/en-gb/media/press-releases/statement-gsk-supports-gold-committee-s-efforts-to-further-personalise-copd-management/ 2025-04-01T16:27:46.763Z https://www.gsk.com/en-gb/media/press-releases/once-daily-trelegy-ellipta-gains-expanded-copd-indication-in-europe/ 2025-04-01T16:27:47.163Z https://www.gsk.com/en-gb/media/press-releases/kozenis-tafenoquine-approved-by-the-australian-therapeutic-goods-administration-for-the-radical-cure-of-p-vivax-malaria/ 2025-04-01T16:27:40.703Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-us-regulatory-filing-to-expand-the-use-of-nucala-in-children-with-severe-eosinophilic-asthma/ 2025-04-01T16:27:41.153Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine/ 2025-04-01T16:27:41.62Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-kyowa-hakko-kirin-sign-strategic-commercialisation-deal-in-japan-for-daprodustat-a-potential-new-oral-treatment-for-anaemia-associated-with-chronic-kidney-disease/ 2025-04-01T16:27:42.137Z https://www.gsk.com/en-gb/media/press-releases/juluca-dolutegravirrilpivirine-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/ 2025-04-01T16:27:42.537Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-divest-horlicks-and-other-consumer-healthcare-nutrition-products-to-unilever/ 2025-04-01T16:27:42.967Z https://www.gsk.com/en-gb/media/press-releases/two-positive-phase-iii-studies-of-tafenoquine-for-the-radical-cure-of-plasmodium-vivax-malaria-published-in-the-new-england-journal-of-medicine/ 2025-04-01T16:27:43.397Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-tesaro-an-oncology-focused-biopharmaceutical-company/ 2025-04-01T16:27:43.837Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-merck-kgaa-darmstadt-germany-announce-global-alliance-to-jointly-develop-and-commercialise-m7824-a-novel-immunotherapy-with-potential-in-multiple-difficult-to-treat-cancers/ 2025-04-01T16:27:37.507Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-sales-earnings-and-cash-flow-growth-in-2018/ 2025-04-23T14:51:54.883Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-a-positive-chmp-opinion-for-intravenous-zanamivir-for-the-treatment-of-complicated-influenza/ 2025-04-01T16:27:38.52Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-two-pivotal-phase-iii-studies/ 2025-04-01T16:27:38.93Z https://www.gsk.com/en-gb/media/press-releases/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer/ 2025-04-01T16:27:39.357Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-juluca-dolutegravirrilpivirine-maintains-hiv-viral-suppression-at-148-weeks/ 2025-04-01T16:27:39.807Z https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-viiv-healthcare-s-dovato-dolutegravirlamivudine-the-first-once-daily-single-tablet-two-drug-regimen-for-treatment-naive-hiv-1-adults/ 2025-04-01T16:27:40.247Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-for-dovato-dolutegravirlamivudine-as-a-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-infection/ 2025-04-01T16:27:34.267Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-of-benlysta-for-intravenous-use-in-children-with-lupus-aged-five-years-and-above/ 2025-04-01T16:27:34.7Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-the-first-monthly-injectable-two-drug-regimen-of-cabotegravir-and-rilpivirine-for-treatment-of-hiv/ 2025-04-01T16:27:35.157Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-sales-of-77-billion-plus6-aer-plus5-cer/ 2025-04-23T14:23:22.863Z https://www.gsk.com/en-gb/media/press-releases/update-on-consumer-healthcare-joint-venture-with-pfizer/ 2025-04-01T16:27:36.21Z https://www.gsk.com/en-gb/media/press-releases/gsk-changes-sales-representative-incentive-programme/ 2025-04-01T16:27:36.643Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-approval-of-shingrix-in-china-for-prevention-of-shingles-in-adults-aged-50-and-over/ 2025-04-01T16:27:37.06Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-receives-positive-chmp-opinion-for-new-self-administration-options/ 2025-04-01T16:27:31.03Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-gains-fda-approval-for-two-new-self-administration-options/ 2025-04-01T16:27:31.503Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-data-on-anti-bcma-antibody-drug-conjugate-in-patients-with-relapsedrefractory-multiple-myeloma-to-be-presented-at-european-hematology-association-eha-congress/ 2025-04-01T16:27:31.953Z https://www.gsk.com/en-gb/media/press-releases/gsk-joins-forces-with-the-university-of-california-to-advance-genomic-research-and-improve-drug-discovery/ 2025-04-01T16:27:32.44Z https://www.gsk.com/en-gb/media/press-releases/us-food-and-drug-administration-accepts-gsk-s-application-for-zejula-niraparib-in-late-stage-ovarian-cancer-with-priority-review/ 2025-04-01T16:27:32.92Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-start-for-its-anti-gm-csf-antibody-otilimab-in-patients-with-rheumatoid-arthritis-ra/ 2025-04-01T16:27:33.353Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-eu-marketing-authorisation-for-dovato-dolutegravirlamivudine-a-new-once-daily-single-pill-two-drug-regimen-for-the-treatment-of-hiv-1-infection/ 2025-04-01T16:27:33.823Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint/ 2025-04-01T16:27:27.66Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-sales-and-earnings-growth-in-q2-2019/ 2025-04-23T14:23:01.797Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-transaction-with-pfizer-to-form-new-world-leading-consumer-healthcare-joint-venture/ 2025-04-01T16:27:28.713Z https://www.gsk.com/en-gb/media/press-releases/gsk-grants-exclusive-technology-license-for-clinical-stage-ebola-vaccines-to-sabin-vaccine-institute/ 2025-04-01T16:27:29.15Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-leadership-changes-in-the-us/ 2025-04-01T16:27:29.66Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-phase-iii-study-results-of-investigational-long-acting-injectable-hiv-treatment-regimen-administered-every-two-months/ 2025-04-01T16:27:30.117Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-present-data-from-its-innovative-oncology-portfolio-at-esmo-congress-2019/ 2025-04-01T16:27:30.617Z https://www.gsk.com/en-gb/media/press-releases/nucala-is-the-first-biologic-approved-in-the-us-for-six-to-11-year-old-children-with-severe-eosinophilic-asthma/ 2025-04-01T16:27:24.383Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-for-intravenous-benlysta-in-children-with-lupus-aged-five-years-and-above/ 2025-04-01T16:27:24.813Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-showing-promising-anti-tumour-activity-with-gsk3359609/ 2025-04-01T16:27:25.313Z https://www.gsk.com/en-gb/media/press-releases/phase-3-prima-trial-of-zejula-niraparib-is-the-first-study-to-show-a-parp-inhibitor-significantly-improves-pfs-regardless-of-biomarker-status/ 2025-04-01T16:27:25.757Z https://www.gsk.com/en-gb/media/press-releases/nucala-significantly-reduces-exacerbations-in-first-global-prospective-real-world-study-of-a-biologic-in-severe-eosinophilic-asthma/ 2025-04-01T16:27:26.357Z https://www.gsk.com/en-gb/media/press-releases/gsk-submits-filing-to-fda-for-trelegy-ellipta-use-in-patients-with-asthma/ 2025-04-01T16:27:26.78Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-lyell-immunopharma-join-forces-to-develop-the-next-generation-of-cancer-cell-therapies/ 2025-04-01T16:27:27.243Z https://www.gsk.com/en-gb/media/press-releases/gsk-agrees-to-divest-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic/ 2025-04-01T16:27:21.33Z https://www.gsk.com/en-gb/media/press-releases/gsk-starts-a-phase-iii-clinical-programme-for-a-potential-first-in-class-antibiotic-gepotidacin/ 2025-04-01T16:27:21.753Z https://www.gsk.com/en-gb/media/press-releases/gsk-candidate-vaccine-demonstrates-sustained-level-of-protection-against-active-pulmonary-tuberculosis/ 2025-04-01T16:27:22.153Z https://www.gsk.com/en-gb/media/press-releases/intravenous-benlysta-is-the-first-biologic-treatment-to-be-approved-for-children-with-lupus-in-europe/ 2025-04-01T16:27:22.6Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-sales-of-94-billion-plus16-aer-plus11-cer-pro-forma-plus6-cerstar/ 2025-04-23T14:22:38.887Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-is-the-first-treatment-to-show-a-significant-reduction-in-flares-for-patients-with-hypereosinophilic-syndrome-hes/ 2025-04-01T16:27:23.48Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-exclusive-licensing-agreement-with-the-national-institutes-of-health-for-investigational-bnab-with-potential-for-long-acting-hiv-treatment-and-prevention/ 2025-04-01T16:27:23.963Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-the-fda-for-fostemsavir-an-investigational-first-in-class-attachment-inhibitor-for-the-treatment-of-hiv-in-adults/ 2025-04-01T16:27:17.803Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-in-phase-3-study-of-benlysta-in-patients-with-lupus-nephritis/ 2025-04-01T16:27:18.267Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-complete-response-letter-from-us-fda-for-use-of-investigational-cabotegravir-and-rilpivirine-long-acting-regimen-in-the-treatment-of-hiv/ 2025-04-01T16:27:18.683Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-divestment-of-rabies-and-tick-borne-encephalitis-vaccines-to-bavarian-nordic/ 2025-04-01T16:27:19.16Z https://www.gsk.com/en-gb/media/press-releases/dovato-dolutegravirlamivudine-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/ 2025-04-01T16:27:19.61Z https://www.gsk.com/en-gb/media/press-releases/deborah-waterhouse-ceo-of-viiv-healthcare-to-join-gsk-corporate-executive-team-cet/ 2025-04-01T16:27:20.307Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-regulatory-application-to-the-european-medicines-agency-for-fostemsavir/ 2025-04-01T16:27:20.843Z https://www.gsk.com/en-gb/media/press-releases/world-s-first-meningitis-b-national-infant-vaccination-programme-shows-75-drop-in-cases-over-three-years/ 2025-04-01T16:27:14.283Z https://www.gsk.com/en-gb/media/press-releases/gsk-licenses-tuberculosis-vaccine-candidate-to-the-bill-melinda-gates-medical-research-institute-for-continued-development/ 2025-04-01T16:27:14.767Z https://www.gsk.com/en-gb/media/press-releases/cepi-and-gsk-announce-collaboration-to-strengthen-the-global-effort-to-develop-a-vaccine-for-the-2019-ncov-virus/ 2025-04-01T16:27:15.203Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-2019-sales-of-338-billion-plus10-aer-plus8-cer-pro-forma-plus4-cerstar/ 2025-04-23T14:21:02.123Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-voltaren-arthritis-pain-for-over-the-counter-use-in-the-united-states/ 2025-04-01T16:27:16.377Z https://www.gsk.com/en-gb/media/press-releases/clover-and-gsk-announce-research-collaboration-to-evaluate-coronavirus-covid-19-vaccine-candidate-with-pandemic-adjuvant-system/ 2025-04-01T16:27:16.787Z https://www.gsk.com/en-gb/media/press-releases/us-fda-accepts-gsk-s-snda-application-for-zejula-niraparib-for-first-line-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer/ 2025-04-01T16:27:17.273Z https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-accepts-submission-of-gsk-s-marketing-authorisation-application-for-zejula-niraparib-in-first-line-maintenance-treatment/ 2025-04-01T16:27:11.163Z https://www.gsk.com/en-gb/media/press-releases/first-of-its-kind-global-collaboration-launched-to-develop-transformative-treatment-regimens-for-tuberculosis/ 2025-04-01T16:27:11.66Z https://www.gsk.com/en-gb/media/press-releases/gsk-filing-accepted-by-european-medicines-agency-for-trelegy-ellipta-use-in-adult-patients-with-asthma/ 2025-04-01T16:27:12.12Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-advil-dual-action-with-acetaminophen-for-over-the-counter-use-in-the-united-states/ 2025-04-01T16:27:12.59Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-48-week-data-from-phase-iii-study-showing-every-two-month-regimen-of-investigational-long-acting/ 2025-04-01T16:27:12.993Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-long-term-data-from-phase-iii-study-demonstrating-efficacy-and-safety-of-cabotegravir-and-rilpivirine/ 2025-04-01T16:27:13.41Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-and-unc-chapel-hill-announce-five-year-renewal-of-innovative-hiv-cure-partnership/ 2025-04-01T16:27:13.84Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-first-global-regulatory-approval-of-cabenuva-the-first-complete-long-acting-regimen-for-the-treatment-of-hiv/ 2025-04-01T16:27:07.54Z https://www.gsk.com/en-gb/media/press-releases/zejula-niraparib-is-the-first-and-only-once-daily-parp-inhibitor-fda-approved-as-a-first-line-monotherapy-maintenance-treatment-for-women-with-advanced-ovarian-cancer/ 2025-04-01T16:27:07.973Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-zejula-niraparib-as-the-only-once-daily-parp-inhibitor-in-first-line-monotherapy-maintenance-treatment-for-women-with-platinum-responsive-advanced-ovarian-cancer/ 2025-04-01T16:27:08.46Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-is-the-first-anti-il5-biologic-to-report-positive-phase-3-results-in-patients-with-nasal-polyps/ 2025-04-01T16:27:09.013Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-enter-collaboration-to-find-coronavirus-solutions/ 2025-04-01T16:27:09.457Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-join-forces-in-unprecedented-vaccine-collaboration-to-fight-covid-19/ 2025-04-01T16:27:09.87Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-from-the-garnet-study-demonstrating-potential-of-dostarlimab-to-treat-a-subset-of-women-with-recurrent-or-advanced-endometrial-cancer/ 2025-04-01T16:27:10.3Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q1-sales-91-billion-plus19-aer-plus19-cer-proforma-plus10-cerstar/ 2025-04-23T14:15:56.157Z https://www.gsk.com/en-gb/media/press-releases/global-hiv-prevention-study-to-stop-early-after-viiv-healthcare-s-long-acting-injectable-shows-higher-efficacy-than-daily-oral-prep/ 2025-04-01T16:27:03.973Z https://www.gsk.com/en-gb/media/press-releases/gsk-partners-with-samsung-biologics/ 2025-04-01T16:27:04.44Z https://www.gsk.com/en-gb/media/press-releases/fda-grants-priority-review-of-nucala-for-patients-with-hypereosinophilic-syndrome-hes/ 2025-04-01T16:27:04.823Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-intention-to-produce-1-billion-doses-of-pandemic-vaccine-adjuvant/ 2025-04-01T16:27:05.35Z https://www.gsk.com/en-gb/media/press-releases/ideaya-and-gsk-announce-a-broad-partnership-in-synthetic-lethality-an-emerging-field-in-precision-medicine-oncology/ 2025-04-01T16:27:05.83Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-proposed-unregistered-offering-of-senior-notes-exchangeable-into-theravance-biopharma-ordinary-shares/ 2025-04-01T16:27:06.263Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-fda-advisory-committee-meeting-to-review-belantamab-mafodotin-for-the-treatment-of-patients-with-relapsedrefractory-multiple-myeloma/ 2025-04-01T16:27:06.707Z https://www.gsk.com/en-gb/media/press-releases/gsk-covid-19-vaccine-development-collaboration-with-clover-biopharmaceuticals-begins-clinical-trials/ 2025-04-01T16:27:07.1Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-first-regulatory-approval-for-duvroq-daprodustat-in-japan-for-patients-with-anaemia-due-to-chronic-kidney-disease/ 2025-04-01T16:27:00.857Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-for-rukobia-fostemsavir-a-first-in-class-treatment-for-hiv-in-adults-with-few-treatment-options-available/ 2025-04-01T16:27:01.303Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-q2-sales-of-76-billion-2-aer-3-cer-pro-forma-10-cerstar/ 2025-04-23T14:19:53.583Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-in-advanced-discussions-with-european-union-to-supply-up-to-300-million-doses-of-covid-19-vaccine/ 2025-04-01T16:27:02.3Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-phase-12-clinical-trial-of-covid-19-adjuvanted-recombinant-protein-based-vaccine-candidate/ 2025-04-01T16:27:02.703Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-confirm-agreement-with-european-union-to-supply-up-to-300-million-doses-of-adjuvanted-covid-19-vaccine/ 2025-04-01T16:27:03.12Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-sign-agreements-with-the-government-of-canada-to-supply-up-to-72-million-doses-of-adjuvanted-covid-19-vaccine/ 2025-04-01T16:27:03.59Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-confirm-intent-to-supply-covax-with-at-least-200-million-doses-of-adjuvanted-covid-19-vaccine/ 2025-04-01T16:26:57.143Z https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-global-expansion-to-phase-3-of-comet-ice-study-evaluating-vir-7831-for-the-treatment-of-covid-19/ 2025-04-01T16:26:57.607Z https://www.gsk.com/en-gb/media/press-releases/gsk-nucala-mepolizumab-filings-accepted-by-european-medicines-agency-for-three-additional-eosinophil-driven-diseases/ 2025-04-01T16:26:57.983Z https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-zejula-niraparib-as-first-line-monotherapy-maintenance-treatment-in-advanced-ovarian-cancer/ 2025-04-01T16:26:58.393Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-mmv-present-positive-data-on-treatment-for-plasmodium-vivax-malaria-in-children-from-6-months-up-to-15-years-of-age/ 2025-04-01T16:26:58.837Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-announce-a-delay-in-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-programme-to-improve-immune-response-in-the-elderly/ 2025-04-01T16:26:59.287Z https://www.gsk.com/en-gb/media/press-releases/fda-approves-gsk-s-benlysta-as-the-first-medicine-for-adult-patients-with-active-lupus-nephritis-in-the-us/ 2025-04-01T16:26:59.81Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-ahren-announce-co-led-series-a-investment-in-adrestia/ 2025-04-01T16:27:00.403Z https://www.gsk.com/en-gb/media/press-releases/gsk-mmv-filing-for-kozenis-tafenoquine-in-paediatric-populations-with-plasmodium-vivax-malaria-accepted-by-australian-therapeutic-goods-administration/ 2025-04-01T16:26:53.743Z https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-nhs-supported-agile-study-to-evaluate-vir-7832-in-the-early-treatment-of-covid-19/ 2025-04-01T16:26:54.243Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-novartis-announce-collaboration-to-support-scientific-research-into-genetic-diversity-in-africa/ 2025-04-01T16:26:54.833Z https://www.gsk.com/en-gb/media/press-releases/gsk-ranks-1st-in-the-2021-access-to-medicine-index-with-leading-rd-pipeline-for-priority-diseases/ 2025-04-01T16:26:55.343Z https://www.gsk.com/en-gb/media/press-releases/gsk-path-and-bharat-biotech-sign-product-transfer-agreement-to-help-ensure-long-term-supply-of-rts-sas01e-malaria-vaccine/ 2025-04-01T16:26:55.757Z https://www.gsk.com/en-gb/media/press-releases/lilly-vir-biotechnology-and-gsk-announce-first-patient-dosed-in-expanded-blaze-4-trial/ 2025-04-01T16:26:56.247Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/ 2025-04-01T16:26:56.723Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-gender-and-diversity-aspirational-targets-to-increase-representation-at-senior-levels/ 2025-04-01T16:26:50.033Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-expand-coronavirus-collaboration-to-advance-new-therapeutics-for-influenza/ 2025-04-01T16:26:50.457Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-new-phase-2-study-of-their-adjuvanted-recombinant-protein-based-covid-19-vaccine-candidate/ 2025-04-01T16:26:51.037Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-otilimab-data-for-treatment-of-covid-19/ 2025-04-01T16:26:51.483Z https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-provide-update-on-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/ 2025-04-01T16:26:51.983Z https://www.gsk.com/en-gb/media/press-releases/gsk-makes-landmark-pricing-agreement-for-rotavirus-vaccine-rotarix-for-use-with-children-living-in-humanitarian-crises/ 2025-04-01T16:26:52.387Z https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-vir-7831-reduces-hospitalisation-and-risk-of-death-in-early-treatment-of-adults-with-covid-19/ 2025-04-01T16:26:52.85Z https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/ 2025-04-01T16:26:53.327Z https://www.gsk.com/en-gb/media/press-releases/half-of-parents-surveyed-either-cancelled-or-delayed-their-child-s-scheduled-meningitis-vaccination-during-the-covid-19-pandemic-gsk-survey-shows-1/ 2025-04-01T16:26:46.767Z https://www.gsk.com/en-gb/media/press-releases/moncef-slaoui-departs-galvani-bioelectronics-board-of-directors/ 2025-04-01T16:26:47.227Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-submission-of-emergency-use-authorization-request-to-fda-for-vir-7831-for-the-early-treatment-of-covid-19/ 2025-04-01T16:26:47.67Z https://www.gsk.com/en-gb/media/press-releases/lilly-vir-biotechnology-and-gsk-announce-positive-topline-data-from-the-phase-2-blaze-4-trial-evaluating-bamlanivimab-with-vir-7831-in-low-risk-adults-with-covid-19/ 2025-04-01T16:26:48.107Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-support-manufacture-of-novavax-covid-19-vaccine/ 2025-04-01T16:26:48.543Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-ema-review-of-dual-action-monoclonal-antibody-vir-7831-for-the-early-treatment-of-covid-19/ 2025-04-01T16:26:49.17Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-the-start-of-the-ema-rolling-review-of-vir-7831-sotrovimab-for-the-early-treatment-of-covid-19/ 2025-04-01T16:26:49.603Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-covid-19-vaccine-candidate-demonstrates-strong-immune-responses-across-all-adult-age-groups-in-phase-2-trial/ 2025-04-01T16:26:43.2Z https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-positive-interim-phase-2-results-for-adjuvanted-covid-19-vaccine-candidate/ 2025-04-01T16:26:43.617Z https://www.gsk.com/en-gb/media/press-releases/ema-issues-positive-scientific-opinion-on-gsk-and-vir-biotechnology-s-sotrovimab-for-the-early-treatment-of-covid-19/ 2025-04-01T16:26:44.04Z https://www.gsk.com/en-gb/media/press-releases/gsk-announced-as-a-principal-partner-of-cop26-un-climate-change-conference/ 2025-04-01T16:26:44.47Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-initiate-global-phase-3-clinical-efficacy-study-of-covid-19-vaccine-candidate/ 2025-04-01T16:26:44.94Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-continuing-progress-of-the-comet-clinical-development-programme-for-sotrovimab/ 2025-04-01T16:26:45.503Z https://www.gsk.com/en-gb/media/press-releases/new-gsk-to-deliver-step-change-in-growth-and-performance-over-next-ten-years/ 2025-04-01T16:26:45.913Z https://www.gsk.com/en-gb/media/press-releases/elliott-advisors-uk-letter-to-gsk/ 2025-04-01T16:26:46.353Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-alector-collaboration-in-immuno-neurology/ 2025-04-01T16:26:39.59Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-daprodustat-phase-3-headline-results/ 2025-04-01T16:26:40.033Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-study-shows-new-long-acting-hiv-regimen-cabenuva-can-be-successfully-implemented/ 2025-04-01T16:26:40.533Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-data-from-second-dovato-switch-study/ 2025-04-01T16:26:40.96Z https://www.gsk.com/en-gb/media/press-releases/shingrix-approved-in-the-us-for-prevention-of-shingles-in-immunocompromised-adults/ 2025-04-01T16:26:41.397Z https://www.gsk.com/en-gb/media/press-releases/second-generation-mrna-covid-19-vaccine-candidate/ 2025-04-01T16:26:41.927Z https://www.gsk.com/en-gb/media/press-releases/sk-bioscience-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/ 2025-04-01T16:26:42.347Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-major-renewable-energy-investment-and-low-carbon-inhaler-programme-alongside-life-sciences-sector-race-to-zero-breakthrough-at-nyc-climate-week/ 2025-04-01T16:26:42.793Z https://www.gsk.com/en-gb/media/press-releases/fda-grants-priority-review-to-viiv-healthcare-s-new-drug-application-for-cabotegravir-long-acting-for-prevention-of-hiv/ 2025-04-01T16:26:36.083Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-submits-fda-application-for-first-dispersible-single-tablet-regimen-containing-dolutegravir-dtg-for-children-living-with-hiv/ 2025-04-01T16:26:36.497Z https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-who-recommendation-for-broad-roll-out-of-its-rts-sas01e-rts-s-malaria-vaccine/ 2025-04-01T16:26:36.937Z https://www.gsk.com/en-gb/media/press-releases/gsk-unveils-plan-for-uk-headquarters-of-new-consumer-healthcare-company/ 2025-04-01T16:26:37.377Z https://www.gsk.com/en-gb/media/press-releases/less-talk-more-action-new-report-sponsored-by-viiv-healthcare-provides-roadmap-to-achieve-health-equity-by-2040/ 2025-04-01T16:26:37.827Z https://www.gsk.com/en-gb/media/press-releases/gsk-consumer-healthcare-solidifies-commitment-to-pharmacists-with-3-year-pharmacist-support-programme/ 2025-04-01T16:26:38.27Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-phase-iii-efficacy-and-safety-data-for-daprodustat-in-patients-with-anaemia-due-to-chronic-kidney-disease/ 2025-04-01T16:26:38.683Z https://www.gsk.com/en-gb/media/press-releases/primary-endpoint-met-in-comet-tail-phase-iii-trial-evaluating-intramuscular-administration-of-sotrovimab-for-early-treatment-of-covid-19/ 2025-04-01T16:26:39.113Z https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-nucala-mepolizumab-in-three-additional-eosinophil-driven-diseases/ 2025-04-01T16:26:32.453Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreements-to-purchase-sotrovimab-a-covid-19-treatment/ 2025-04-01T16:26:32.88Z https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-phil-dormitzer-md-phd-as-global-head-of-vaccines-rd/ 2025-04-01T16:26:33.29Z https://www.gsk.com/en-gb/media/press-releases/preclinical-data-demonstrate-sotrovimab-retains-activity-against-key-omicron-mutations-new-sars-cov-2-variant/ 2025-04-01T16:26:33.707Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-the-university-of-oxford-launch-new-oxford-gsk-institute-to-harness-advanced-technology-and-unravel-mechanisms-of-disease/ 2025-04-01T16:26:34.13Z https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-gavi-decision-to-fund-the-roll-out-of-malaria-vaccines-for-children/ 2025-04-01T16:26:34.58Z https://www.gsk.com/en-gb/media/press-releases/sotrovimab-retains-activity/ 2025-04-01T16:26:34.987Z https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-positive-phase-3-efficacy-and-safety-results/ 2025-10-07T08:22:11.547Z https://www.gsk.com/en-gb/media/press-releases/new-data-presented-at-ash-2021-highlight-potential-of-blenrep/ 2025-04-01T16:26:29.223Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-sanofi-announce-positive-preliminary-booster-data-for-their-covid-19-vaccine-candidate/ 2025-04-01T16:26:29.673Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-vir-biotechnology-announce-united-states-government-agreement-to-purchase-additional-supply-of-sotrovimab/ 2025-04-01T16:26:30.2Z https://www.gsk.com/en-gb/media/press-releases/update-gsk-consumer-healthcare/ 2025-04-01T16:26:30.657Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-cabenuva-cabotegravir-rilpivirine-for-use-every-two-months-expanding-the-label-of-the-first-and-only-complete-long-acting-hiv-treatment/ 2025-04-01T16:26:31.073Z https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-to-seek-regulatory-authorization-for-covid-19-vaccine/ 2025-10-07T08:20:41.647Z https://www.gsk.com/en-gb/media/press-releases/medicago-and-gsk-announce-the-approval-by-health-canada-of-covifenz/ 2025-04-01T16:26:31.953Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-further-update-on-phase-iii-rsv-maternal-vaccine-candidate-programme/ 2025-04-01T16:26:26.587Z https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-ema-accepts-marketing-authorisation-application-for-daprodustat/ 2025-04-01T16:26:27.073Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-label-update-for-its-long-acting-hiv-treatment-cabenuva-cabotegravir-rilpivirine-to-be-initiated-with-or-without-an-oral-lead-in-period/ 2025-04-01T16:26:27.493Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-us-fda-approval-of-triumeq-pd-the-first-dispersible-single-tablet-regimen-containing-dolutegravir-a-once-daily-treatment-for-children-living-with-hiv/ 2025-04-01T16:26:27.933Z https://www.gsk.com/en-gb/media/press-releases/us-food-and-drug-administration-accepts-new-drug-application-for-daprodustat/ 2025-04-01T16:26:28.383Z https://www.gsk.com/en-gb/media/press-releases/sk-bioscience-and-gsk-s-adjuvanted-covid-19-vaccine-candidate-meets-coprimary-objectives-in-a-phase-iii-study/ 2025-04-01T16:26:28.777Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-commits-to-grant-voluntary-licence-for-patents-relating-to-cabotegravir-long-acting-for-prep-to-medicines-patent-pool/ 2025-04-01T16:26:25.597Z https://www.gsk.com/en-gb/media/press-releases/china-approves-cervarix-two-dose-vaccine-schedule-for-girls-aged-9-to-14-against-certain-types-of-cancer-causing-human-papillomavirus/ 2025-04-01T16:26:26.017Z https://www.gsk.com/en-gb/media/press-releases/gsk-unveils-latest-research-advances-at-asco-and-eha/ 2025-04-01T16:26:25.047Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-further-appointments-to-designate-haleon-board/ 2025-04-01T16:26:24.597Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-marketing-approval-by-japan-s-ministry-of-health-labour-and-welfare-for-vocabria-cabotegravir-used-in-combination-with-rekambys-rilpivirine/ 2025-04-01T16:26:24.14Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-clinical-stage-biopharmaceutical-company-affinivax-inc/ 2025-04-01T16:26:23.687Z https://www.gsk.com/en-gb/media/press-releases/update-proposed-demerger-of-the-consumer-healthcare-business-from-gsk-to-form-haleon/ 2025-04-01T16:26:23.21Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-us-fda-approval-of-priorix-for-the-prevention-of-measles-mumps-and-rubella-in-individuals-12-months-of-age-and-older/ 2025-04-01T16:26:22.76Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-pivotal-phase-iii-data-for-its-respiratory-syncytial-virus-rsv-vaccine-candidate-for-older-adults/ 2025-04-01T16:26:22.343Z https://www.gsk.com/en-gb/media/press-releases/gsk-publishes-prospectus-and-circular/ 2025-04-01T16:26:21.863Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-present-new-data-from-the-b-clear-phase-iib-trial-for-bepirovirsen-in-chronic-hepatitis-b-at-the-international-liver-congress-2022/ 2025-04-01T16:26:21.41Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-1-billion-rd-investment-over-ten-years-to-get-ahead-of-infectious-diseases-in-lower-income-countries/ 2025-04-01T16:26:20.86Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-promising-new-data-for-bepirovirsen-an-investigational-treatment-for-chronic-hepatitis-b/ 2025-04-01T16:26:20.283Z https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-accepts-shingrix-regulatory-submission-to-prevent-shingles-in-at-risk-adults-aged-18-years-and-older/ 2025-04-01T16:26:19.663Z https://www.gsk.com/en-gb/media/press-releases/gsk-selects-target-the-future-grant-recipient-in-innovation-challenge-supporting-multiple-myeloma-community/ 2025-04-01T16:26:19.147Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-sierra-oncology/ 2025-04-01T16:26:18.663Z https://www.gsk.com/en-gb/media/press-releases/result-of-general-meeting/ 2025-04-01T16:26:18.223Z https://www.gsk.com/en-gb/media/press-releases/gsk-gathers-global-experts-to-discuss-role-of-vaccines-in-protecting-people-and-the-planet/ 2025-04-01T16:26:17.627Z https://www.gsk.com/en-gb/media/press-releases/completion-of-the-demerger-of-haleon-and-share-consolidation-of-gsk/ 2025-04-01T16:26:17.017Z https://www.gsk.com/en-gb/media/press-releases/completion-of-gsk-share-consolidation/ 2025-04-01T16:26:16.523Z https://www.gsk.com/en-gb/media/press-releases/board-committee-changes/ 2025-04-01T16:26:15.993Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-new-data-from-innovative-hiv-treatment-and-prevention-portfolio-at-aids-2022/ 2025-04-01T16:26:15.55Z https://www.gsk.com/en-gb/media/press-releases/gsk-signs-agreement-to-support-pandemic-preparedness-in-europe/ 2025-04-01T16:26:15.063Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-2022-sales-of-69-billion/ 2025-04-23T14:12:33.34Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-new-data-at-aids-2022-from-unblinded-phase-of-hptn-084-study-in-women/ 2025-04-01T16:26:14.023Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-and-the-medicines-patent-pool-sign-new-voluntary-licensing-agreement/ 2025-04-01T16:26:13.61Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-offer-to-repurchase-exchangeable-senior-notes-due-2023/ 2025-04-01T16:26:13.187Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation/ 2025-04-01T16:26:12.75Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-affinivax-inc/ 2025-04-01T16:26:12.33Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-us-litigation/ 2025-04-01T16:26:11.92Z https://www.gsk.com/en-gb/media/press-releases/us-fda-accepts-new-drug-application-for-gsk-s-momelotinib-for-the-treatment-of-myelofibrosis/ 2025-04-01T16:26:11.47Z https://www.gsk.com/en-gb/media/press-releases/gsk-board-changes/ 2025-04-01T16:26:11.04Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-highlight-the-latest-advances-in-cancer-research-from-across-its-portfolio-and-pipeline-at-esmo/ 2025-04-01T16:26:10.567Z https://www.gsk.com/en-gb/media/press-releases/who-grants-prequalification-to-gsk-s-mosquirix-the-first-and-only-approved-malaria-vaccine/ 2025-04-01T16:26:10.09Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-update-on-us-fda-regulatory-review-of-daprodustat-in-anaemia-of-chronic-kidney-disease/ 2025-04-01T16:26:09.677Z https://www.gsk.com/en-gb/media/press-releases/zejula-niraparib-shows-durable-and-sustained-long-term-progression-free-survival-benefit-in-the-prima-study-of-first-line-platinum-responsive-advanced-ovarian-cancer/ 2025-04-01T16:26:09.147Z https://www.gsk.com/en-gb/media/press-releases/gsk-launches-sustainable-procurement-programme-for-suppliers/ 2025-04-01T16:26:08.677Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-microsoft-in-collaboration-with-the-centre-for-health-and-disease-studies/ 2025-04-01T16:26:08.197Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-spero-therapeutics-announce-exclusive-licence-agreement-for-tebipenem-hbr-a-late-stage-antibiotic-that-may-treat-complicated-urinary-tract-infections/ 2025-04-01T16:26:07.757Z https://www.gsk.com/en-gb/media/press-releases/oncologic-drugs-advisory-committee-to-review-zejula-overall-survival-data-from-the-nova-phase-iii-trial-in-recurrent-ovarian-cancer/ 2025-04-01T16:26:07.33Z https://www.gsk.com/en-gb/media/press-releases/iain-mackay-chief-financial-officer-to-retire-from-gsk-julie-brown-appointed-as-successor/ 2025-04-01T16:26:06.84Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-from-perla-the-phase-ii-trial-of-jemperli-dostarlimab-plus-chemotherapy-in-patients-with-metastatic-non-squamous-non-small-cell-lung-cancer/ 2025-04-01T16:26:06.377Z https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-boostrix-for-immunisation-during-pregnancy-for-the-prevention-of-whooping-cough-in-newborn-infants/ 2025-04-01T16:26:05.773Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-present-updates-on-its-industry-leading-infectious-disease-portfolio-at-idweek-2022/ 2025-04-01T16:26:05.25Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-older-adult-respiratory-syncytial-virus-rsv-vaccine-candidate/ 2025-04-01T16:26:04.643Z https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-menveo-in-a-new-single-vial-presentation-to-help-prevent-disease-caused-by-meningococcal-bacteria-serogroups-a-c-y-and-w/ 2025-04-01T16:26:04.133Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-expanded-collaboration-with-tempus-in-precision-medicine-to-accelerate-rd/ 2025-04-01T16:26:03.61Z https://www.gsk.com/en-gb/media/press-releases/new-data-show-shingrix-can-provide-at-least-10-years-of-protection-against-shingles-in-adults-aged-50-years-and-over/ 2025-04-01T16:26:03.107Z https://www.gsk.com/en-gb/media/press-releases/gsk-regulatory-submission-accepted-by-japanese-regulator-for-respiratory-syncytial-virus-older-adult-vaccine-candidate/ 2025-04-01T16:26:02.61Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-positive-proof-of-concept-findings-for-n6ls/ 2025-04-01T16:26:02.097Z https://www.gsk.com/en-gb/media/press-releases/gsk-reports-outcome-from-us-fda-advisory-committee-meeting-on-daprodustat-for-anaemia-of-ckd/ 2025-04-01T16:26:01.617Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-contrast-phase-iii-programme-for-otilimab-in-the-treatment-of-moderate-to-severe-rheumatoid-arthritis/ 2025-04-01T16:26:01.067Z https://www.gsk.com/en-gb/media/press-releases/gsk-marketing-authorisation-application-for-respiratory-syncytial-virus-older-adult-vaccine-candidate-accepted-by-european-medicines-agency-under-accelerated-assessment/ 2025-04-01T16:26:00.57Z https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-validates-viiv-healthcare-s-marketing-authorisation-application-for-cabotegravir-long-acting-injectable-for-hiv-prevention/ 2025-04-01T16:26:00.063Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q3-2022-sales-of-78-billion-plus18-aer-plus9-cer/ 2025-04-23T14:12:06.76Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-oa-vaccine-candidate-granted-priority-review-by-us-fda/ 2025-04-01T16:25:58.75Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-phase-iii-trials-for-gepotidacin/ 2025-04-01T16:25:58.187Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/ 2025-04-01T16:25:57.527Z https://www.gsk.com/en-gb/media/press-releases/positive-data-for-bepirovirsen-from-b-clear-phase-iib-trial/ 2025-04-01T16:25:57.023Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-an-update-on-zejula-niraparib-us-prescribing-information/ 2025-04-01T16:25:56.39Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-phase-iia-study-results-for-a-new-first-in-class-candidate-medicine/ 2025-04-01T16:25:55.803Z https://www.gsk.com/en-gb/media/press-releases/gsk-tops-access-to-medicine-index-atmi-for-eighth-consecutive-time/ 2025-04-01T16:25:55.203Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-blenrep-us-marketing-authorisation/ 2025-04-01T16:25:54.41Z https://www.gsk.com/en-gb/media/press-releases/new-global-survey-reveals-opportunities-to-address-organ-damage-risk-with-people-living-with-lupus-earlier-in-the-course-of-their-disease/ 2025-04-01T16:25:53.513Z https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-ruby-phase-iii-trial-met-its-primary-endpoint-in-a-planned-interim-analysis-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-04-01T16:25:52.743Z https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-accepts-marketing-authorisation-application-for-momelotinib-for-the-treatment-of-myelofibrosis/ 2025-04-01T16:25:51.88Z https://www.gsk.com/en-gb/media/press-releases/perla-phase-ii-trial-of-jemperli-dostarlimab-plus-chemotherapy-shows-positive-results-in-first-line-metastatic-non-squamous-non-small-cell-lung-cancer/ 2025-04-01T16:25:50.763Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-litigation/ 2025-04-01T16:25:50.2Z https://www.gsk.com/en-gb/media/press-releases/new-data-at-ash-underscore-the-potential-for-durable-clinically-important-responses-with-momelotinib-for-myelofibrosis-patients/ 2025-04-01T16:25:49.65Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-global-headquarters-in-central-london/ 2025-04-01T16:25:49.24Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-wave-life-sciences-announce-collaboration-to-drive-discovery-and-development-of-oligonucleotide-therapeutics-focusing-on-novel-genetic-targets/ 2025-04-01T16:25:48.727Z https://www.gsk.com/en-gb/media/press-releases/vidprevtyn-beta-covid-19-booster-vaccine-approved-for-use-in-great-britain/ 2025-04-01T16:25:48.307Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2022-performance-with-full-year-sales-of-293-billion/ 2025-04-22T15:29:57.43Z https://www.gsk.com/en-gb/media/press-releases/benlysta-granted-orphan-drug-designation-by-us-fda-for-the-potential-treatment-of-systemic-sclerosis/ 2025-04-01T16:25:47.027Z https://www.gsk.com/en-gb/media/press-releases/jesduvroq-daprodustat-approved-by-us-fda-for-anaemia-of-chronic-kidney-disease-in-adults-on-dialysis/ 2025-04-14T09:48:29.087Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-results-from-17-year-retrospective-study-on-us-clinical-trial-diversity/ 2025-04-01T16:25:45.85Z https://www.gsk.com/en-gb/media/press-releases/us-fda-advisory-committee-votes-in-support-of-trials-designed-to-evaluate-jemperli-dostarlimab-gxly-as-a-potential-treatment-for-dmmrmsi-h-locally-advanced-rectal-cancer/ 2025-04-01T16:25:45.263Z https://www.gsk.com/en-gb/media/press-releases/us-fda-grants-regular-approval-for-jemperli-for-the-treatment-of-patients-with-recurrent-or-advanced-mismatch-repair-deficient-endometrial-cancer/ 2025-04-01T16:25:44.693Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-first-head-to-head-data-for-long-acting-hiv-treatment-cabenuva-against-daily-oral-biktarvy-at-croi-2023/ 2025-04-01T16:25:44.127Z https://www.gsk.com/en-gb/media/press-releases/nejm-publication-reinforces-potential-of-gsk-s-respiratory-syncytial-virus-older-adult-vaccine-candidate/ 2025-04-01T16:25:43.667Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-12-month-findings-from-the-solar-study/ 2025-04-01T16:25:43.243Z https://www.gsk.com/en-gb/media/press-releases/us-fda-advisory-committee-votes-to-support-effectiveness-and-safety-of-gsk-s-rsv-older-adult-vaccine-candidate/ 2025-04-01T16:25:42.727Z https://www.gsk.com/en-gb/media/press-releases/china-national-medical-products-administration-accepts-regulatory-submission-for-nucala-mepolizumab-in-severe-eosinophilic-asthma/ 2025-04-01T16:25:42.32Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-pivotal-phase-iii-data-for-5-in-1-meningococcal-abcwy-vaccine-candidate/ 2025-04-01T16:25:41.853Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-24-march/ 2025-04-01T16:25:41.403Z https://www.gsk.com/en-gb/media/press-releases/phase-iii-ruby-clinical-trial-demonstrates-potential-of-jemperli-plus-chemotherapy-to-redefine-the-treatment-of-primary-advanced-or-recurrent-endometrial-cancer/ 2025-04-01T16:25:40.913Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-scynexis-announce-an-exclusive-agreement-to-commercialise-and-further-develop-brexafemme-ibrexafungerp/ 2025-04-01T16:25:40.213Z https://www.gsk.com/en-gb/media/press-releases/medicines-patent-pool-signs-sublicences-with-aurobindo-cipla-and-viatris-to-produce-generic-versions-of-viiv-healthcare-s-innovative-long-acting-hiv-prevention-medicine/ 2025-04-01T16:25:39.427Z https://www.gsk.com/en-gb/media/press-releases/gepotidacin-s-positive-phase-iii-data-shows-potential-to-be-the-first-in-a-new-class-of-oral-antibiotics-for-uncomplicated-urinary-tract-infections/ 2025-04-01T16:25:38.843Z https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-to-acquire-late-stage-biopharmaceutical-company-bellus-health/ 2025-04-01T16:25:37.983Z https://www.gsk.com/en-gb/media/press-releases/european-medicines-agency-validates-marketing-authorisation-application-for-jemperli-dostarlimab/ 2025-04-01T16:25:37.36Z https://www.gsk.com/en-gb/media/press-releases/gsk-momentum-continues-with-strong-start-to-2023/ 2025-04-16T08:23:03.97Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-respiratory-syncytial-virus-older-adult-vaccine-candidate-gains-positive-european-medicines-agency-chmp-opinion/ 2025-04-01T16:25:35.433Z https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2025-04-01T16:25:34.367Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-pivotal-data-at-espid/ 2025-04-01T16:25:33.517Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-1/ 2025-04-01T16:25:32.927Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-file-acceptance-for-jemperli/ 2025-04-01T16:25:32.37Z https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2025-04-01T16:25:31.827Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-extension-of-fda-review-period-for-momelotinib/ 2025-04-16T08:19:03.457Z https://www.gsk.com/en-gb/media/press-releases/gsk-shares-positive-data-for-arexvy-its-respiratory-syncytial-virus-older-adult-vaccine-indicating-protection-over-two-rsv-seasons/ 2025-04-16T08:17:24.377Z https://www.gsk.com/en-gb/media/press-releases/cdc-and-prevention-acip-votes-to-recommend-arexvy/ 2025-04-16T08:16:10.383Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion/ 2025-04-16T08:13:52.447Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-2/ 2025-04-16T08:12:45.977Z https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-approves-shingrix-for-the-prevention-of-shingles-in-at-risk-adults-aged-18-and-over/ 2025-04-16T08:11:08.507Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-investigational-vaccine-against-gonorrhoea/ 2025-04-16T08:10:03.42Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-bellus-health/ 2025-04-16T08:09:00.163Z https://www.gsk.com/en-gb/media/press-releases/medicines-and-healthcare-products-regulatory-agency-authorises-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/ 2025-04-16T08:07:25.183Z https://www.gsk.com/en-gb/media/press-releases/new-analysis-shows-lost-ground-on-adult-immunisation-during-the-pandemic-with-100-million-doses-potentially-missed/ 2025-04-16T08:06:08.51Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-s-cabotegravir-for-hiv-prevention-receives-positive-chmp-opinion-from-european-medicines-agency/ 2025-04-16T08:04:58.973Z https://www.gsk.com/en-gb/media/press-releases/strong-performance-and-momentum-drive-upgraded-guidance/ 2025-04-16T08:02:14.47Z https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-chemotherapy-approved-in-us-for-new-indication/ 2025-04-16T07:58:21.47Z https://www.gsk.com/en-gb/media/press-releases/new-research-published-in-science-highlights-potential-of-a-naturally-occurring-bacterium-to-help-eradicate-malaria/ 2025-04-16T07:46:38.59Z https://www.gsk.com/en-gb/media/press-releases/new-shingrix-data-demonstrate-100-vaccine-efficacy-in-prevention-shingles/ 2025-04-01T16:25:22.233Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-regulatory-submission-accepted-for-review-by-japanese-regulator-for-use-of-nucala-mepolizumab/ 2025-04-01T16:25:21.67Z https://www.gsk.com/en-gb/media/press-releases/gsk-regulatory-submission-for-momelotinib-for-the-treatment-of-myelofibrosis-accepted-for-review-by-japanese-regulator/ 2025-04-01T16:25:21.023Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-renew-award-winning-partnership/ 2025-04-01T16:25:20.317Z https://www.gsk.com/en-gb/media/press-releases/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia/ 2025-04-01T16:25:19.447Z https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-viiv-healthcare-s-apretude/ 2025-04-01T16:25:18.287Z https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-approves-gsk-s-arexvy/ 2025-04-01T16:25:17.627Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-wendy-becker-to-join-the-board-as-non-executive-director/ 2025-04-01T16:25:17.12Z https://www.gsk.com/en-gb/media/press-releases/gsk-survey-finds-parents-know-less-about-meningitis-compared-to-some-other-childhood-diseases/ 2025-04-01T16:25:16.543Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-zhifei-announce-exclusive-strategic-vaccine-partnership-in-china/ 2025-04-01T16:25:15.977Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-viiv-healthcare-to-present-scientific-advancements-at-idweek-2023/ 2025-04-01T16:25:15.447Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-11-october-2023/ 2025-04-01T16:25:14.857Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-scientific-advances-to-improve-patient-outcomes-at-the-american-association-for-the-study-of-liver-diseases-the-liver-meeting-2023/ 2025-05-14T15:14:04.473Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-recommending-approval-of-jemperli-dostarlimab-plus-chemotherapy/ 2025-04-01T16:25:13.42Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-23-abstracts-from-innovative-hiv-treatment-and-prevention-portfolio-at-eacs-2023/ 2025-04-01T16:25:12.773Z https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-new-data-in-non-small-cell-lung-cancer-and-endometrial-cancer-at-esmo/ 2025-04-01T16:25:12.183Z https://www.gsk.com/en-gb/media/press-releases/gsk-launches-6m-programme-to-boost-stem-career-progression-for-young-people-from-under-represented-groups-in-the-uk/ 2025-04-01T16:25:11.43Z https://www.gsk.com/en-gb/media/press-releases/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20089/ 2025-04-01T16:25:10.77Z https://www.gsk.com/en-gb/media/press-releases/new-data-for-arexvy-show-potential-to-help-protect-adults-aged-50-to-59/ 2025-04-01T16:25:10.137Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-receives-approval-from-nmpa-for-vocabria-in-combination-with-rekambys/ 2025-04-01T16:25:09.48Z https://www.gsk.com/en-gb/media/press-releases/phase-iii-ruby-trial-of-jemperli-dostarlimab-plus-chemotherapy-meets-endpoint-of-overall-survival-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-04-01T16:25:08.8Z https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-obtain-exclusive-license-for-jnj-3989/ 2025-04-01T16:25:08.147Z https://www.gsk.com/en-gb/media/press-releases/strong-year-to-date-and-q3-performance-drives-upgrade-to-full-year-guidance/ 2025-04-17T11:16:16.993Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-positive-chmp-opinion-recommending-momelotinib-for-myelofibrosis-patients-with-anaemia/ 2025-04-01T16:25:06.723Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-major-step-towards-sustainability-ambitions-with-advancement-of-low-carbon-ventolin-programme-to-phase-iii-trials/ 2025-04-01T16:25:06.117Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-dreamm-7-head-to-head-phase-iii-trial-for-blenrep/ 2025-04-01T16:25:05.36Z https://www.gsk.com/en-gb/media/press-releases/new-global-survey-finds-widespread-misunderstandings-about-shingles-despite-its-lifetime-prevalence/ 2025-04-01T16:25:04.49Z https://www.gsk.com/en-gb/media/press-releases/new-global-analysis-across-five-cities-shows-inequities-in-adult-immunisation-uptake/ 2025-04-01T16:25:03.473Z https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-chemotherapy-approved-as-the-first-and-only-frontline-immuno-oncology-treatment-in-the-european-union/ 2025-04-01T16:25:02.38Z https://www.gsk.com/en-gb/media/press-releases/japan-accepts-arexvy-regulatory-application-to-prevent-rsv-disease-in-adults-aged-50-59/ 2025-04-01T16:25:01.773Z https://www.gsk.com/en-gb/media/press-releases/jemperli-plus-zejula-combination-significantly-improved-progression-free-survival-in-endometrial-cancer-phase-iii-trial/ 2025-04-01T16:25:01.227Z https://www.gsk.com/en-gb/media/press-releases/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093/ 2025-04-01T16:25:00.68Z https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-aiolos-bio/ 2025-04-01T16:25:00.123Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-approved-in-china-for-use-in-severe-asthma-with-an-eosinophilic-phenotype/ 2025-04-01T16:24:59.54Z https://www.gsk.com/en-gb/media/press-releases/arexvy-accepted-for-regulatory-review-by-ema-for-prevention-of-rsv-in-adults-50-59/ 2025-04-01T16:24:58.967Z https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-gsk-s-omjjara-momelotinib/ 2025-04-01T16:24:58.473Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-1-february-2024/ 2025-04-01T16:24:57.9Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2023-performance-and-upgrades-growth-outlooks/ 2025-04-17T11:17:46.517Z https://www.gsk.com/en-gb/media/press-releases/regulatory-application-for-shingrix-for-the-prevention-of-shingles-adults-aged-18-and-over-accepted-for-review-in-china/ 2025-04-01T16:24:56.56Z https://www.gsk.com/en-gb/media/press-releases/arexvy-accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk/ 2025-09-08T18:44:06.16Z https://www.gsk.com/en-gb/media/press-releases/dreamm-7-phase-iii-trial-shows-pfs-improvement-and-strong-os-trend-for-blenrep-combo-versus-soc-combo-in-multiple-myeloma/ 2025-04-01T16:24:55.27Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-fast-track-designation-for-bepirovirsen-in-chronic-hepatitis-b/ 2025-04-01T16:24:54.473Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-aiolos-bio/ 2025-04-01T16:24:53.677Z https://www.gsk.com/en-gb/media/press-releases/latitude-phase-iii-interim-trial-data-indicates-cabenuva-has-superior-efficacy-compared-to-daily-therapy/ 2025-04-01T16:24:52.503Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-present-data-for-its-next-generation-of-ultra-long-acting-treatments-for-hiv/ 2025-04-01T16:24:51.86Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-results-from-eagle-1-phase-iii-trial-for-gepotidacin-in-uncomplicated-urogenital-gonorrhoea-gc/ 2025-04-01T16:24:51.207Z https://www.gsk.com/en-gb/media/press-releases/eagle-1-phase-iii-data-show-potential-for-gepotidacin-as-a-new-oral-treatment-option-for-uncomplicated-gc/ 2025-04-01T16:24:50.343Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-3/ 2025-04-01T16:24:49.183Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-dr-jeannie-lee-to-join-the-board-as-non-executive-director/ 2025-09-08T18:44:05.863Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-phase-i-clinical-trial-findings-of-a-cabotegravir-long-acting-injectable-investigational-formulation/ 2025-04-01T16:24:47.433Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-interim-data-at-croi-indicating-superior-efficacy-of-long-acting-injectable-hiv-treatment-cabenuva-compared-to-daily-oral-therapy/ 2025-09-08T18:44:05.577Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-dreamm-8-phase-iii-trial-for-blenrep-versus-standard-of-care-combination-in-relapsedrefractory-multiple-myeloma/ 2025-04-01T16:24:46.27Z https://www.gsk.com/en-gb/media/press-releases/positive-ruby-phase-iii-data-show-potential-for-jemperli-dostarlimab-combinations-in-more-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-04-01T16:24:45.507Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-5-in-1-meningococcal-abcwy-vaccine-candidate-accepted-for-regulatory-review-by-us-fda/ 2025-04-01T16:24:44.787Z https://www.gsk.com/en-gb/media/press-releases/new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles-in-adults-aged-50-and-over-for-more-than-a-decade/ 2025-04-01T16:24:44.053Z https://www.gsk.com/en-gb/media/press-releases/fda-accepts-gsk-application-expanded-indication-of-jemperli-dostarlimab-plus-chemotherapy-include-all-adult-patients-primary-advanced-recurrent-endometrial-cancer/ 2025-04-01T16:24:43.153Z https://www.gsk.com/en-gb/media/press-releases/gsk-makes-a-strong-start-to-2024-with-improving-outlook-for-the-year/ 2025-04-14T09:58:33.59Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-become-a-founding-partner-of-fleming-initiative-to-fight-antimicrobial-resistance-amr/ 2025-04-01T16:24:41.86Z https://www.gsk.com/en-gb/media/press-releases/new-data-at-asco-showcases-the-transformational-potential-of-gsks-oncology-portfolio/ 2025-04-01T16:24:41.12Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-severe-asthma-trials-of-depemokimab/ 2025-04-01T16:24:40.07Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-valadez-and-williams-cases/ 2025-04-01T16:24:39.47Z https://www.gsk.com/en-gb/media/press-releases/blenrep-combination-reduced-the-risk-of-disease-progression/ 2025-04-01T16:24:38.807Z https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-trial-continues-to-show-unprecedented-results/ 2025-04-01T16:24:37.993Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-delaware-state-court-daubert-ruling/ 2025-04-15T10:17:40.507Z https://www.gsk.com/en-gb/media/press-releases/gsk-accelerates-oligonucleotide-platform-and-pipeline-medicines-with-acquisition-of-elsie-biotechnologies/ 2025-04-01T16:24:36.303Z https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-expanded-age-indication-for-gsk-s-arexvy-the-first-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/ 2025-04-01T16:24:35.647Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-kasza-case/ 2025-04-01T16:24:34.89Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-gsk-starts-process-for-appeal-of-recent-delaware-daubert-decision/ 2025-04-01T16:24:34.25Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis/ 2025-04-01T16:24:33.34Z https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-plus-chemotherapy-application-accepted-for-review-by-ema/ 2025-04-01T16:24:32.31Z https://www.gsk.com/en-gb/media/press-releases/statement-us-centers-for-disease-control-and-prevention-s-advisory-committee-on-immunisation-practices-updates-recommendations-on-adult-rsv-vaccines-ahead-of-the-next-season/ 2025-04-01T16:24:31.653Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-gross-case/ 2025-04-15T10:01:27.967Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-restructure-collaboration-into-new-licensing-agreement/ 2025-04-01T16:24:30.473Z https://www.gsk.com/en-gb/media/press-releases/brazil-and-thailand-become-first-malaria-endemic-countries-to-launch-new-single-dose-radical-cure-medicine/ 2025-04-15T12:50:44.447Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-announce-data-from-largest-head-to-head-randomised-clinical-trial-for-2-drug-regimen-dovato-at-aids-2024/ 2025-04-01T16:24:29.267Z https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-in-multiple-myeloma-application-accepted-for-review-by-the-european-medicines-agency/ 2025-04-01T16:24:28.627Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-new-data-for-apretude-use-during-pregnancy-at-aids-2024/ 2025-04-01T16:24:27.91Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-data-demonstrating-2-drug-regimen-dovato-is-as-effective-as-3-drug-regimen-biktarvy-for-maintenance-therapy-of-hiv-1/ 2025-04-01T16:24:27.387Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-premieres-early-data-showing-antiviral-activity-against-integrase-resistance-from-its-investigational-third-generation-integrase-inhibitor/ 2025-04-01T16:24:26.88Z https://www.gsk.com/en-gb/media/press-releases/arexvy-receives-positive-ema-chmp-opinion-for-adults-aged-50-59-at-increased-risk-for-rsv-disease/ 2025-04-01T16:24:26.377Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-kimbrow-case/ 2025-04-24T13:27:34.92Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-flagship-pioneering-partner-to-discover-novel-medicines-and-vaccines/ 2025-04-24T13:29:26.387Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-new-data-at-the-alzheimers-association-international-conference-2024/ 2025-04-01T16:24:24.58Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-continued-strong-performance-and-upgrades-2024-guidance/ 2025-04-15T09:17:14.71Z https://www.gsk.com/en-gb/media/press-releases/us-fda-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-04-01T16:24:22.673Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-joiner-case/ 2025-04-01T16:24:21.957Z https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-breakthrough-therapy-designation/ 2025-04-01T16:24:21.343Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-florida-state-court-daubert-ruling-in-wilson-case/ 2025-04-01T16:24:20.613Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-nucala-mepolizumab-approved-in-japan-for-treatment-of-adults-with-chronic-rhinosinusitis-with-nasal-polyps/ 2025-04-01T16:24:19.867Z https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-granted-senku-designation-in-japan-for-chronic-hepatitis-b/ 2025-04-01T16:24:18.75Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-delaware-supreme-court-to-review-superior-court-s-daubert-decision/ 2025-04-01T16:24:17.783Z https://www.gsk.com/en-gb/media/press-releases/european-commission-approves-expanded-age-indication-for-gsk-s-arexvy-the-first-respiratory-syncytial-virus-rsv-vaccine-for-adults-aged-50-59-at-increased-risk/ 2025-09-08T18:44:05.317Z https://www.gsk.com/en-gb/media/press-releases/gsk-aims-to-redefine-the-future-of-respiratory-medicine-at-the-european-respiratory-society-international-congress/ 2025-04-01T16:24:16.437Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-phase-iii-trial-of-nucala-mepolizumab-in-copd/ 2025-04-01T16:24:15.793Z https://www.gsk.com/en-gb/media/press-releases/depemokimab-late-breaking-data-presented-at-ers-show-a-54-reduction-in-severe-asthma-exacerbations/ 2025-09-08T18:44:05.037Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-therapeutic-herpes-simplex-virus-hsv-vaccine-trial/ 2025-04-01T16:24:14.097Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-dixon-case/ 2025-04-24T10:45:19.337Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-headline-data-from-phase-ii-seasonal-influenza-mrna-vaccine-programme/ 2025-09-08T18:44:04.68Z https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-designation-in-china-for-treatment-of-relapsedrefractory-multiple-myeloma/ 2025-09-08T18:44:04.403Z https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-in-relapsedrefractory-multiple-myeloma-accepted-for-regulatory-review-in-japan/ 2025-04-01T16:24:11.547Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-russell-and-hughes-cases-2/ 2025-04-01T16:24:10.84Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-menveo-meningococcal-vaccine-in-new-single-vial-fully-liquid-presentation-receives-positive-european-chmp-opinion/ 2025-04-01T16:24:10.337Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-triple-annual-supply-of-long-acting-hiv-prep-for-low-and-middle-income-countries/ 2025-04-01T16:24:09.837Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-for-arexvy-its-rsv-vaccine-indicating-protection-over-three-rsv-seasons/ 2025-04-01T16:24:09.3Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-viiv-healthcare-to-showcase-advances-across-industry-leading-infectious-disease-portfolio-at-idweek-2024/ 2025-04-01T16:24:08.72Z https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-settlement-agreements-reached/ 2025-04-01T16:24:08.097Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-phase-iii-results-from-anchor-trials/ 2025-04-01T16:24:07.387Z https://www.gsk.com/en-gb/media/press-releases/gepotidacin-accepted-for-priority-review-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections-in-female-adults-and-adolescents/ 2025-04-01T16:24:06.383Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-shows-more-than-99-effectiveness-in-real-world-studies-for-apretude/ 2025-04-01T16:24:05.713Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-cambridge-university-announce-new-five-year-collaboration-in-kidney-and-respiratory-disease/ 2025-04-01T16:24:05.133Z https://www.gsk.com/en-gb/media/press-releases/new-data-for-arexvy-show-potential-to-help-protect-a-broader-group-of-adults-at-increased-risk-for-rsv-disease/ 2025-04-01T16:24:04.443Z https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-cmg1a46-from-chimagen-biosciences/ 2025-04-01T16:24:03.487Z https://www.gsk.com/en-gb/media/press-releases/gsk-on-track-to-deliver-2024-outlooks-with-further-good-progress-made-in-rd/ 2025-04-14T15:53:01.27Z https://www.gsk.com/en-gb/media/press-releases/new-gsk-sponsored-survey-reveals-unique-gaps-in-care-and-support-facing-patients-with-gynaecologic-cancers/ 2025-04-01T16:24:01.727Z https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-key-data-from-hepatology-portfolio-at-the-aasld-s-the-liver-meeting-2024-emphasising-patient-impact-in-areas-of-high-unmet-need/ 2025-09-08T18:44:04.12Z https://www.gsk.com/en-gb/media/press-releases/blenrep-shows-overall-survival-benefit-in-head-to-head-dreamm-7-phase-iii-trial-for-relapsedrefractory-multiple-myeloma/ 2025-04-01T16:24:00.63Z https://www.gsk.com/en-gb/media/press-releases/arexvy-approval-expanded-to-adults-aged-50-59-at-increased-risk-of-severe-rsv-disease-in-japan/ 2025-04-01T16:23:59.827Z https://www.gsk.com/en-gb/media/press-releases/linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus/ 2025-04-01T16:23:59.07Z https://www.gsk.com/en-gb/media/press-releases/statement-gsk-continues-to-show-strong-leadership-in-its-access-to-medicines-index-ranking/ 2025-04-01T16:23:58.403Z https://www.gsk.com/en-gb/media/press-releases/blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsedrefractory-multiple-myeloma/ 2025-04-01T16:23:57.697Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-fully-liquid-menveo-meningococcal-vaccine-approved-by-european-commission/ 2025-04-01T16:23:56.963Z https://www.gsk.com/en-gb/media/press-releases/first-single-dose-medicine-for-p-vivax-malaria-prequalified-by-who/ 2025-04-01T16:23:56.33Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-zhifei-revise-and-extend-strategic-vaccine-collaboration-in-china/ 2025-04-01T16:23:55.637Z https://www.gsk.com/en-gb/media/press-releases/us-fda-accepts-gsk-s-submission-for-the-use-of-nucala-mepolizumab-in-copd/ 2025-04-01T16:23:54.753Z https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combination-accepted-for-priority-review-in-china-in-relapsedrefractory-multiple-myeloma/ 2025-04-01T16:23:54.08Z https://www.gsk.com/en-gb/media/press-releases/blenrep-shows-significant-overall-survival-benefit-reducing-the-risk-of-death-by-42-in-multiple-myeloma-at-or-after-first-relapse/ 2025-05-14T15:14:10.687Z https://www.gsk.com/en-gb/media/press-releases/b7-h3-targeted-antibody-drug-conjugate-receives-ema-priority-medicines-designation-in-relapsed-extensive-stage-small-cell-lung-cancer/ 2025-09-08T18:44:03.59Z https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-plus-chemotherapy-receives-positive-chmp-opinion-to-expand-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-04-01T16:23:51.33Z https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-receives-us-fda-breakthrough-therapy-designation-for-locally-advanced-dmmrmsi-h-rectal-cancer/ 2025-04-01T16:23:50.5Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-for-vocabria-plus-rekambys-the-first-and-only-complete-long-acting-hiv-treatment-for-adolescents-in-europe/ 2025-04-01T16:23:49.453Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-first-trial-met-its-primary-endpoint-of-progression-free-survival-in-first-line-advanced-ovarian-cancer/ 2025-04-01T16:23:48.733Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-nucala-mepolizumab-approved-in-china-for-treatment-of-adults-with-chronic-rhinosinusitis-with-nasal-polyps/ 2025-04-01T16:23:47.767Z https://www.gsk.com/en-gb/media/press-releases/gsk-b7-h3-targeted-antibody-drug-conjugate-gsk227-receives-us-fda-breakthrough-therapy-designation-in-late-line-relapsed-or-refractory-osteosarcoma/ 2025-04-01T16:23:46.523Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-new-prefilled-syringe-presentation-accepted-for-review-by-us-fda/ 2025-04-01T16:23:45.897Z https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-idrx-inc/ 2025-04-01T16:23:45.343Z https://www.gsk.com/en-gb/media/press-releases/european-commission-expands-jemperli-dostarlimab-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer/ 2025-04-01T16:23:44.593Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-new-prefilled-syringe-presentation-accepted-for-review-by-european-medicines-agency/ 2025-04-01T16:23:43.813Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-oxford-establish-the-gsk-oxford-cancer-immuno-prevention-programme-to-advance-novel-cancer-research/ 2025-04-01T16:23:43.267Z https://www.gsk.com/en-gb/media/press-releases/depemokimab-accepted-for-review-by-the-european-medicines-agency-for-use-in-asthma/ 2025-04-01T16:23:42.587Z https://www.gsk.com/en-gb/media/press-releases/depemokimab-applications-accepted-for-review-in-china-and-japan/ 2025-05-29T10:49:02.407Z https://www.gsk.com/en-gb/media/press-releases/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents/ 2025-05-29T11:19:03.04Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2024-performance-with-further-improvement-to-long-term-growth-outlook/ 2025-04-14T13:34:47.563Z https://www.gsk.com/en-gb/media/press-releases/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy/ 2025-05-29T11:15:51.98Z https://www.gsk.com/en-gb/media/press-releases/nucala-application-for-copd-accepted-for-review-in-china/ 2025-04-01T16:23:39.313Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-dr-gavin-screaton-to-join-the-board-as-non-executive-director/ 2025-04-01T16:23:38.767Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-idrx-inc/ 2025-04-01T16:23:38.153Z https://www.gsk.com/en-gb/media/press-releases/gsk-plc-commences-share-buyback-programme/ 2025-04-01T16:23:37.593Z https://www.gsk.com/en-gb/media/press-releases/depemokimab-delivers-clinically-meaningful-and-statistically-significant-improvements-for-patients-with-chronic-rhinosinusitis-with-nasal-polyps-crswnp/ 2025-05-29T11:09:29.95Z https://www.gsk.com/en-gb/media/press-releases/depemokimab-applications-accepted-for-review-by-the-us-fda/ 2025-04-01T16:23:36.29Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-continues-to-deliver-long-acting-injectable-hiv-innovation-at-croi-2025/ 2025-06-05T10:26:45.87Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-showcase-latest-research-at-the-international-rsv-symposium-to-advance-rsv-prevention-in-adults/ 2025-05-29T11:03:56.37Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-new-implementation-study-data-showing-zero-cases-of-hiv-with-apretude-the-only-long-acting-injectable-approved-for-hiv-prep/ 2025-05-29T10:57:00.86Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-s-investigational-broadly-neutralising-antibody-n6ls-successfully-maintains-viral-suppression-in-long-acting-treatment-of-hiv/ 2025-06-05T08:22:30.46Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-showcases-leadership-in-long-acting-injectables-innovation-at-croi-2025-with-data-on-insti-and-highly-potent-capsid-inhibitor-against-hiv-1/ 2025-05-29T11:00:13.457Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-application-to-expand-use-of-nucala-for-the-treatment-of-copd-accepted-for-review-by-the-ema/ 2025-04-01T16:23:32.403Z https://www.gsk.com/en-gb/media/press-releases/gsk-uk-dementia-research-institute-uk-dri-and-health-data-research-uk-hdr-uk-to-collaborate-on-first-of-its-kind-dementia-research-initiative/ 2025-05-29T10:53:28.107Z https://www.gsk.com/en-gb/media/press-releases/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections/ 2025-04-01T16:23:30.987Z https://www.gsk.com/en-gb/media/press-releases/arexvy-recommended-for-adults-aged-50-59-at-increased-risk-for-severe-respiratory-syncytial-virus-rsv-disease-by-us-advisory-committee-on-immunization-practices/ 2025-05-16T08:18:18.673Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-5-in-1-meningococcal-vaccine-penmenvy-receives-positive-recommendation-from-us-advisory-committee-on-immunization-practices/ 2025-05-16T08:35:28.607Z https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-approved-by-uk-mhra-in-relapsedrefractory-multiple-myeloma/ 2025-05-16T09:23:01.883Z https://www.gsk.com/en-gb/media/press-releases/gsk-makes-strong-start-to-2025-with-growth-in-sales-profits-and-earnings/ 2025-05-16T10:07:05.887Z https://www.gsk.com/en-gb/media/press-releases/gsk-continues-to-advance-the-future-of-respiratory-medicine/ 2025-05-16T10:30:38.707Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-delivers-clinically-meaningful-and-statistically-significant-reduction-in-copd-exacerbations-with-positive-matinee-trial-results-published-in-nejm/ 2025-05-16T10:39:34.143Z https://www.gsk.com/en-gb/media/press-releases/glisten-phase-iii-trial-results-show-linerixibat-significantly-improves-cholestatic-pruritus/ 2025-05-16T11:06:30.52Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-belrestotug-development-programme/ 2025-05-16T11:17:10.907Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-efimosfermin-a-phase-iii-ready-potential-best-in-class-specialty-medicine-to-treat-and-prevent-progression-of-steatotic-liver-disease-sld/ 2025-05-16T11:30:22.68Z https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-approved-in-japan/ 2025-05-20T14:44:48.99Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-approved-by-us-fda/ 2025-05-23T09:12:22.17Z https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-receive-positive-chmp-opinion-in-relapsedrefractory-multiple-myeloma/ 2025-05-28T12:53:55.97Z https://www.gsk.com/en-gb/media/press-releases/pivot-po-phase-iii-study-for-tebipenem-hbr-stopped-early-for-efficacy-following-review-by-independent-data-monitoring-committee/ 2025-05-29T08:17:25.49Z https://www.gsk.com/en-gb/media/press-releases/gsk-data-at-asco-and-eha-showcase-latest-research-and-innovation-across-the-oncology-portfolio/ 2025-05-29T16:19:03.933Z https://www.gsk.com/en-gb/media/press-releases/linerixibat-new-drug-application-nda-accepted-for-review-by-the-us-fda/ 2025-06-02T08:12:23.533Z https://www.gsk.com/en-gb/media/press-releases/gsk-licenses-shigella-vaccine-candidate-to-bharat-biotech-for-continued-development/ 2025-06-12T08:29:48.327Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-by-the-european-medicines-agency-to-expand-use-in-adults-18-years-and-older/ 2025-06-13T06:03:39.493Z https://www.gsk.com/en-gb/media/press-releases/price-of-world-s-first-malaria-vaccine-rts-s-for-children-in-endemic-countries-to-be-reduced/ 2025-06-25T07:02:51.617Z https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-accepts-regulatory-application-to-expand-use-of-gsk-s-rsv-vaccine-arexvy/ 2025-06-20T06:07:46.937Z https://www.gsk.com/en-gb/media/press-releases/linerixibat-accepted-for-review-by-the-european-medicines-agency/ 2025-06-23T07:26:41.203Z https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-shingrix-in-a-prefilled-syringe-presentation/ 2025-07-17T06:02:49.06Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-efimosfermin/ 2025-07-07T15:01:32.77Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-new-data-demonstrating-positive-real-world-impact-of-its-innovative-long-acting-injectables-for-hiv-at-ias-2025/ 2025-07-08T13:31:30.233Z https://www.gsk.com/en-gb/media/press-releases/us-fda-accepts-application-to-review-expanded-use-of-gsk-s-rsv-vaccine/ 2025-07-14T06:02:41.073Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-data-show-89-of-treatment-naive-people-with-hiv-choose-to-switch-to-long-acting-injectable-vocabria-plus-rekambys-from-daily-pills-after-achieving-rapid-viral-suppression/ 2025-07-14T13:36:30.46Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-extends-voluntary-licensing-agreement-with-medicines-patent-pool-to-enable-access-to-innovative-long-acting-injectable-hiv-treatment/ 2025-07-14T13:06:27.963Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-us-fda-advisory-committee-review-of-blenrep-belantamab-mafodotin-blmf-combinations-for-patients-with-relapsedrefractory-multiple-myeloma/ 2025-07-17T20:49:31.19Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-extension-of-us-food-and-drug-administration-review-period-for-blenrep-belantamab-mafodotin-blmf-in-relapsedrefractory-multiple-myeloma/ 2025-07-23T16:03:50.33Z https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-combinations-approved-in-eu-for-treatment-of-relapsedrefractory-multiple-myeloma/ 2025-07-24T16:06:11.65Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-hengrui-pharma-enter-agreements/ 2025-07-28T06:03:55.843Z https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-new-findings-on-dementia-and-alzheimer-s-disease-at-aaic-2025-building-on-leadership-in-immunology-and-inflammation/ 2025-07-29T13:01:37.617Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-continued-strong-performance/ 2025-07-30T06:04:47.04Z https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-us-settlement-of-curevacbiontech-mrna-patent-litigation/ 2025-08-08T06:03:34.37Z https://www.gsk.com/en-gb/media/press-releases/gepotidacin-accepted-for-priority-review-by-the-us-fda-for-the-oral-treatment-of-uncomplicated-urogenital-gonorrhoea/ 2025-08-11T06:04:51.313Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-showcase-new-research-from-its-broad-respiratory-portfolio-at-the-european-respiratory-society-ers-congress-2025/ 2025-09-15T16:11:16.56Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-invest-30-billion-in-rd-and-manufacturing-in-the-united-states-over-next-5-years/ 2025-09-16T23:02:38.737Z https://www.gsk.com/en-gb/media/press-releases/gsk-to-submit-label-update-for-wellcovorin-leucovorin-at-us-fda-s-request/ 2025-09-22T21:23:48.533Z https://www.gsk.com/en-gb/media/press-releases/luke-miels-appointed-ceo-designate-for-gsk/ 2025-09-29T14:12:34.327Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-pivotal-phase-iii-data-for-next-generation-low-carbon-version-of-ventolin-salbutamol-metered-dose-inhaler/ 2025-10-22T06:29:03.363Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-approved-in-china-for-prevention-of-shingles-in-adults-aged-18/ 2025-10-14T06:13:02Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-s-clarity-study-shows-long-acting-cabotegravir-more-acceptable-than-lenacapavir-injections-after-a-single-dose-with-90-preferring-cabotegravir/ 2025-10-15T11:05:55.647Z https://www.gsk.com/en-gb/media/press-releases/global-fund-welcomes-renewed-commitment-from-gsk-and-viiv-healthcare-to-expand-community-led-health-solutions-with-6-million-joint-pledge/ 2025-10-20T20:50:37.93Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-new-prefilled-syringe-presentation-receives-positive-chmp-opinion/ 2025-10-21T06:13:36.523Z https://www.gsk.com/en-gb/media/press-releases/positive-pivot-po-phase-iii-data-show-tebipenem-hbr-s-potential-as-the-first-oral-carbapenem-antibiotic-for-patients-with-complicated-urinary-tract-infections-cutis/ 2025-10-21T06:08:01.73Z https://www.gsk.com/en-gb/media/press-releases/blenrep-approved-by-us-fda-for-use-in-treatment-of-relapsedrefractory-multiple-myeloma/ 2025-10-23T20:13:09.057Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-empirico-enter-license-agreement-for-clinical-stage-first-in-class-oligonucleotide-candidate/ 2025-10-28T07:09:53.667Z https://www.gsk.com/en-gb/media/press-releases/gsk-acquires-exclusive-rights-from-syndivia-for-antibody-drug-conjugate/ 2025-10-27T07:03:39.997Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-b7-h3-targeted-antibody-drug-conjugate-gsk-227-receives-orphan-drug-designation-in-the-eu/ 2025-10-28T07:02:47.043Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q3-performance-and-upgrades-2025-guidance/ 2025-10-29T07:02:20.02Z https://www.gsk.com/en-gb/media/press-releases/gsk-presents-data-from-its-advancing-liver-pipeline-at-aasld-2025/ 2025-11-10T08:47:53.657Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-fleming-initiative-scientists-unite-to-target-amr-with-advanced-ai/ 2025-11-18T06:44:32.657Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-ltz-announce-strategic-collaboration-to-advance-novel-myeloid-cell-engagers-in-oncology/ 2025-11-19T07:04:54.437Z https://www.gsk.com/en-gb/media/press-releases/depemokimab-receives-positive-chmp-opinion-for-severe-asthma-with-type-2-inflammation/ 2025-12-12T13:49:37.64Z https://www.gsk.com/en-gb/media/press-releases/tesaro-a-gsk-subsidiary-initiates-litigation-against-anaptysbio-inc/ 2025-11-20T23:26:22.76Z https://www.gsk.com/en-gb/media/press-releases/gsk-data-at-ash-show-potential-to-redefine-outcomes-for-people-living-with-blood-cancers/ 2025-12-09T10:42:33.693Z https://www.gsk.com/en-gb/media/press-releases/gsk-227-a-b7-h3-targeted-antibody-drug-conjugate-granted-orphan-drug-designation-in-small-cell-lung-cancer-by-the-us-fda/ 2025-12-10T07:03:56.733Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-receives-positive-chmp-opinion-for-all-adults-18-years-and-older/ 2025-12-12T07:06:37.76Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-receives-positive-chmp-opinion-for-treatment-of-chronic-obstructive-pulmonary-disease/ 2025-12-12T13:57:57.42Z https://www.gsk.com/en-gb/media/press-releases/blujepa-gepotidacin-approved-by-us-fda-as-oral-option-for-treatment-of-uncomplicated-urogenital-gonorrhoea-ugc/ 2025-12-11T22:35:19.393Z https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-in-the-uk-for-treatment-of-asthma-with-type-2-inflammation-and-chronic-rhinosinusitis-with-nasal-polyps/ 2025-12-15T21:14:33.707Z https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-asthma/ 2025-12-17T13:04:18.343Z https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-with-us-government-to-lower-drug-prices-and-expand-access-to-respiratory-medicines-for-millions-of-americans/ 2025-12-19T20:12:36.66Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-approved-in-china/ 2026-01-06T07:34:08.803Z https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-in-japan/ 2026-01-06T07:25:44.907Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-recombinant-zoster-vaccine-prefilled-syringe-presentation-approved-by-the-european-commission/ 2026-01-07T07:10:20.137Z https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-b-well-1-and-b-well-2-phase-iii-trials-for-bepirovirsen-a-potential-first-in-class-treatment-for-chronic-hepatitis-b/ 2026-01-07T07:31:41.673Z https://www.gsk.com/en-gb/media/press-releases/gsk-pfizer-and-shionogi-agree-on-changes-to-viiv-healthcare-shareholding/ 2026-01-20T07:01:20.313Z https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-rapt-therapeutics/ 2026-01-20T07:07:43.427Z https://www.gsk.com/en-gb/media/press-releases/trelegy-ellipta-approved-in-china/ 2026-01-23T07:03:41.23Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-receives-european-approval-for-expanded-use-in-all-adults-18-years-and-older/ 2026-01-26T07:05:07.313Z https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-2025-performance-and-re-affirms-long-term-outlooks/ 2026-02-04T07:02:16.957Z https://www.gsk.com/en-gb/media/press-releases/nucala-mepolizumab-approved-by-the-european-commission/ 2026-02-06T07:01:48.947Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-accepted-for-regulatory-review-in-china-for-adults-aged-60-years-and-older/ 2026-02-10T07:02:59.367Z https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-by-the-european-commission/ 2026-02-17T07:02:32.39Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-arexvy-associated-with-reductions-in-certain-rsv-related-risks-including-heart-attack-stroke-and-severe-flare-ups-of-copd-and-asthma-real-world-study-shows/ 2026-02-17T12:03:07.597Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-s-long-acting-cabenuva-cabotegravir-plus-rilpivirine-for-hiv-demonstrates-superior-efficacy-compared-to-daily-oral-therapy-for-people-with-adherence-challenges-results-published-in-nejm/ 2026-02-18T22:15:51.783Z https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-35pharma-inc/ 2026-02-25T07:05:04.333Z https://www.gsk.com/en-gb/media/press-releases/linerixibat-accepted-for-priority-review-in-china-for-cholestatic-pruritus-in-patients-with-primary-biliary-cholangitis/ 2026-02-26T07:08:57.323Z https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-regulatory-review-in-japan/ 2026-03-05T15:08:21.78Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-12-month-data-showing-investigational-bnab-lotivibart-n6ls-maintains-high-levels-of-viral-suppression-in-long-acting-hiv-treatment-regimen/ 2026-02-25T19:02:12.733Z https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-pipeline-data-for-two-investigational-hiv-treatment-therapies-with-potential-for-twice-yearly-dosing/ 2026-02-25T19:03:54.36Z https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-rapt-therapeutics/ 2026-03-05T15:04:44.887Z https://www.gsk.com/en-gb/media/press-releases/gsk-and-alfasigma-announce-agreement/ 2026-03-09T09:17:19.327Z https://www.gsk.com/en-gb/media/press-releases/gsk-tops-antimicrobial-resistance-amr-benchmark-report/ 2026-03-10T11:12:23.583Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-rsv-vaccine-arexvy-approved-in-us-for-expanded-age-indication-in-adults-aged-18-49-years-at-increased-risk/ 2026-03-13T10:34:11.96Z https://www.gsk.com/en-gb/media/press-releases/lynavoy-linerixibat-approved-by-the-us-fda/ 2026-03-19T12:02:01.56Z https://www.gsk.com/en-gb/media/press-releases/gsk-s-b7-h3-targeted-antibody-drug-conjugate-risvutatug-rezetecan-granted-orphan-drug-designation-for-small-cell-lung-cancer-in-japan/ 2026-03-23T07:06:55.2Z https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-review-by-the-european-medicines-agency-as-a-potential-first-in-class-treatment-for-chronic-hepatitis-b/ 2026-03-27T07:00:56.84Z https://www.gsk.com/en-gb/media/press-releases/bepirovirsen-accepted-for-regulatory-review-in-china-as-a-potential-first-in-class-functional-cure-for-chronic-hepatitis-b/ 2026-03-30T06:12:21.023Z https://www.gsk.com/en-gb/media/press-releases/exdensur-depemokimab-approved-in-china-for-the-treatment-of-severe-asthma/ 2026-03-30T06:02:00.217Z https://www.gsk.com/en-gb/media/media-contacts/ 2026-01-22T16:48:15.703Z https://www.gsk.com/en-gb/media/media-library/ 2026-01-22T16:49:06.347Z https://www.gsk.com/en-gb/media/zantac-litigation/ 2026-01-22T16:49:41.927Z https://www.gsk.com/en-gb/media/social-media/ 2026-03-30T09:54:11.853Z https://www.gsk.com/en-gb/media/podcasts/ 2026-01-21T14:11:18.52Z https://www.gsk.com/en-gb/media/rss-feeds/ 2026-01-30T12:21:49.78Z https://www.gsk.com/en-gb/media/rss/ 2026-02-09T14:09:14.803Z https://www.gsk.com/en-gb/careers/ 2026-04-01T15:42:58.357Z https://www.gsk.com/en-gb/careers/search-jobs/ 2025-09-29T14:49:05.97Z https://www.gsk.com/en-gb/careers/featured-careers/ 2026-01-26T11:11:46.533Z https://www.gsk.com/en-gb/careers/featured-careers/a-career-in-data/ 2026-01-26T11:12:42.427Z https://www.gsk.com/en-gb/careers/life-at-gsk/ 2026-04-01T15:41:54.19Z https://www.gsk.com/en-gb/careers/experienced-professionals/ 2025-09-29T16:03:38.267Z https://www.gsk.com/en-gb/careers/experienced-professionals/business-operations/ 2025-09-29T14:50:55.007Z https://www.gsk.com/en-gb/careers/experienced-professionals/engineering/ 2025-09-29T16:04:09.527Z https://www.gsk.com/en-gb/careers/experienced-professionals/global-supply-chain/ 2026-03-05T10:00:09.763Z https://www.gsk.com/en-gb/careers/experienced-professionals/sales-and-marketing/ 2026-03-05T09:59:28.447Z https://www.gsk.com/en-gb/careers/experienced-professionals/research-and-development/ 2026-03-05T09:58:34.897Z https://www.gsk.com/en-gb/careers/experienced-professionals/research-and-development/chemical-manufacturing-and-controls-cmc-medicine-development-and-supply-mds/ 2025-09-29T14:52:00.433Z https://www.gsk.com/en-gb/careers/experienced-professionals/research-and-development/genomic-sciences/ 2026-03-05T09:57:56.91Z https://www.gsk.com/en-gb/careers/experienced-professionals/technology/ 2025-09-29T14:52:21.767Z https://www.gsk.com/en-gb/careers/early-careers/ 2025-10-23T14:18:04.653Z https://www.gsk.com/en-gb/careers/early-careers/application-process/ 2025-09-29T14:53:02.183Z https://www.gsk.com/en-gb/careers/early-careers/apprentice-programmes/ 2025-09-29T14:53:12.867Z https://www.gsk.com/en-gb/careers/early-careers/internships-and-placements/ 2025-09-29T14:53:23.823Z https://www.gsk.com/en-gb/careers/early-careers/graduate-programme/ 2026-01-26T11:18:32.99Z https://www.gsk.com/en-gb/careers/early-careers/graduate-programme/business-operations/ 2025-09-29T14:53:47.683Z https://www.gsk.com/en-gb/careers/early-careers/graduate-programme/engineering/ 2025-09-29T14:53:58.887Z https://www.gsk.com/en-gb/careers/early-careers/graduate-programme/manufacturing-supply/ 2026-01-26T11:19:19.29Z https://www.gsk.com/en-gb/careers/early-careers/graduate-programme/commercial/ 2025-09-29T14:54:18.39Z https://www.gsk.com/en-gb/careers/early-careers/graduate-programme/research-development/ 2026-01-26T11:19:59.447Z https://www.gsk.com/en-gb/careers/early-careers/graduate-programme/digital-tech/ 2026-01-26T11:20:48.99Z https://www.gsk.com/en-gb/careers/early-careers/graduate-programme/manufacturing-sciences-technology/ 2026-01-26T11:21:37.437Z https://www.gsk.com/en-gb/careers/early-careers/post-graduate-opportunities/ 2026-01-26T11:22:41.747Z https://www.gsk.com/en-gb/careers/early-careers/frequently-asked-questions/ 2026-01-26T11:23:36.203Z https://www.gsk.com/en-gb/careers/veterans/ 2026-01-26T11:24:26.097Z https://www.gsk.com/en-gb/careers/our-global-and-regional-hubs/ 2025-09-29T14:55:42.753Z https://www.gsk.com/en-gb/careers/how-we-hire/ 2026-01-26T11:25:27.203Z https://www.gsk.com/en-gb/careers/how-we-hire/fraudulent-internet-recruitment-activities/ 2026-01-26T11:26:15.717Z https://www.gsk.com/en-gb/careers/how-we-hire/frequently-asked-questions/ 2025-09-29T14:56:18.597Z https://www.gsk.com/en-gb/contact-us/ 2026-03-03T15:48:26.05Z https://www.gsk.com/en-gb/contact-us/worldwide/ 2026-03-26T14:26:30.817Z https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/ 2025-09-29T14:56:55.7Z https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/enquiries-privacy-notice/ 2025-09-29T14:57:07.207Z https://www.gsk.com/en-gb/accessibility/ 2026-02-09T14:06:36.45Z https://www.gsk.com/en-gb/digital-sustainability/ 2025-09-29T18:11:58.453Z https://www.gsk.com/en-gb/terms-of-use/ 2025-09-29T14:57:38.793Z https://www.gsk.com/en-gb/cookie-policy/ 2026-03-02T17:17:00.247Z https://www.gsk.com/en-gb/sitemap/ 2026-01-08T18:04:39.997Z https://www.gsk.com/en-gb/search/ 2025-06-17T13:28:33.193Z